Crystalline forms of a compound for targeted androgen receptor degradation

Description

"Crystalline Forms of a Compound for Targeted Degradation of the Androgen Receptor" RELATED ORDERS

[001] This application claims priority and the benefit of U.S. Provisional Application No. 63 / 493,245, filed March 30, 2023, which is incorporated by reference in its entirety for all purposes. FIELD OF TECHNIQUE

[002] The disclosure provides new salts and salt forms of Compound A: and to the processes for their preparation. The disclosure also extends to pharmaceutical compositions containing at least one salt or salt form and to the therapeutic and / or prophylactic use of such salts, salt forms and compositions thereof. These salts and salt forms are useful as modulators of targeted ubiquitination, especially with respect to a variety of polypeptides and other proteins, which are degraded and / or otherwise inhibited by the salts and salt forms of the present disclosure. FUNDAMENTALS

[003] Most small molecule drugs bind to enzymes or receptors in tight, well-defined pockets. On the other hand, protein-protein interactions are notoriously difficult to achieve using small molecules due to their large contact surfaces and the shallow grooves or planar interfaces involved. E3 ubiquitin ligases (of which hundreds are known in humans) confer substrate specificity for ubiquitination and are therefore attractive therapeutic targets. The development of E3 ligase ligands has proven challenging, in part due to the fact that they must disrupt protein-protein interactions. However, recent developments have provided specific ligands. Petition 870250101903, dated 06 / 11 / 2025, page 6 / 230 2 / 175 that bind to these ligases.

[004] One E3 ubiquitin ligase with therapeutic potential is cereblon. Cereblon is a protein that in humans is encoded by the CRBN gene. Thalidomide and its analogues, for example, pomalidomide and lenalidomide, are known to bind to cereblon. These agents bind to cereblon, altering the specificity of the complex to induce ubiquitination and degradation of transcription factors essential for multiple myeloma growth. In fact, higher cereblon expression has been associated with increased efficacy of imide drugs in the treatment of multiple myeloma.

[005] The Androgen Receptor (AR) belongs to a family of nuclear hormone receptors that is activated by androgens, such as testosterone and dihydrotestosterone (Pharmacol. Rev. 2006, 58(4), 782-97; Vitam. Horn. 1999, 55:30952.). In the absence of androgens, the AR is bound by Heat Shock Protein 90 (Hsp90) in the cytosol. When an androgen binds to the AR, its conformation changes to release the AR from Hsp90 and expose the Nuclear Localization Signal (NLS). This last one allows AR to translocate to the nucleus, where AR acts as a transcription factor to promote gene expression responsible for male sexual characteristics (Endocr. Rev. 1987, 8(1):1-28; Mol. Endocrinol. 2002, 16(10), 2181-7). AR deficiency leads to Androgen Insensitivity Syndrome, formerly called testicular feminization.

[006] Although AR is responsible for the development of male sexual characteristics, it is also a well-documented oncogene in certain forms of cancer, including prostate cancer (Endocr. Rev. 2004, 25(2), 276308). A commonly measured target gene of AR activity is the secreted Prostate-Specific Antigen (PSA) protein. The current treatment regimen for prostate cancer involves inhibition of the androgen-AR axis by two methods. The first approach relies on androgen reduction, while the second strategy targets Petition 870250101903, dated 06 / 11 / 2025, page 7 / 230 3 / 175 inhibit AR function (Nat. Rev. Drug Discovery, 2013, 12, 823-824). Despite the development of effective targeted therapies, most patients develop resistance and the disease progresses. An alternative approach to prostate cancer treatment involves eliminating the AR protein.

[007] As RA is a critical tumorigenesis factor in many forms of prostate cancer, its elimination should lead to a therapeutically beneficial response. There is a continuing need in the field for effective treatments for diseases, especially cancer, prostate cancer, and Kennedy's disease.

[008] However, nonspecific effects, and the inability to target and modulate certain classes of proteins in their entirety, such as transcription factors, remain obstacles to the development of effective anticancer agents. As such, small molecule therapeutic agents that leverage or enhance cereblon substrate specificity and, at the same time, are scalable so that a wide range of protein classes can be targeted and modulated with specificity would be very useful as a therapeutic. SUMMARY

[009] This disclosure is directed to Compound A: and salts and solid forms thereof.

[010] In some respects, the present disclosure is directed to a freebase form of Compound A.

[011] In some forms, Compound A is crystalline.

[012] In some embodiments, Compound A is amorphous.

[013] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by two or three selected XRPD signals from Petition 870250101903, dated 06 / 11 / 2025, p. 8 / 230 4 / 175 group consisting of 18.6 °2θ, 13.9 °2θ and 15.3 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by XRPD signals at 18.6 °2θ, 13.9 °2θ and 15.3 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation).

[014] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 80 or FIG. 86.

[015] In some embodiments, the solid form of compound A is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, or forty-one XRPD signals selected from those set out in Table 1.

[016] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 14.4 °2θ, 19.1 °2θ and 15.8 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu radiation to1). In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by XRPD signals at 14.4 °2θ, 19.1 °2θ and 15.8 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu radiation ^1).

[017] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 87.

[018] In some embodiments, the solid form of compound A is a polymorphic crystalline form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, Petition 870250101903, dated 06 / 11 / 2025, page 9 / 230 5 / 175 nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, or forty XRPD signals selected from those set out in Table 2.

[019] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.6 °2θ, 16.1 °2θ, 16.3 °2θ, 17.3 °2θ and 16.8 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by XRPD signals at 20.6 °2θ, 16.1 °2θ, 16.3 °2θ, 17.3 °2θ and 16.8 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu^1 radiation).

[020] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 88.

[021] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen or nineteen XRPD signals selected from those set out in Table 3.

[022] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 14.6 °2θ, 17.7 °2θ and 16.7 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by XRPD signals at 14.6 °2θ, 17.7 °2θ and 16.7 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation).

[023] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 89. Petition 870250101903, dated 06 / 11 / 2025, page 10 / 230 6 / 175

[024] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three or twenty-four XRPD signals selected from those set out in Table 4.

[025] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 14.9 °2θ, 22.6 °2θ and 7.1 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by XRPD signals at 14.9 °2θ, 22.6 °2θ and 7.1 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation).

[026] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 90.

[027] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, or thirty-five XRPD signals selected from those set forth in Table 5.

[028] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 3.5 °2θ, 3.6 °2θ and 15.7 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by XRPD signals at 3.5 °2θ, 3.6 °2θ and 15.7 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). Petition 870250101903, dated 06 / 11 / 2025, page 11 / 230 7 / 175

[029] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 91.

[030] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five or thirty-six XRPD signals selected from those set forth in Table 6.

[031] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 4.8 °2θ, 15.7 °2θ and 17.9 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu radiation to1). In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by XRPD signals at 4.8 °2θ, 15.7 °2θ and 17.9 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu radiation ^1).

[032] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 92.

[033] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen or sixteen XRPD signals selected from those set out in Table 7.

[034] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 4.9 °2θ, 15.9 °2θ and 18.2 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu radiation to1). In some embodiments, the solid form of Compound A is a Petition 870250101903, dated 06 / 11 / 2025, page 12 / 230 8 / 175 crystalline polymorphic form characterized by XRPD signals at 4.9 °2θ, 15.9 °2θ and 18.2 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation).

[035] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 93.

[036] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one or twenty-two XRPD signals selected from those set out in Table 8.

[037] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 17.2 °2θ, 21.0 °2θ and 24.2 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by XRPD signals at 17.2 °2θ, 21.0 °2θ and 24.2 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation).

[038] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 94.

[039] In some embodiments, the solid form of Compound A is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, or forty-two XRPD signals selected from those set forth in Table 9. Petition 870250101903, dated 06 / 11 / 2025, page 13 / 230 9 / 175

[040] In some respects, the present disclosure is directed to a tosylate salt of Compound A.

[041] In some forms, the tosylate salt is crystalline.

[042] In some forms, the tosylate salt is amorphous.

[043] In some embodiments, the tosylate salt is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 3.5 °2θ, 22.0 °2θ and 23.0 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). In some embodiments, the tosylate salt is a crystalline polymorphic form characterized by XRPD signals at 3.5 °2θ, 22.0 °2θ and 23.0 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation).

[044] In some embodiments, the tosylate salt is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 95.

[045] In some embodiments, the tosylate salt is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve or thirteen XRPD signals selected from those set out in Table 10.

[046] In some embodiments, the tosylate salt is a tosylate salt:Compound A 1:1.

[047] In some embodiments, the tosylate salt is a tosylate salt:Compound A 2:1.

[048] In some embodiments, the tosylate salt is a tosylate salt:Compound A 1:2.

[049] In some respects, the present disclosure is directed to a phosphate salt of Compound A.

[050] In some embodiments, the phosphate salt is crystalline.

[051] In some embodiments, the phosphate salt is amorphous. Petition 870250101903, dated 06 / 11 / 2025, page 14 / 230 10 / 175

[052] In some embodiments, the phosphate salt is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 23.6 °2θ, 3.3 °2θ and 19.9 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). In some embodiments, the phosphate salt is a crystalline polymorphic form characterized by XRPD signals at 23.6 °2θ, 3.3 °2θ and 19.9 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation).

[053] In some embodiments, the phosphate salt is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 96.

[054] In some embodiments, the phosphate salt is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen XRPD signals selected from those set out in Table 11.

[055] In some embodiments, the phosphate salt is a phosphate salt: Compound A 1:1, that is, a monophosphate salt of Compound A.

[056] In some embodiments, the phosphate salt is a phosphate salt: Compound A 2:1, that is, a bisphosphate salt of Compound A.

[057] In some embodiments, the phosphate salt is a phosphate salt:Compound A 1:1 or a phosphate salt:Compound A 2:1.

[058] In some embodiments, the phosphate salt is a 1:2 phosphate:Compound A salt, that is, a hemiphosphate salt of Compound A.

[059] In some respects, the present disclosure is directed to a besylate salt of Compound A.

[060] In some forms, the besylate salt is crystalline.

[061] In some embodiments, the besylate salt is amorphous.

[062] In some embodiments, the besylate salt is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group that Petition 870250101903, dated 06 / 11 / 2025, page 15 / 230 11 / 175 consists of 18.5 °2θ, 18.3 °2θ and 22.6 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). In some embodiments, the besylate salt is a crystalline polymorphic form characterized by XRPD signals at 18.5 °2θ, 18.3 °2θ and 22.6 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation).

[063] In some embodiments, the besylate salt is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 97.

[064] In some embodiments, the besylate salt is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine or thirty XRPD signals selected from those set out in Table 12.

[065] In some embodiments, the besylate salt is a besylate salt: Compound A 1:1.

[066] In some embodiments, the besylate salt is a besylate salt: Compound A 2:1.

[067] In some embodiments, the besylate salt is a besylate salt: Compound A 1:2.

[068] In some respects, the present disclosure is directed to a chloride salt of Compound A.

[069] In some embodiments, the chloride salt is a chloride salt:Compound A 1:1.

[070] In some embodiments, the chloride salt is a chloride salt:Compound A 2:1.

[071] In some embodiments, the chloride salt is a chloride salt:Compound A 1:1 or a chloride salt:Compound A 2:1. Petition 870250101903, dated 06 / 11 / 2025, page 16 / 230 12 / 175

[072] In some embodiments, the chloride salt is a chloride salt:Compound A 1: 2.

[073] In some respects, the present disclosure is directed to a method of treating prostate cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a solid form or salt of Compound A disclosed in this document.

[074] In some forms, the method also involves administering an effective amount of at least one additional anticancer agent to the subject.

[075] In some forms, prostate cancer is metastatic prostate cancer.

[076] In some forms, prostate cancer is castration-resistant prostate cancer.

[077] In some forms, prostate cancer is metastatic castration-resistant prostate cancer.

[078] In some forms, prostate cancer is castration-sensitive prostate cancer.

[079] In some forms, prostate cancer is metastatic castration-sensitive prostate cancer.

[080] In some modalities, prostate cancer has not been previously treated with a second-generation antiandrogen. In some modalities, prostate cancer has not been previously treated with an androgen biosynthesis inhibitor or an androgen receptor blocker. In some modalities, prostate cancer has not been previously treated with an androgen biosynthesis inhibitor. In some modalities, prostate cancer has not been previously treated with an androgen receptor blocker. In some modalities, prostate cancer has not been previously treated with abiraterone acetate. In some modalities, prostate cancer has not been previously treated with a Petition 870250101903, dated 06 / 11 / 2025, page 17 / 230 13 / 175 selected androgen receptor blocker of enzalutamide, darolutamide, and apalutamide. In some embodiments, the subject has not been previously administered a second-generation antiandrogen. In some embodiments, the subject has not previously received an androgen biosynthesis inhibitor or an androgen receptor blocker. In some embodiments, the subject has not previously received an androgen biosynthesis inhibitor. In some embodiments, the subject has not previously received an androgen receptor blocker. In some embodiments, the subject has not previously been administered abiraterone acetate. In some embodiments, the subject has not previously been administered an androgen receptor blocker of enzalutamide, darolutamide, and apalutamide.

[081] In some embodiments, prostate cancer is naive to novel hormonal agents (NHAs). In some embodiments, prostate cancer not exposed to novel hormonal agents (NHAs) has not been previously treated with one or more second-generation antiandrogens. In some embodiments, prostate cancer not exposed to novel hormonal agents (NHAs) has not been previously treated with an androgen biosynthesis inhibitor or an androgen receptor blocker. In some embodiments, prostate cancer not exposed to novel hormonal agents (NHAs) has not been previously treated with an androgen biosynthesis inhibitor. In some embodiments, prostate cancer not exposed to novel hormonal agents (NHAs) has not been previously treated with an androgen receptor blocker. In some embodiments, prostate cancer not exposed to novel hormonal agents (NHAs) has not been previously treated with abiraterone acetate.In some modalities, prostate cancer not exposed to novel hormonal agents (NHAs) has not been previously treated with an androgen receptor blocker selected from enzalutamide, darolutamide, and apalutamide. Petition 870250101903, dated 06 / 11 / 2025, p. 18 / 230 14 / 175

[082] In some embodiments, the prostate cancer is metastatic prostate cancer not exposed to new hormonal agents (NHA). In some embodiments, metastatic prostate cancer not exposed to new hormonal agents (NHA) has not been previously treated with one or more second-generation antiandrogens. In some embodiments, metastatic prostate cancer not exposed to new hormonal agents (NHA) has not been previously treated with an androgen biosynthesis inhibitor or an androgen receptor blocker. In some embodiments, metastatic prostate cancer not exposed to new hormonal agents (NHA) has not been previously treated with an androgen biosynthesis inhibitor. In some embodiments, metastatic prostate cancer not exposed to new hormonal agents (NHA) has not been previously treated with an androgen receptor blocker.In some modalities, metastatic prostate cancer not previously treated with abiraterone acetate has not been exposed to novel hormonal agents (NHA). In some modalities, metastatic prostate cancer not previously treated with a selected androgen receptor blocker of enzalutamide, darolutamide, and apalutamide has also not been previously treated with a selected androgen receptor blocker.

[083] In some embodiments, the prostate cancer is castration-resistant prostate cancer not exposed to novel hormonal agents (NHA). In some embodiments, castration-resistant prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with one or more second-generation antiandrogens. In some embodiments, castration-resistant prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with an androgen biosynthesis inhibitor or an androgen receptor blocker. In some embodiments, castration-resistant prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with an androgen biosynthesis inhibitor. In some embodiments, the Petition 870250101903, dated 06 / 11 / 2025, p. 19 / 230 15 / 175 castration-resistant prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with an androgen receptor blocker. In some embodiments, castration-resistant prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with abiraterone acetate. In some embodiments, castration-resistant prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with an androgen receptor blocker selected from enzalutamide, darolutamide, and apalutamide.

[084] In some embodiments, the prostate cancer is castration-sensitive prostate cancer not exposed to novel hormonal agents (NHA). In some embodiments, castration-sensitive prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with one or more second-generation antiandrogens. In some embodiments, castration-sensitive prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with an androgen biosynthesis inhibitor or an androgen receptor blocker. In some embodiments, castration-sensitive prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with an androgen biosynthesis inhibitor. In some embodiments, castration-sensitive prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with an androgen receptor blocker.In some embodiments, castration-sensitive prostate cancer not previously exposed to novel hormonal agents (NHAs) has not been treated with abiraterone acetate. In some embodiments, castration-sensitive prostate cancer not previously exposed to novel hormonal agents (NHAs) has not been treated with an androgen receptor blocker selected from enzalutamide, darolutamide, and apalutamide.

[085] In some forms, prostate cancer is metastatic castration-resistant prostate cancer not exposed to new hormonal agents (NHA). Petition 870250101903, dated 06 / 11 / 2025, p. 20 / 230 16 / 175 In some embodiments, metastatic castration-resistant prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with one or more second-generation antiandrogens. In some embodiments, metastatic castration-resistant prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with an androgen biosynthesis inhibitor or an androgen receptor blocker. In some embodiments, metastatic castration-resistant prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with an androgen biosynthesis inhibitor. In some embodiments, metastatic castration-resistant prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with an androgen receptor blocker.In some embodiments, metastatic castration-resistant prostate cancer not previously exposed to novel hormonal agents (NHA) has not been treated with abiraterone acetate. In some embodiments, metastatic castration-resistant prostate cancer not previously exposed to novel hormonal agents (NHA) has not been treated with an androgen receptor blocker selected from enzalutamide, darolutamide, and apalutamide.

[086] In some embodiments, the prostate cancer is metastatic castration-sensitive prostate cancer not exposed to novel hormonal agents (NHA). In some embodiments, metastatic castration-sensitive prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with one or more second-generation antiandrogens. In some embodiments, metastatic castration-sensitive prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with an androgen biosynthesis inhibitor or an androgen receptor blocker. In some embodiments, metastatic castration-sensitive prostate cancer not exposed to novel hormonal agents (NHA) has not been previously treated with an androgen biosynthesis inhibitor. In some embodiments, metastatic castration-sensitive prostate cancer is not Petition 870250101903, dated 06 / 11 / 2025, page 21 / 230 In some embodiments, metastatic castration-sensitive prostate cancer not exposed to novel hormonal agents (NHAs) has not been previously treated with an androgen receptor blocker. In some embodiments, metastatic castration-sensitive prostate cancer not exposed to novel hormonal agents (NHAs) has not been previously treated with abiraterone acetate. In some embodiments, metastatic castration-sensitive prostate cancer not exposed to novel hormonal agents (NHAs) has not been previously treated with an androgen receptor blocker selected from enzalutamide, darolutamide, and apalutamide.

[087] In some forms, the second-generation antiandrogen is an inhibitor of androgen biosynthesis or an androgen receptor blocker.

[088] In some modalities, the inhibitor of androgen biosynthesis is abiraterone acetate.

[089] In some modalities, the androgen receptor blocker is selected from enzalutamide, darolutamide, and apalutamide.

[090] Features, advantages and additional aspects of this disclosure are set forth or evident from consideration of the following detailed description, drawings and claims. Furthermore, it should be understood that both the preceding summary of this disclosure and the following detailed description are illustrative and are intended to provide further explanation without limiting the scope of this disclosure as claimed. BRIEF DESCRIPTION OF THE FIGURES

[091] The accompanying drawings, which are included to provide a further understanding of this disclosure, are incorporated into and form part of this descriptive report, illustrate aspects of this disclosure and, together with the detailed description, serve to explain the principles of this disclosure. The patent filing or application contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and Petition 870250101903, dated 06 / 11 / 2025, page 22 / 230 18 / 175 payment of the required fee.

[092] FIG. 1 represents an XRPD pattern of Compound A.

[093] FIG. 2 represents a 1H-NMR spectrum of Compound A, recorded in DMSO-d6.

[094] FIG. 3 represents a 19F-NMR spectrum of Compound A, recorded in DMSO-d6.

[095] FIG. 4 represents a TG / DSC thermogram of Compound A.

[096] FIG. 5 represents a DSC thermogram of Compound A (first heating cycle).

[097] FIG. 6 represents a DSC thermogram of Compound A (first cooling cycle).

[098] FIG. 7 represents a DSC thermogram of Compound A (second heating cycle).

[099] FIG. 8 represents a DSC thermogram of Compound A (second cooling cycle).

[0100] FIG. 9 represents VT-XRPD patterns of Compound A.

[0101] FIG. 10 represents a DVS isotherm plot of Compound A.

[0102] FIG. 11 represents a kinetic graph of DVS for Compound A.

[0103] FIG. 12 represents a superposition of the XRPD pattern of Compound A (top) and the XRPD pattern of Compound A after DVS analysis (bottom).

[0104] FIG. 13 represents a TG / DSC thermogram of Compound A.

[0105] FIG. 14 represents an FT-IR spectrum of DCM:methanol potential chloride Standard 2 (50:50% v / v).

[0106] FIG. 15 represents a TG / DSC thermogram of DCM potential chloride Standard 2.

[0107] FIG. 16 represents a TG / DSC thermogram of Standard 2 chloride. Petition 870250101903, dated 06 / 11 / 2025, page 23 / 230 19 / 175 DCM:methanol potential (50:50% v / v).

[0108] FIG. 17 represents an FT-IR spectrum of THF tosylate Standard 1.

[0109] FIG. 18 represents a TG / DSC thermogram of THF tosylate Standard 1.

[0110] FIG. 19 represents a 1H-NMR spectrum of THF tosylate Standard 1, recorded on DMSO-d6.

[0111] FIG. 20 represents an FT-IR spectrum of Standard 1 of THF besylate:water (98:2% v / v).

[0112] FIG. 21 represents a TG / DSC thermogram of Standard 1 of THF besylate:water (98:2%v / v).

[0113] FIG. 22 represents a 1H-NMR spectrum of THF besylate:water (98:2%v / v) Standard 1, recorded on DMSO-d6.

[0114] FIG. 23 represents an FT-IR spectrum of Standard 1 of THF phosphate:water (98:2% v / v).

[0115] FIG. 24 represents a TG / DSC thermogram of Standard 1 of THF phosphate:water (98:2% v / v).

[0116] FIG. 25 represents a 1H-NMR spectrum of THF phosphate:water (98:2% v / v) Standard 1, recorded on DMSO-d6.

[0117] FIG. 26 represents a 31P-NMR spectrum of THF phosphate:water (98:2% v / v) Standard 1, recorded on DMSO-d6.

[0118] FIG. 27 represents a TG / DSC thermogram of amorphous chloride.

[0119] FIG. 28 represents a DSC thermogram of amorphous chloride (first heating cycle).

[0120] FIG. 29 represents a DSC thermogram of amorphous chloride (cooling cycle).

[0121] FIG. 30 represents a DSC thermogram of amorphous chloride (according to Petition 870250101903, dated 06 / 11 / 2025, page 24 / 230 20 / 175 heating cycle).

[0122] FIG. 31 represents an additional DSC thermogram of amorphous chloride (first heating cycle).

[0123] FIG. 32 represents an additional DSC thermogram of amorphous chloride (cooling cycle).

[0124] FIG. 33 represents an additional DSC thermogram of amorphous chloride (second heating cycle).

[0125] FIG. 34 represents an overlay of XRPD patterns of 1,4-dioxane / L-Histidine freebase Standard 9 (top), Post-storage freebase Standard 4 at 40°C / 75% RH (middle) and Freebase Standard 4 (bottom).

[0126] FIG. 35 represents a TG / DSC thermogram of the free-base Standard 9.

[0127] FIG. 36 represents an overlay of the XRPD patterns of the acetonitrile and anisole crystallization screening samples before and after temperature cycling.

[0128] FIG. 37 represents an overlay of the XRPD patterns of the ethyl formate and isopropyl acetate crystallization screen samples before and after temperature cycling.

[0129] FIG. 38 represents an overlay of the XRPD patterns of the THF and toluene crystallization screening samples before and after temperature cycling.

[0130] FIG. 39 represents a TG / DSC thermogram of the freebase Standard 1 from 2-ethoxyethanol.

[0131] FIG. 40 represents an FT-IR spectrum of the THF base-free Standard 1.

[0132] FIG. 41 represents a TG / DSC thermogram of the Baseline Standard 2. Petition 870250101903, dated 06 / 11 / 2025, page 25 / 230 21 / 175 free of DCM:methanol (50:50% v / v).

[0133] FIG. 42 represents an FT-IR spectrum of DCM:methanol (50:50% v / v) free base Standard 2.

[0134] FIG. 43 represents a TG / DSC thermogram of the free base Standard 3 from 1,4-dioxane and succinic acid.

[0135] FIG. 44 represents an FT-IR spectrum of the free base Standard 3 from 1,4-dioxane and hydrochloric acid.

[0136] FIG. 45 represents a TG / DSC thermogram of the free base Standard 4 from 1,4-dioxane and malonic acid.

[0137] FIG. 46 represents an FT-IR spectrum of the freebase Standard 4 from 1,4-dioxane and benzoic acid.

[0138] FIG. 47 represents a TG / DSC thermogram of the freebase Standard 6 from the DCM post-temperature cycle.

[0139] FIG. 48 represents an FT-IR spectrum of the free-base Standard 6 from the DCM post-temperature cycle.

[0140] FIG. 49 represents a TG / DSC thermogram of the Anisole-free base Standard 8.

[0141] FIG. 50 represents a TG / DSC thermogram of the free-base Standard 8 from anisole (additionally dried).

[0142] FIG. 51 represents a TG / DSC thermogram of the free-base Standard 8 from toluene.

[0143] FIG. 52 represents an FT-IR spectrum of the Anisole-free base Standard 8.

[0144] FIG. 53 represents an FT-IR spectrum of toluene freebase Standard 8.

[0145] FIG. 54 represents a TG / DSC thermogram of the free-base Standard 1. Petition 870250101903, dated 06 / 11 / 2025, page 26 / 230 22 / 175

[0146] FIG. 55 represents a 1H-NMR spectrum of free-base Standard 1, recorded on DMSO-d6.

[0147] FIG. 56 represents a DSC thermogram of the free-base Standard 1 (first heating cycle).

[0148] FIG. 57 represents a DSC thermogram of the free-base Standard 1 (cooling cycle).

[0149] FIG. 58 represents a DSC thermogram of the free-base Standard 1 (second heating cycle).

[0150] FIG. 59 represents a modulated DSC thermogram of the 3-gram batch of freebase Standard 1.

[0151] FIG. 60 represents a DVS isotherm plot of the free-base Standard 1.

[0152] FIG. 61 represents a kinetic graph of DVS of the free-base Pattern 1.

[0153] FIG. 62 represents an overlay of the XRPD pattern of the freebase Pattern 1 (top) and the XRPD pattern of the post-DVS analysis of the freebase Pattern 1 (bottom).

[0154] FIG. 63 represents a TG / DSC thermogram of the free-base Standard 2.

[0155] FIG. 64 represents a 1H-NMR spectrum of the free-base Standard 2, recorded on DMSO-d6.

[0156] FIG. 65 represents a TG / DSC thermogram of the free-base Standard 6.

[0157] FIG. 66 represents a 1H-NMR spectrum of the free-base Standard 6, recorded on DMSO-d6.

[0158] FIG. 67 represents a 1H-NMR spectrum of freebase Standard 1 after heating at 250°C, recorded on DMSO-d6. Petition 870250101903, dated 06 / 11 / 2025, page 27 / 230 23 / 175

[0159] FIG. 68 represents a 1H-NMR spectrum of Tosylate Standard 1, recorded on DMSO-d6.

[0160] FIG. 69 represents a TG / DSC thermogram of Tosylate Standard 1.

[0161] FIG. 70 represents a 1H-NMR spectrum of besylate Standard 1, recorded in DMSO-d6.

[0162] FIG. 71 represents a TG / DSC thermogram of Standard 1 besylate.

[0163] FIG. 72 represents a 1H-NMR spectrum of phosphate Standard 1, recorded on DMSO-d6.

[0164] FIG. 73 represents a 31P-NMR spectrum of phosphate Standard 1, recorded in DMSO-d6.

[0165] FIG. 74 represents a TG / DSC thermogram of phosphate Standard 1.

[0166] FIG. 75 represents an overlay of the patterns of XRPD from the post-stability analysis of the free-base Pattern 1.

[0167] FIG. 76 represents an overlay of the patterns of XRPD from the post-stability analysis of the free-base Pattern 2.

[0168] FIG. 77 represents an overlay of the patterns of XRPD from the post-stability analysis of Standard 1 tosylate.

[0169] FIG. 78 represents an overlay of the patterns of XRPD from the post-stability analysis of Standard 1 besylate.

[0170] FIG. 79 represents an overlay of XRPD patterns from ethanol scale-up attempts.

[0171] FIG. 80 represents an XRPD pattern from the enlarged batch of the Free Base Pattern.

[0172] FIG. 81 represents a 1H-NMR spectrum of the 3-gram batch of Freebase standard 1, registered in DMSO-d6.

[0173] FIG. 82 represents a TG / DSC thermogram of a 3-gram batch of freebase Standard 1. Petition 870250101903, dated 06 / 11 / 2025, page 28 / 230 24 / 175

[0174] FIG. 83 represents a DSC thermogram of a 3-gram batch of Freebase pattern 1 (first heating cycle).

[0175] FIG. 84 represents a DSC thermogram of a 3-gram batch of Freebase pattern 1 (cooling cycle).

[0176] FIG. 85 represents a DSC thermogram of a 3-gram batch of Freebase pattern 1 (second heating cycle).

[0177] FIG. 86 represents a free-base XRPD pattern of Pattern 1.

[0178] FIG. 87 represents a freebase Pattern 2 XRPD pattern.

[0179] FIG. 88 represents a freebase Standard 3 XRPD pattern.

[0180] FIG. 89 represents a freebase Pattern 4 XRPD pattern.

[0181] FIG. 90 represents a freebase Standard 5 XRPD pattern.

[0182] FIG. 91 represents a freebase Standard 6 XRPD pattern.

[0183] FIG. 92 represents a freebase Standard 7 XRPD pattern.

[0184] FIG. 93 represents a freebase Pattern 8 XRPD pattern.

[0185] FIG. 94 represents a freebase Standard 9 XRPD pattern.

[0186] FIG. 95 represents an XRPD pattern of Tosylate Pattern 1.

[0187] FIG. 96 represents an XRPD standard of Phosphate Standard 1.

[0188] FIG. 97 represents an XRPD pattern of Besylate Pattern 1. DETAILED DESCRIPTION

[0189] This disclosure provides salts and polymorphic salt forms of Compound A that are useful in the preparation of a medicament and / or as pharmaceutical agents. In some embodiments, one or more of the salts and / or salt forms described herein may be formulated into a pharmaceutical composition. Definitions

[0190] Compound A of the present disclosure refers to 4-(4-((1-(4(((1R,3R)-3-(4-cyano-3-methoxyphenoxy)-2,2,4,4tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-N-((S)-2,6Petition 870250101903, of 11 / 06 / 2025, page 29 / 230 25 / 175 dioxopiperidin-3-yl)-2-fluorobenzamide, which has the following structure: (Compound A).

[0191] In some embodiments, Compound A may be prepared as described in US Patent Application Publication 2021 / 0196710 A1, which is incorporated herein by reference.

[0192] The terms powder X-ray diffraction pattern, PXRD pattern, powder X-ray diffraction pattern, and XRPD pattern are used interchangeably and refer to the experimentally observed diffractogram or parameters derived from it. Powder X-ray diffraction patterns are typically characterized by peak position (abscissa) and peak intensities (ordinate). The term peak intensities refers to relative signal intensities within a given X-ray diffraction pattern. Factors that can affect relative peak intensities are sample thickness and preferred orientation (i.e., crystalline particles are not randomly distributed). The term peak positions, as used herein, refers to measured and observed X-ray reflection positions in powder X-ray diffraction experiments. Peak positions are directly related to unit cell dimensions.The peaks, identified by their respective peak positions, are extracted from the diffraction patterns for the various polymorphic salt forms of Compound A.

[0193] The terms 2θ, 2θ, 2θ, °2θ or °2θ value refer to the peak position in degrees based on the experimental setup of the X-ray diffraction experiment and is a common abscissa unit in diffraction standards. In general, the experimental setup requires that if a reflection is diffracted when the incoming beam forms an angle θ (θ) with a certain grating plane, the reflected beam is recorded at an angle 2θ (2θ). It should be understood that the Petition 870250101903, dated 06 / 11 / 2025, page 30 / 230 26 / 175 Reference in this document to specific 2Θ values ​​for a specific polymorphic form is intended to mean the 2Θ values ​​(in degrees) as measured using the X-ray diffraction experimental conditions as described in this document.

[0194] Preferred orientation effects refer to varying peak intensities or differences in relative intensity between different PXRD measurements of the same samples that may be due to particle orientation. Without wishing to be limited by theory, in PXRD it may be desirable to have a sample in which the particles are randomly oriented (e.g., a powder). However, it may be difficult or, in some cases, impossible to achieve truly random particle orientations in practice. As particle size increases, the randomness of particle orientation may decrease, leading to greater challenges in obtaining a preferred orientation. Without wishing to be limited by theory, a smaller particle size may reduce the technical challenges associated with preferred orientation and allow for a more accurate representation of the peaks.However, someone skilled in the art will understand how to reduce or mitigate orientation-preference effects and will recognize orientation-preference effects that may exist even between two different measurements of the same sample. For example, in some modalities, differences in resolution or relative peak intensities can be attributed to orientation-preference effects.

[0195] As used herein, the term substantially pure with reference to a particular salt (or a mixture of two or more salts) of a compound indicates that the salt (or a mixture) includes less than 10%, less than 5%, less than 3%, less than 1%, less than 0.5%, less than 0.2% or less than 0.1% by weight of impurities, including other salt forms of the compound. Such purity may be determined, for example, by X-ray diffraction on powder.

[0196] As used herein, the term polymorph or salt form refers Petition 870250101903, dated 06 / 11 / 2025, p. 31 / 230 27 / 175 to different crystalline forms of the same compound and other solid-state molecular forms, including pseudo-polymorphs, such as hydrates (e.g., bound water present in the crystal structure) and solvates (e.g., bound solvents other than water) of the same compound. Different crystalline polymorphs have different crystal structures due to different packing of molecules in the lattice. This results in different crystal symmetry and / or unit cell parameters that directly influence their physical properties, such as the X-ray diffraction characteristics of crystals or powders. A different polymorph, for example, will generally diffract at a different set of angles and give different values ​​for the intensities. Therefore, X-ray powder diffraction can be used to identify different polymorphs, or a solid form comprising more than one polymorph, in a reproducible and reliable manner (S.Byrn et al, Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations, Pharmaceutical research, Vol. 12, No. 7, p. 945-954, 1995; J. K. Haleblian and W. McCrone, Pharmaceutical Applications of Polymorphism, Journal of Pharmaceutical Sciences, Vol. 58, No. 8, p. 91 1 -929, 1969).

[0197] Crystalline polymorphic forms are of interest to the pharmaceutical industry and especially to those involved in the development of suitable dosage forms. If the polymorphic form is not kept constant during clinical or stability studies, the exact dosage form used or studied may not be comparable from batch to batch. It is also desirable to have processes to produce a compound with the selected polymorphic form in high purity when the compound is used in clinical studies or commercial products, since impurities present may produce undesirable toxicological effects. Certain polymorphic forms may exhibit enhanced thermodynamic stability or may be more easily manufactured in high purity in large quantities and are therefore more suitable for inclusion in pharmaceutical formulations. Petition 870250101903, dated 06 / 11 / 2025, page 32 / 230 28 / 175 Certain polymorphs may exhibit other advantageous physical properties, such as lack of hygroscopic tendencies, improved solubility, and increased dissolution rates due to different lattice energies.

[0198] The term amorphous refers to any solid substance that (i) lacks order in three dimensions, or (ii) exhibits order in less than three dimensions, order only at short distances (e.g., less than 10 Å), or both. Thus, amorphous substances include partially crystalline materials and crystalline mesophases with, for example, one- or two-dimensional translational order (liquid crystals), orientational disturbance (orientally disordered crystals), or conformational disturbance (conformationally disordered crystals). Amorphous solids can be characterized by known techniques, including powder X-ray diffraction crystallography (PXRD), solid-state nuclear magnetic resonance spectroscopy (ssNMR), differential scanning calorimetry (DSC), or some combination of these techniques. Amorphous solids give diffuse PXRD patterns, typically composed of one or two broad peaks (i.e., peaks with base widths of about 5° 2Θ or greater).

[0199] The term crystalline refers to any solid substance exhibiting three-dimensional order, which, in contrast to an amorphous solid substance, gives a distinct PXRD pattern with sharply defined peaks.

[0200] The term ambient temperature refers to a temperature condition typically found in a laboratory environment. This includes the approximate temperature range of about 20 to about 30 °C.

[0201] The term detectable quantity refers to a quantity or amount per unit volume that can be detected using conventional techniques such as X-ray powder diffraction, differential scanning calorimetry, HPLC, Fourier Transform Infrared Spectroscopy (FTIR), Raman spectroscopy and the like. Petition 870250101903, dated 06 / 11 / 2025, p. 33 / 230 29 / 175

[0202] The term solvate describes a molecular complex comprising the drug substance and a stoichiometric or non-stoichiometric amount of one or more solvent molecules (e.g., ethanol). When the solvent is tightly bound to the drug, the resulting complex will have a well-defined stoichiometry that is independent of moisture. When, however, the solvent is weakly bound, as in channel solvates and hygroscopic compounds, the solvent content will depend on moisture and drying conditions. In such cases, the complex may be non-stoichiometric.

[0203] The term hydrate describes a solvate comprising the medicinal substance and a stoichiometric or non-stoichiometric amount of water.

[0204] The term relative humidity refers to the ratio between the amount of water vapor in the air at a given temperature and the maximum amount of water vapor that can be held at that temperature and pressure, expressed as a percentage.

[0205] The term relative intensity refers to an intensity value derived from a sample X-ray diffraction pattern. The full ordinate range scale for a diffraction pattern is given a value of 100. A peak with intensity falling between about 50% to about 100% on this intensity scale is termed very strong (vs); a peak with intensity falling between about 50% to about 25% is termed strong (s). Additional weaker peaks are present in typical diffraction patterns and are characteristic of a given polymorph, wherein the additional peaks are termed medium (m), weak (w), and very weak (vw).

[0206] The term paste refers to a solid substance suspended in a liquid medium, typically water or an organic solvent.

[0207] The term under vacuum refers to typical pressures obtained by a laboratory oil or oil-free diaphragm vacuum pump. Petition 870250101903, dated 06 / 11 / 2025, page 34 / 230 30 / 175

[0208] The term pharmaceutical composition refers to a composition comprising one or more of the polymorphic salt forms of Compound A described in this document and other chemical components, such as physiologically / pharmaceutically acceptable carriers, diluents, vehicles and / or excipients. The purpose of a pharmaceutical composition is to facilitate the administration of a compound to an organism, such as a human or other mammals.

[0209] The term pharmaceutically acceptable carrier, diluent, vehicle or excipient refers to a material (or materials) that may be included with a specific pharmaceutical agent to form a pharmaceutical composition and may be solid or liquid. Exemplary solid carriers are lactose, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time-delay or time-release material known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methyl methacrylate and the like.

[0210] The term "treat," as used in this document, unless otherwise indicated, means to reverse, alleviate, or inhibit the progression of the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment," as used herein, unless otherwise indicated, refers to the act of treating, as defined immediately above. For example, the terms "treat," "treating," and "treatment" may refer to a method for alleviating or reversing a particular disorder and / or one or more of its concomitant symptoms.

[0211] As used in this document, subject means a human or animal (in the case of an animal, the subject may be a mammal). In one aspect, the subject is a human. In one aspect, the subject is a man.

[0212] Prostate cancer is the uncontrolled growth of cells Petition 870250101903, dated 06 / 11 / 2025, page 35 / 230 31 / 175 cancers in the prostate. In some forms, prostate cancer is metastatic prostate cancer, castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, castration-sensitive prostate cancer, metastatic castration-sensitive prostate cancer, hormone-naive (NHA) prostate cancer, metastatic hormone-naive (NHA) prostate cancer, castration-resistant (NHA) prostate cancer, metastatic hormone-naive (NHA) prostate cancer, castration-resistant (NHA) prostate cancer, metastatic hormone-naive (NHA) castration-sensitive (NHA) prostate cancer, or metastatic hormone-naive (NHA) castration-sensitive (NHA) prostate cancer.

[0213] Metastatic prostate cancer, or metastases, refers to prostate cancer that has spread beyond the prostate to other parts of the body, for example, bones, lymph nodes, liver, lungs, brain.

[0214] Castration-resistant prostate cancer or castration-resistant prostate cancer (or prostate cancer that is resistant to castration or castration) is a type of prostate cancer that continues to grow even when the amount of testosterone in the body is reduced to very low levels.

[0215] Metastatic castration-resistant prostate cancer is a type of prostate cancer that has metastasized and continues to grow even when the amount of testosterone in the body is reduced to very low levels.

[0216] Castration-sensitive prostate cancer (CSPC), or prostate cancer that is sensitive to castration, is prostate cancer that can be controlled by reducing the amount of androgens (male hormones) in the body (for example, through castration) and / or prostate cancer that requires androgens to grow and stops growing when androgens are not present. CSPC is also referred to as androgen-dependent prostate cancer, androgen-sensitive prostate cancer, or Petition 870250101903, dated 06 / 11 / 2025, page 36 / 230 32 / 175 hormone-sensitive prostate cancer (HSPC).

[0217] Metastatic castration-sensitive prostate cancer is a type of castration-sensitive prostate cancer that has metastasized and requires androgens to grow and stops growing when androgens are not present, or can be controlled by reducing the amount of androgens in the body (for example, through castration).

[0218] Non-newly treated (NHA) prostate cancer is prostate cancer that has not been previously treated with one or more second-generation antiandrogens, such as androgen biosynthesis inhibitors or androgen receptor blockers. In some embodiments, the androgen biosynthesis inhibitor is abiraterone (e.g., abiraterone acetate). In some embodiments, the androgen receptor blocker is enzalutamide, darolutamide, or apalutamide.

[0219] Metastatic prostate cancer not exposed to new hormonal agents (NHA) is metastatic prostate cancer that has not been previously treated with second-generation antiandrogens, such as androgen biosynthesis inhibitors or androgen receptor blockers. In some embodiments, the androgen biosynthesis inhibitor is abiraterone (e.g., abiraterone acetate). In some embodiments, the androgen receptor blocker is enzalutamide, darolutamide, or apalutamide.

[0220] Non-new hormonal agent-exposed castration-resistant prostate cancer (NHA) is castration-resistant prostate cancer that has not been previously treated with second-generation antiandrogens, such as androgen biosynthesis inhibitors or androgen receptor blockers. In some embodiments, the androgen biosynthesis inhibitor is abiraterone (e.g., abiraterone acetate). In some embodiments, the androgen receptor blocker is enzalutamide, darolutamide, or apalutamide. Petition 870250101903, dated 06 / 11 / 2025, p. 37 / 230 33 / 175

[0221] Non-newly treated castration-sensitive prostate cancer (NHA) is castration-sensitive prostate cancer that has not been previously treated with second-generation antiandrogens, such as androgen biosynthesis inhibitors or androgen receptor blockers. In some embodiments, the androgen biosynthesis inhibitor is abiraterone (e.g., abiraterone acetate). In some embodiments, the androgen receptor blocker is enzalutamide, darolutamide, or apalutamide.

[0222] Metastatic castration-resistant prostate cancer not exposed to novel hormonal agents (NHAs) is metastatic castration-resistant prostate cancer that has not been previously treated with second-generation antiandrogens, such as androgen biosynthesis inhibitors or androgen receptor blockers. In some embodiments, the androgen biosynthesis inhibitor is abiraterone (e.g., abiraterone acetate). In some embodiments, the androgen receptor blocker is enzalutamide, darolutamide, or apalutamide.

[0223] Metastatic castration-sensitive prostate cancer not exposed to new hormonal agents (NHAs) is metastatic castration-sensitive prostate cancer that has not been previously treated with second-generation antiandrogens, such as androgen biosynthesis inhibitors or androgen receptor blockers. In some embodiments, the androgen biosynthesis inhibitor is abiraterone (e.g., abiraterone acetate). In some embodiments, the androgen receptor blocker is enzalutamide, darolutamide, or apalutamide.

[0224] As used in this document, the term anticancer agent is used to describe an anticancer agent or a therapeutic agent administered concomitantly with an anticancer agent (e.g., palonosetron), with which it may be co-administered and / or co-formulated with a disclosure compound to treat cancer and side effects associated with cancer treatment. These agents include, for example, everolimus, trabectedin, abraxane, TLK 286, AV-299, Petition 870250101903, dated 06 / 11 / 2025, page 38 / 230 34 / 175 DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, an FLT-3 inhibitor, a VEGFR inhibitor, an EGFR TK inhibitor, an aurora kinase inhibitor, a PIK-1 modulator, a Bcl-2 inhibitor, an HDAC inhibitor, a c-MET inhibitor, a PARP inhibitor, a CDK inhibitor, an EGFR TK inhibitor, an IGFR-TK inhibitor, an antibody anti-HGF, a PI3 kinase inhibitor, an AKT inhibitor, an mTORC1 / 2 inhibitor, a JAK / STAT inhibitor, a checkpoint-1 or 2 inhibitor, a focal adhesion kinase inhibitor, a MAP kinase (MEK) inhibitor, a VEGF trap antibody, pemetrexed, erlotinib, dasatanib, nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, AZD2171, batabulin, ofatumumab, zanolimumab, edothecarin, tetrandrine, rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab, gossypol,Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490, cilengitide, gimatecan, IL13-PE38QQR, INO 1001, IPdR1 KRX-0402, lucantone, LY317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, doxorubicin, liposomal doxorubicin, 5'-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709, seliciclib; PD0325901, AZD6244, capecitabine, L-glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1Hpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt, heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrozole, exemestane, letrozole, DES (diethylstilbestrol), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-1C11, CHIR-258); 3-[5-(methylsulfonylpiperadinemethyl)indolyl-quinolone, vatalanib, AG-013736, AVE-0005, goserelin acetate, leuprolide acetate, triptorelin pamoate, medroxyprogesterone acetate,Hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714; TAK-165, HKI-272, erlotinib, lapatanib, Petition 870250101903, dated 06 / 11 / 2025, page 39 / 230 35 / 175 canertinib, ABX-EGF antibody, erbitux, EKB-569, PKI-166, GW-572016, lonafarnib, BMS-214662, tipifarnib; amifostine, NVP-LAQ824, suberoyl analyte, hydroxamic acid, valproic acid, trichostatin A, FK-228, SU11248, sorafenib, KRN951, aminoglutethimide, arnsacrine, anagrelide, L-asparaginase, Bacillus Calmette-Guérin (BCG) vaccine, adriamycin, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, gleevec, gemcitabine, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide, Levamisole, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide,testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard, uracil mustard, estramustine, altretamine, floxuridine, 5-deoxyuridine, cytosine arabinoside, 6-mecaptopurine, deoxycholic acid, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, razoxane, marimastat, COL-3, neovastat, BMS-275291, squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin-12, IM862, angiostatin, vitaxin, droloxifene, idoxifene, spironolactone, finasteride, cimitidine, trastuzumab, denileukin diftitox, gefitinib, bortezomib, paclitaxel, paclitaxel without cremophore, docetaxel, epitilone B, BMS- 247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifen, ERA-923, arzoxifene, fulvestrant, acolbifen, lasofoxifen, idoxifen, TSE-424, HMR- 3339, ZK186619, topotecan, PTK787 / ZK 222584, VX-745, PD 184352, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001, ABT-578, BC-210,LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L-779450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zoledronate, prednisone, cetuximab, factor, Petition 870250101903, dated 06 / 11 / 2025, page 40 / 230 36 / 175 granulocyte and macrophage colony stimulator, histrelin, pegylated interferon alfa-2a, interferon alfa-2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all-trans-retinoic acid, ketoconazole, interleukin-2, megestrol, immunoglobulin, nitrogen mustard, methylprednisolone, ibritumomab, tiuxetane, androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, etidronate, mitotane, cyclosporine, liposomal daunorubicin, edwina-asparaginase, strontium 89, casopitant, netupitant, an NK-1 receptor antagonist, palonosetron, aprepitant, diphenhydramine, hydroxyzine, metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin, epoetin alfa,darbepoetin alfa and mixtures thereof. In one embodiment, the anticancer agent is selected from the group consisting of abiraterone, estramustine, docetaxel, ketoconazole, goserelin, histrelin, triptorelin, buserelin, cyproterone, flutamide, bicalutamide, nilutamide, pamidronate, and zoledronate. In one embodiment, the anticancer agent is selected from the group consisting of FLT-3 inhibitor, androgen receptor inhibitor, VEGFR inhibitor, EGFR TK inhibitor, aurora kinase inhibitor, PIK-1 modulator, Bcl-2 inhibitor, HDAC inhibitor, c-Met inhibitor, PARP inhibitor, CDK 4 / 6 inhibitor, anti-HGF antibody, IGFR TK inhibitor, PI3 kinase inhibitor, AKT inhibitor, JAK / STAT inhibitor, checkpoint 1 inhibitor, checkpoint 2 inhibitor, focal adhesion kinase inhibitor, MAP kinase inhibitor, VEGF trap antibody, and chemical castration agent.

[0225] In some embodiments, the anticancer agent is selected from the group consisting of temozolomide, capecitabine, irinotecan, tamoxifen, anastrozole, exemestane, letrozole, DES, estradiol, estrogen, bevacizumab, goserelin acetate, leuprolide acetate, triptorelin pamoate, acetate Petition 870250101903, dated 06 / 11 / 2025, page 41 / 230 37 / 175 medroxyprogesterone, hydroxyprogesterone caproate, raloxifene, megestrol acetate, carboplatin, cisplatin, dacarbazine, methotrexate, vinblastine, vinorelbine, topotecan, finasteride, arzoxifene, fulvestrant, prednisone, abiraterone, enzalutamide, apalutamide, darolutamide, sipuleucel-T, pembrolizumab, nivolumab, cemiplimab, atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi), docetaxel (Taxotere), cabazitaxel (Jevtana), mitoxantrone (Novantrone), estramustine (Emcyt), docetaxel, ketoconazole, histrelin, triptorelin, buserelin, cyproterone, flutamide, bicalutamide, nilutamide, pamidronate, and zolendronate.

[0226] The term about is used in this document to mean approximately, in the region of, approximately, or around. When the term about is used in conjunction with a numerical range, it modifies that range by extending the limits above and below the stated numerical values. In general, the term about is used in this document to modify a numerical value above and below the stated value by a variance of 20%, a variance of 10%, a variance of 5%, a variance of 3%, or a variance of 1%. When used in the context of XRPD peak values, the term about may indicate a peak value ±0.20, ±0.15, ±0.10, ±0.05, or ±0.01 °2θ. In some embodiments, when used in the context of XRPD peak values, about may indicate a peak value substantially exactly at the published peak value. Crystalline Forms of Compound A

[0227] As set forth below, Compound A can form salts with different acids. In some embodiments, the salts of Compound A described in this document exist in various crystalline forms. All PXRD peaks described herein are at °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Kα1 radiation). Furthermore, all PXRD spectra are obtained using Cu Kα1 X-rays at a wavelength of 1.5406 Å. Compound A 1 Free Base Standard Petition 870250101903, dated 06 / 11 / 2025, page 42 / 230 38 / 175

[0228] In some embodiments, the present disclosure provides solid forms of Compound A, for example, crystalline forms of the freebase Standard 1 of Compound A. In some embodiments, the XRPD profile of the freebase Standard 1 of Compound A is substantially similar to that shown in FIG. 80 or FIG. 86. In some embodiments, the FT-IR spectrum of the freebase Standard 1 of Compound A is substantially similar to that shown in FIG. 40. In some embodiments, the NMR spectrum of the freebase 11H Standard of Compound A is substantially similar to that shown in FIG. 55 or FIG. 81. In some embodiments, the TGA profile of the freebase Standard 1 of Compound A is substantially similar to that shown in FIG. 13, FIG. 39, FIG. 54 or FIG. 82. In some embodiments, the DSC profile of the freebase Standard 1 of Compound A is substantially similar to that shown in FIG. 13, FIG. 39, FIG. 54 or FIG. 82.

[0229] In some embodiments, the solid form of the freebase Pattern 1 of Compound A is the crystalline freebase Pattern 1 of Compound A characterized by two or three XRPD signals selected from the group consisting of 18.6°2θ, 13.9°2θ and 15.3°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 1 of Compound A is the crystalline freebase Pattern 1 of Compound A characterized by XRPD signals at 18.6°2θ, 13.9°2θ and 15.3°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0230] In some embodiments, the solid form of the freebase Pattern 1 of Compound A is the crystalline freebase Pattern 1 of Compound A characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.6°2θ, 13.9°2θ, 15.3°2θ, 16.3°2θ and 16.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu radiation to1). In some embodiments, the solid form of the freebase Standard 1 of Compound A is the crystalline freebase Standard 1 of Compound A characterized by XRPD signals at 18.6°2θ, 13.9°2θ, 15.3°2θ, 16.3°2θ and 16.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). Petition 870250101903, dated 06 / 11 / 2025, page 43 / 230 39 / 175

[0231] In some embodiments, the solid form of the freebase Pattern 1 of Compound A is the crystalline freebase Pattern 1 of Compound A characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.6 °2θ, 13.9°2θ, 15.3°2θ, 16.3°2θ, 16.0°2θ, 24.2 °2θ and 20.8 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). In some embodiments, the solid form of the freebase Standard 1 of Compound A is the crystalline freebase Standard 1 of Compound A characterized by XRPD signals at 18.6°2θ, 13.9°2θ, 15.3°2θ, 16.3°2θ, 16.0°2θ, 24.2°2θ and 20.8°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0232] In some embodiments, the solid form of the Compound A freebase Pattern 1 is the crystalline Compound A freebase Pattern 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.6 °2θ, 13.9°2θ, 15.3°2θ, 16.3°2θ, 16.0°2θ, 24.2°2θ, 20.8°2θ, 22.5°2θ, 14.9 °2θ and 3.7 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). In some embodiments, the solid form of the freebase Standard 1 of Compound A is the crystalline freebase Standard 1 of Compound A characterized by XRPD signals at 18.6°2θ, 13.9°2θ, 15.3°2θ, 16.3°2θ, 16.0°2θ, 24.2°2θ, 20.8°2θ, 22.5°2θ, 14.9°2θ and 3.7°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0233] In some embodiments, the freebase Pattern 1 of crystalline Compound A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, or forty-one XRPD signals selected from those set forth in Table 1. Table 1: Peak XRPD table of Freebase Pattern 1 No. Pos. [°2θ] Spacing d [Â] Height [cts] Internal King [%] 1 3.7000 23.88057 641.16 29.77 Petition 870250101903, dated 06 / 11 / 2025, page 44 / 230 40 / 175 2 6.3237 13.97714 59.09 2.74 3 7.3807 11.97772 44.38 2.06 4 7.9467 11.12582 125.42 5.82 5 11.1345 7.94666 389.66 18.10 6 11.6773 7.57845 93.78 4.35 7 12.5277 7.06587 184.13 8.55 8 13.3953 6.61013 315.10 14.63 9 13.9133 6.36516 1642.97 76.30 10 14.8622 5.96084 872.25 40.51 11 15.2763 5.80015 1511.82 70.21 12 15.5103 5.71317 372.73 17.31 13 16.0052 5.53762 1268.84 58.92 14 16.3082 5.43540 1331.24 61.82 15 16.6231 5.33315 301.68 14.01 16 16.8305 5.26790 229.03 10.64 17 17.3267 5.11814 93.56 4.34 18 18.5579 4.78127 2153.36 100 19 19.2152 4.61917 219.40 10.19 20 20.0526 4.42812 303.49 14.09 21 20.4657 4.33967 404.08 18.77 22 20.7944 4.27180 996.66 46.28 23 21.5336 4.12680 392.13 18.21 24 22.2132 4.00206 226.38 10.51 25 22.4984 3.95197 882.82 41.00 26 22.9853 3.86934 544.07 25.27 27 23.2645 3.82354 578.73 26.88 28 24.2381 3.67212 1186.56 55.10 Petition 870250101903, dated 06 / 11 / 2025, p. 45 / 230 41 / 175 29 24.8457 3.58368 239.10 11.10 30 25.1442 3.54180 332.80 15.46 31 25.7829 3.45549 185.60 8.62 32 26.5158 3.36163 283.85 13.18 33 27.0060 3.30172 116.95 5.43 34 27.9072 3.19711 131.95 6.13 35 28.4031 3.14241 152.44 7.08 36 28.9434 3.08496 152.29 7.07 37 30.4651 2.93425 92.39 4.29 38 30.8466 2.89882 76.26 3.54 39 31.1968 2.86708 104.15 4.84 40 32.2339 2.77716 63.57 2.95 41 34.3944 2.60750 68.99 3.20 Compound A2 Free Base Standard

[0234] In some embodiments, the present disclosure provides solid forms of Compound A, for example, crystalline forms of the freebase Standard 2 of Compound A. In some embodiments, the XRPD profile of the freebase Standard 2 of Compound A is substantially similar to that shown in FIG. 87. In some embodiments, the FT-IR spectrum of the freebase Standard 2 of Compound A is substantially similar to that shown in FIG. 42. In some embodiments, the NMR spectrum of the freebase 21H Standard of Compound A is substantially similar to that shown in FIG. 64. In some embodiments, the TGA profile of the freebase Standard 2 of Compound A is substantially similar to that shown in FIG. 41 or FIG. 63. In some embodiments, the DSC profile of the freebase Standard 2 of Compound A is substantially similar to that shown in FIG. 41 or FIG. 63.

[0235] In some forms, the solid form of the Freebase Pattern 2 of Petition 870250101903, dated 06 / 11 / 2025, page 46 / 230 42 / 175 Compound A is the freebase Pattern 2 of crystalline Compound A characterized by two or three XRPD signals selected from the group consisting of 14.4°2θ, 19.1°2θ, and 15.8°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 2 of Compound A is the freebase Pattern 2 of crystalline Compound A characterized by XRPD signals at 14.4°2θ, 19.1°2θ, and 15.8°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0236] In some embodiments, the solid form of the Compound A freebase Pattern 2 is the crystalline Compound A freebase Pattern 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.4°2θ, 19.1°2θ, 15.8°2θ, 16.2°2θ and 23.5°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu radiation to1). In some embodiments, the solid form of the freebase Pattern 2 of Compound A is the crystalline freebase Pattern 2 of Compound A characterized by XRPD signals at 14.4°2θ, 19.1°2θ, 15.8°2θ, 16.2°2θ and 23.5°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0237] In some embodiments, the solid form of the Compound A freebase Pattern 2 is the crystalline Compound A freebase Pattern 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.4°2θ, 19.1°2θ, 15.8°2θ, 16.2°2θ, 23.5°2θ, 15.1°2θ and 20.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 2 of Compound A is the crystalline freebase Pattern 2 of Compound A characterized by XRPD signals at 14.4°2θ, 19.1°2θ, 15.8°2θ, 16.2°2θ, 23.5°2θ, 15.1°2θ and 20.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0238] In some embodiments, the solid form of the freebase Pattern 2 of Compound A is the crystalline freebase Pattern 2 of Compound A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.4°2θ, 19.1°2θ, 15.8°2θ, 16.2°2θ, 23.5°2θ, 15.1°2θ, 20.0°2θ, 18.9°2θ, 14.1°2θ and 15.6°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, Petition 870250101903, dated 06 / 11 / 2025, page 47 / 230 43 / 175 The solid form of the freebase Standard 2 of Compound A is the crystalline freebase Standard 2 of Compound A characterized by XRPD signals at 14.4°2θ, 19.1°2θ, 15.8°2θ, 16.2°2θ, 23.5°2θ, 15.1°2θ, 20.0°2θ, 18.9°2θ, 14.1°2θ and 15.6°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0239] In some embodiments, the freebase Pattern 2 of crystalline Compound A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine or forty XRPD signals selected from those set forth in Table 2. Table 2: XRPD peak table of Compound A freebase Standard 2 No. Pos. [°2θ] spacing d [Â] Height [cts] King. Int. [%] 1 3.5938 24.58631 471.26 6.74 2 6.3918 13.82845 370.61 5.30 3 10.8342 8.16620 101.22 1.45 4 12.4874 7.08856 202.93 2.90 5 13.1596 6.72796 328.63 4.70 6 13.8368 6.40018 585.70 8.38 7 14.1142 6.27501 1463.28 20.93 8 14.3971 6.15234 6990.97 100 9 15.1415 5.85148 1990.42 28.47 10 15.5564 5.69637 1276.45 18.26 11 15.7884 5.61318 2452.85 35.09 12 16.1703 5.48145 2435.14 34.83 13 16.6720 5.31762 172.04 2.46 14 17.2093 5.15277 270.44 3.87 Petition 870250101903, dated 06 / 11 / 2025, p. 48 / 230 44 / 175 15 17.4536 5.08121 191.78 2.74 16 18.6940 4.74676 599.68 8.58 17 18.9051 4.69424 1571.65 22.48 18 19.1353 4.63828 2498.87 35.74 19 19.3359 4.59061 1067.30 15.27 20 19.9557 4.44941 1696.27 24.26 21 20.4790 4.33688 93.58 1.34 22 21.2716 4.17704 874.54 12.51 23 21.4850 4.13602 756.05 10.81 24 21.8580 4.06292 644.56 9.22 25 21.9276 4.05354 588.96 8.42 26 22.1715 4.00950 409.04 5.85 27 23.0424 3.85988 160.96 2.30 28 23.5394 3.77951 2160.71 30.91 29 24.0647 3.69817 353.88 5.06 30 24.3750 3.65180 637.30 9.12 31 25.2690 3.52459 606.07 8.67 32 26.1682 3.40549 127.50 1.82 33 26.5622 3.35586 238.17 3.41 34 27.8794 3.20023 550.50 7.87 35 28.4715 3.13501 139.12 1.99 36 29.0143 3.07758 457.90 6.55 37 29.8633 2.99200 192.73 2.76 38 30.3918 2.94116 127.53 1.82 39 31.4577 2.84389 222.04 3.18 40 32.4282 2.76096 63.32 0.91 Compound A3 Free Base Standard Petition 870250101903, dated 06 / 11 / 2025, page 49 / 230 45 / 175

[0240] In some embodiments, the present disclosure provides solid forms of Compound A, for example, crystalline forms of the freebase Standard 3 of Compound A. In some embodiments, the XRPD profile of the freebase Standard 3 of Compound A is substantially similar to that shown in FIG. 88. In some embodiments, the FT-IR spectrum of the freebase Standard 3 of Compound A is substantially similar to that shown in FIG. 44. In some embodiments, the TGA profile of the freebase Standard 3 of Compound A is substantially similar to that shown in FIG. 43. In some embodiments, the DSC profile of the freebase Standard 3 of Compound A is substantially similar to that shown in FIG. 43.

[0241] In some embodiments, the solid form of the freebase Pattern 3 of Compound A is the crystalline freebase Pattern 3 of Compound A characterized by two or three XRPD signals selected from the group consisting of 20.6°2θ, 16.1°2θ and 16.3°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 3 of Compound A is the crystalline freebase Pattern 3 of Compound A characterized by XRPD signals at 20.6°2θ, 16.1°2θ and 16.3°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0242] In some embodiments, the solid form of the Compound A freebase Pattern 3 is the crystalline Compound A freebase Pattern 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.6°2θ, 16.1°2θ, 16.3°2θ, 17.3°2θ and 16.8°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu radiation to1). In some embodiments, the solid form of the freebase Pattern 3 of Compound A is the crystalline freebase Pattern 3 of Compound A characterized by XRPD signals at 20.6°2θ, 16.1°2θ, 16.3°2θ, 17.3°2θ and 16.8°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0243] In some embodiments, the solid form of the freebase Pattern 3 of Compound A is the crystalline freebase Pattern 3 of Compound A characterized by Petition 870250101903, dated 06 / 11 / 2025, page 50 / 230 46 / 175 two or more, or three or more XRPD signals selected from the group consisting of 20.6°2θ, 16.1°2θ, 16.3°2θ, 17.3°2θ, 16.8°2θ, 18.1°2θ and 18.7°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 3 of Compound A is the crystalline freebase Pattern 3 of Compound A characterized by XRPD signals at 20.6°2θ, 16.1°2θ, 16.3°2θ, 17.3°2θ, 16.8°2θ, 18.1°2θ and 18.7°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0244] In some embodiments, the solid form of the Compound A freebase Pattern 3 is the crystalline Compound A freebase Pattern 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.6°2θ, 16.1°2θ, 16.3°2θ, 17.3°2θ, 16.8°2θ, 18.1°2θ, 18.7°2θ, 19.4°2θ, 15.2°2θ and 22.1°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 3 of Compound A is the crystalline freebase Pattern 3 of Compound A characterized by XRPD signals at 20.6°2θ, 16.1°2θ, 16.3°2θ, 17.3°2θ, 16.8°2θ, 18.1°2θ, 18.7°2θ, 19.4°2θ, 15.2°2θ and 22.1°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0245] In some embodiments, the freebase Pattern 3 of crystalline Compound A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, or nineteen XRPD signals selected from those set forth in Table 3. Table 3: Peak XRPD of Freebase Pattern 3 No. Pos. [°2θ] Spacing d [Â] Height [cts] Internal King [%] 1 3.1533 28.01991 199.81 22.26 2 5.1360 17.20662 133.94 14.92 3 6.4839 13.63215 54.37 6.06 4 7.2865 12.13234 44.57 4.97 5 10.9326 8.09293 142.82 15.91 6 12.3928 7.14247 93.30 10.39 Petition 870250101903, dated 06 / 11 / 2025, page 51 / 230 47 / 175 7 15.1920 5.83216 398.19 44.36 8 16.0588 5.51926 883.64 98.44 9 16.3349 5.42659 773.87 86.21 10 16.7671 5.28766 592.30 65.98 11 17.3470 5.11218 695.50 77.48 12 18.0762 4.90757 585.33 65.21 13 18.7039 4.74428 585.40 65.21 14 19.3582 4.58537 475.42 52.96 15 20.5831 4.31517 897.66 100 16 22.0559 4.03025 361.08 40.22 17 24.0039 3.70741 212.30 23.65 18 25.3280 3.51651 225.68 25.14 19 27.4228 3.25246 95.55 10.64 Compound A4 Free Base Standard

[0246] In some embodiments, the present disclosure provides solid forms of Compound A, for example, crystalline forms of the freebase Standard 4 of Compound A. In some embodiments, the XRPD profile of the freebase Standard 4 of Compound A is substantially similar to that shown in FIG. 89. In some embodiments, the FT-IR spectrum of the freebase Standard 4 of Compound A is substantially similar to that shown in FIG. 46. In some embodiments, the TGA profile of the freebase Standard 4 of Compound A is substantially similar to that shown in FIG. 45. In some embodiments, the DSC profile of the freebase Standard 4 of Compound A is substantially similar to that shown in FIG. 45.

[0247] In some embodiments, the solid form of the freebase Pattern 4 of Compound A is the crystalline freebase Pattern 4 of Compound A characterized by two or three XRPD signals selected from the group consisting of 14.6°2θ, 17.7° Petition 870250101903, dated 06 / 11 / 2025, page 52 / 230 48 / 175 2θ and 16.7 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Kα1 radiation). In some embodiments, the solid form of the freebase Pattern 4 of Compound A is the crystalline freebase Pattern 4 of Compound A characterized by XRPD signals at 14.6 °2θ, 17.7 °2θ and 16.7 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Kβ1 radiation).

[0248] In some embodiments, the solid form of the Compound A freebase Pattern 4 is the crystalline Compound A freebase Pattern 4 characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.6°2θ, 17.7°2θ, 16.7°2θ, 15.5°2θ and 18.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu Ko1 radiation). In some embodiments, the solid form of the freebase Pattern 4 of Compound A is the crystalline freebase Pattern 4 of Compound A characterized by XRPD signals at 14.6°2θ, 17.7°2θ, 16.7°2θ, 15.5°2θ and 18.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu Ko1 radiation).

[0249] In some embodiments, the solid form of the Compound A freebase Pattern 4 is the crystalline Compound A freebase Pattern 4 characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.6°2θ, 17.7°2θ, 16.7°2θ, 15.5°2θ, 18.0°2θ, 17.2°2θ and 20.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu Ko1 radiation). In some embodiments, the solid form of the freebase Pattern 4 of Compound A is the crystalline freebase Pattern 4 of Compound A characterized by XRPD signals at 14.6°2θ, 17.7°2θ, 16.7°2θ, 15.5°2θ, 18.0°2θ, 17.2°2θ and 20.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu Ko1 radiation).

[0250] In some embodiments, the solid form of the Compound A freebase Pattern 4 is the crystalline Compound A freebase Pattern 4 characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.6°2θ, 17.7°2θ, 16.7°2θ, 15.5°2θ, 18.0°2θ, 17.2°2θ, 20.0°2θ, 15.9°2θ, 19.5°2θ and 5.2°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu Ko1 radiation). In some embodiments, the solid form of the freebase Pattern 4 of Compound A is the crystalline freebase Pattern 4 of Compound A characterized by XRPD signals at 14.6°2θ, 17.7°2θ, Petition 870250101903, dated 06 / 11 / 2025, page 53 / 230 49 / 175 16.7°2θ, 15.5°2θ, 18.0°2θ, 17.2°2θ, 20.0°2θ, 15.9°2θ, 19.5°2θ and 5.2°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu Καί radiation).

[0251] In some embodiments, the freebase Pattern 4 of crystalline Compound A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, or twenty-four XRPD signals selected from those set forth in Table 4. Table 4: Peak XRPD table for Freebase Standard 4 No. Pos. [°2θ] spacing d [Â] Height [cts] King. Int. [%] 1 5.2452 16.84856 484.96 56.21 2 5.7086 15.48181 354.75 41.12 3 8.2080 10.77228 203.06 23.54 4 10.2494 8.63082 183.66 21.29 5 11.3960 7.76488 245.49 28.45 6 12.1283 7.29762 290.20 33.64 7 14.0643 6.29716 346.67 40.18 8 14.6344 6.05310 862.77 100 9 15.4641 5.73013 777.06 90.07 10 15.9300 5.56358 553.15 64.11 11 16.6892 5.31219 801.05 92.85 12 17.1572 5.16831 569.68 66.03 13 17.6836 5.01563 845.37 97.98 14 18.0122 4.92488 701.45 81.30 15 19.5261 4.54631 493.83 57.24 16 19.9947 4.44082 556.81 64.54 17 20.7873 4.27325 386.39 44.78 18 21.6418 4.10642 412.68 47.83 Petition 870250101903, dated 06 / 11 / 2025, p. 54 / 230 50 / 175 19 23.2647 3.82350 285.92 33.14 20 23.9294 3.71878 292.03 33.85 21 24.3788 3.65124 304.27 35.27 22 25.5365 3.48828 261.36 30.29 23 28.6029 3.12091 44.50 5.16 24 30.0998 2.96903 19.47 2.26 Compound A 5 Free Base Standard

[0252] In some embodiments, the present disclosure provides solid forms of Compound A, for example, crystalline forms of the freebase Standard 5 of Compound A. In some embodiments, the XRPD profile of the freebase Standard 5 of Compound A is substantially similar to that shown in FIG. 90.

[0253] In some embodiments, the solid form of the freebase Pattern 5 of Compound A is the crystalline freebase Pattern 5 of Compound A characterized by two or three XRPD signals selected from the group consisting of 14.9°2θ, 22.6°2θ and 7.1°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 5 of Compound A is the crystalline freebase Pattern 5 of Compound A characterized by XRPD signals at 14.9°2θ, 22.6°2θ and 7.1°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0254] In some embodiments, the solid form of the Compound A freebase Pattern 5 is the crystalline Compound A freebase Pattern 5 characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9°2θ, 22.6°2θ, 7.1°2θ, 15.1°2θ and 20.6°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu radiation to1). In some embodiments, the solid form of the freebase Pattern 5 of Compound A is the crystalline freebase Pattern 5 of Compound A characterized by XRPD signals at 14.9°2θ, 22.6°2θ, 7.1°2θ, 15.1°2θ and 20.6°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0255] In some forms, the solid form of the freebase Pattern 5 of Petition 870250101903, dated 06 / 11 / 2025, page 55 / 230 51 / 175 Compound A is the freebase Pattern 5 of crystalline Compound A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9°2θ, 22.6°2θ, 7.1°2θ, 15.1°2θ, 20.6°2θ, 24.4°2θ and 16.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu Kα1 radiation). In some embodiments, the solid form of the freebase Pattern 5 of Compound A is the crystalline freebase Pattern 5 of Compound A characterized by XRPD signals at 14.9°2θ, 22.6°2θ, 7.1°2θ, 15.1°2θ, 20.6°2θ, 24.4°2θ and 16.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu Kα1 radiation).

[0256] In some embodiments, the solid form of the Compound A freebase Pattern 5 is the crystalline Compound A freebase Pattern 5 characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9°2θ, 22.6°2θ, 7.1°2θ, 15.1°2θ, 20.6°2θ, 24.4°2θ, 16.0°2θ, 16.5°2θ, 4.7°2θ and 21.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu Kα1 radiation). In some embodiments, the solid form of the freebase Pattern 5 of Compound A is the crystalline freebase Pattern 5 of Compound A characterized by XRPD signals at 14.9°2θ, 22.6°2θ, 7.1°2θ, 15.1°2θ, 20.6°2θ, 24.4°2θ, 16.0°2θ, 16.5°2θ, 4.7°2θ and 21.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu Kα1 radiation).

[0257] In some embodiments, the freebase Pattern 5 of crystalline Compound A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four or thirty-five XRPD signals selected from those set forth in Table 5. Table 5: XRPD Peak Table of Free Base Pattern 5 No. Pos. [°2θ] Spacing d [Â] Height [cts] Internal King [%] 1 4.7342 18.66570 435.02 31.31 2 7.1042 12.44325 805.24 57.96 Petition 870250101903, dated 06 / 11 / 2025, page 56 / 230 52 / 175 3 7.8131 11.31573 94.99 6.84 4 8.8298 10.01502 419.92 30.22 5 12.0610 7.33820 120.56 8.68 6 14.1220 6.27157 357.99 25.77 7 14.4339 6.13674 272.54 19.62 8 14.9492 5.92635 1389.39 100.00 9 15.1267 5.85718 766.21 55.15 10 15.6613 5.65842 298.52 21.49 11 15.9933 5.54173 592.82 42.67 12 16.4914 5.37543 439.69 31.65 13 17.2091 5.15284 88.73 6.39 14 17.7696 4.99155 293.33 21.11 15 18.2593 4.85878 234.14 16.85 16 19.5985 4.52969 135.75 9.77 17 20.6355 4.30433 720.53 51.86 18 20.9882 4.23279 427.27 30.75 19 21.6022 4.11385 216.50 15.58 20 22.6261 3.92996 1216.47 87.55 21 22.9965 3.86748 402.94 29.00 22 23.4912 3.78715 151.02 10.87 23 23.8393 3.73263 132.46 9.53 24 24.4027 3.64772 710.05 51.11 25 24.7362 3.59929 140.17 10.09 26 25.1602 3.53959 129.14 9.29 27 25.4791 3.49600 102.40 7.37 28 26.2265 3.39805 188.29 13.55 29 26.7367 3.33436 346.69 24.95 Petition 870250101903, dated 06 / 11 / 2025, p. 57 / 230 53 / 175 30 27.7251 3.21769 68.09 4.90 31 28.1086 3.17466 153.39 11.04 32 29.3312 3.04505 87.26 6.28 33 30.2210 2.95739 67.79 4.88 34 32.4755 2.75705 34.32 2.47 35 33.4594 2.67820 50.98 3.67 Compound A 6 Free Base Standard

[0258] In some embodiments, the present disclosure provides solid forms of Compound A, for example, crystalline forms of the freebase Standard 6 of Compound A. In some embodiments, the XRPD profile of the freebase Standard 6 of Compound A is substantially similar to that shown in FIG. 91. In some embodiments, the FT-IR spectrum of the freebase Standard 6 of Compound A is substantially similar to that shown in FIG. 48. In some embodiments, the NMR spectrum of the freebase 1H Standard 6 of Compound A is substantially similar to that shown in FIG. 66. In some embodiments, the TGA profile of the freebase Standard 6 of Compound A is substantially similar to that shown in FIG. 47 or FIG. 65. In some embodiments, the DSC profile of the freebase Standard 6 of Compound A is substantially similar to that shown in FIG. 47 or FIG. 65.

[0259] In some embodiments, the solid form of the freebase Pattern 6 of Compound A is the crystalline freebase Pattern 6 of Compound A characterized by two or three XRPD signals selected from the group consisting of 3.5°2θ, 3.6°2θ and 15.7°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 6 of Compound A is the crystalline freebase Pattern 6 of Compound A characterized by XRPD signals at 3.5°2θ, 3.6°2θ and 15.7°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0260] In some forms, the solid form of the freebase Pattern 6 of Petition 870250101903, dated 06 / 11 / 2025, page 58 / 230 54 / 175 Compound A is the freebase Pattern 6 of crystalline Compound A characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.5°2θ, 3.6°2θ, 15.7°2θ, 18.9°2θ and 23.7°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 6 of Compound A is the crystalline freebase Pattern 6 of Compound A characterized by XRPD signals at 3.5°2θ, 3.6°2θ, 15.7°2θ, 18.9°2θ and 23.7°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu Ko1 radiation).

[0261] In some embodiments, the solid form of the Compound A freebase Pattern 6 is the crystalline Compound A freebase Pattern 6 characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.5°2θ, 3.6°2θ, 15.7°2θ, 18.9°2θ, 23.7°2θ, 16.2°2θ and 19.7°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu radiation to1). In some embodiments, the solid form of the freebase Pattern 6 of Compound A is the crystalline freebase Pattern 6 of Compound A characterized by XRPD signals at 3.5°2θ, 3.6°2θ, 15.7°2θ, 18.9°2θ, 23.7°2θ, 16.2°2θ and 19.7°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0262] In some embodiments, the solid form of the Compound A freebase Pattern 6 is the crystalline Compound A freebase Pattern 6 characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.5°2θ, 3.6°2θ, 15.7°2θ, 18.9°2θ, 23.7°2θ, 16.2°2θ, 19.7°2θ, 14.6°2θ, 18.6°2θ and 15.1°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 6 of Compound A is the crystalline freebase Pattern 6 of Compound A characterized by XRPD signals at 3.5°2θ, 3.6°2θ, 15.7°2θ, 18.9°2θ, 23.7°2θ, 16.2°2θ, 19.7°2θ, 14.6°2θ, 18.6°2θ and 15.1°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0263] In some embodiments, the free base Pattern 6 of crystalline Compound A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, Petition 870250101903, dated 06 / 11 / 2025, page 59 / 230 55 / 175 twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five or thirty-six XRPD signals selected from those set out in Table 6. Table 6: Peak XRPD table of the Freebase Standard 6 No. Pos. [°2θ] spacing d [Â] Height [cts] King. Int. [%] 1 3.4705 25.45949 1679.19 100 2 3.5648 24.78610 1608.67 95.80 3 5.2888 16.70955 105.77 6.30 4 6.2078 14.23787 274.03 16.32 5 6.9912 12.64407 68.31 4.07 6 8.6470 10.22631 75.89 4.52 7 9.9575 8.88317 93.78 5.58 8 10.7047 8.26472 201.20 11.98 9 11.4467 7.73062 124.96 7.44 10 12.0019 7.37421 132.67 7.90 11 12.4318 7.12015 204.83 12.20 12 12.9909 6.81498 303.98 18.10 13 13.3689 6.62311 150.21 8.95 14 14.1081 6.27769 282.11 16.80 15 14.3720 6.16303 454.21 27.05 16 14.5990 6.06768 546.02 32.52 17 15.0957 5.86916 483.71 28.81 18 15.7250 5.63567 1415.14 84.27 19 16.1687 5.48200 772.23 45.99 20 16.8342 5.26674 216.30 12.88 21 18.6367 4.76123 530.46 31.59 Petition 870250101903, dated 06 / 11 / 2025, p. 60 / 230 56 / 175 22 18.9323 4.68756 1027.73 61.20 23 19.3543 4.58628 442.11 26.33 24 19.6714 4.51305 757.73 45.12 25 21.0474 4.22101 448.20 26.69 26 21.8493 4.06788 446.56 26.59 27 23.0355 3.86103 280.34 16.69 28 23.6761 3.75799 980.03 58.36 29 24.5613 3.62452 326.92 19.47 30 25.1952 3.53475 231.17 13.77 31 26.0205 3.42448 214.65 12.78 32 27.6762 3.22326 167.57 9.98 33 28.5253 3.12922 147.44 8.78 34 29.0560 3.07326 238.55 14.21 35 31.5100 2.83929 59.23 3.53 36 32.4043 2.76295 49.20 2.93 Compound A 7 Free Base Standard

[0264] In some embodiments, the present disclosure provides solid forms of Compound A, for example, crystalline forms of the freebase Standard 7 of Compound A. In some embodiments, the XRPD profile of the freebase Standard 7 of Compound A is substantially similar to that shown in FIG. 92.

[0265] In some embodiments, the solid form of the freebase Pattern 7 of Compound A is the crystalline freebase Pattern 7 of Compound A characterized by two or three XRPD signals selected from the group consisting of 4.8°2θ, 15.7°2θ and 17.9°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 7 of Compound A is the crystalline freebase Pattern 7 of Compound A characterized by XRPD signals at 4.8°2θ, 15.7°2θ and 17.9°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). Petition 870250101903, dated 06 / 11 / 2025, page 61 / 230 57 / 175

[0266] In some embodiments, the solid form of the Compound A freebase Pattern 7 is the crystalline Compound A freebase Pattern 7 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.8°2θ, 15.7°2θ, 17.9°2θ, 16.0°2θ and 17.4°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu radiation to1). In some embodiments, the solid form of the freebase Pattern 7 of Compound A is the crystalline freebase Pattern 7 of Compound A characterized by XRPD signals at 4.8°2θ, 15.7°2θ, 17.9°2θ, 16.0°2θ and 17.4°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0267] In some embodiments, the solid form of the Compound A freebase Pattern 7 is the crystalline Compound A freebase Pattern 7 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.8°2θ, 15.7°2θ, 17.9°2θ, 16.0°2θ, 17.4°2θ, 15.0°2θ and 22.7°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 7 of Compound A is the crystalline freebase Pattern 7 of Compound A characterized by XRPD signals at 4.8°2θ, 15.7°2θ, 17.9°2θ, 16.0°2θ, 17.4°2θ, 15.0°2θ and 22.7°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0268] In some embodiments, the solid form of the Compound A freebase Pattern 7 is the crystalline Compound A freebase Pattern 7 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.8°2θ, 15.7°2θ, 17.9°2θ, 16.0°2θ, 17.4°2θ, 15.0°2θ, 22.7°2θ, 9.2°2θ, 16.4°2θ and 7.1°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the Compound A freebase Pattern 7 is the crystalline Compound A freebase Pattern 7 characterized by XRPD signals at 4.8°2θ, 15.7°2θ, 17.9°2θ, 16.0°2θ, 17.4°2θ, 15.0°2θ, 22.7°2θ, 9.2°2θ, 16.4°2θ and 7.1°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu Ko1 radiation).

[0269] In some embodiments, the free base Pattern 7 of crystalline Compound A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, Petition 870250101903, dated 06 / 11 / 2025, page 62 / 230 58 / 175 eleven, twelve, thirteen, fourteen, fifteen or sixteen XRPD signals selected from those set out in Table 7. Table 7: Peak XRPD table of the Freebase Standard 7 No. Pos. [°2θ] spacing d [Â] Height [cts] King. Int. [%] 1 4.7846 18.46937 555.74 100 2 7.1460 12.37051 116.68 21.00 3 9.1907 9.62255 166.56 29.97 4 10.8425 8.15997 47.31 8.51 5 12.5754 7.03915 84.85 15.27 6 14.9522 5.92513 187.84 33.80 7 15.7216 5.63688 337.17 60.67 8 16.0360 5.52707 232.80 41.89 9 16.4450 5.39049 147.58 26.56 10 17.4437 5.08406 190.93 34.36 11 17.9433 4.94364 259.48 46.69 12 20.6178 4.30800 90.81 16.34 13 21.2453 4.18214 95.70 17.22 14 22.6860 3.91971 183.18 32.96 15 24.3570 3.65445 85.43 15.37 16 26.8207 3.32410 43.24 7.78 Compound A 8 Free Base Standard

[0270] In some embodiments, the present disclosure provides solid forms of Compound A, for example, crystalline forms of the freebase Standard 8 of Compound A. In some embodiments, the XRPD profile of the freebase Standard 8 of Compound A is substantially similar to that shown in FIG. 93. In some embodiments, the FT-IR spectrum of the freebase Standard 8 of Compound A is substantially similar to that shown in FIG. 52 or FIG. 53. In some Petition 870250101903, dated 06 / 11 / 2025, p. 63 / 230 In 59 / 175 embodiments, the TGA profile of the freebase Pattern 8 of Compound A is substantially similar to that shown in FIG. 49, FIG. 50 or FIG. 51. In some embodiments, the DSC profile of the freebase Pattern 8 of Compound A is substantially similar to that shown in FIG. 49, FIG. 50 or FIG. 51.

[0271] In some embodiments, the solid form of the freebase Pattern 8 of Compound A is the crystalline freebase Pattern 8 of Compound A characterized by two or three XRPD signals selected from the group consisting of 4.9°2θ, 15.9°2θ and 18.2°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 8 of Compound A is the crystalline freebase Pattern 8 of Compound A characterized by XRPD signals at 4.9°2θ, 15.9°2θ and 18.2°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0272] In some embodiments, the solid form of the Compound A freebase Pattern 8 is the crystalline Compound A freebase Pattern 8 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.9°2θ, 15.9°2θ, 18.2°2θ, 9.3°2θ and 17.4°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 8 of Compound A is the crystalline freebase Pattern 8 of Compound A characterized by XRPD signals at 4.9°2θ, 15.9°2θ, 18.2°2θ, 9.3°2θ and 17.4°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu Ko1 radiation).

[0273] In some embodiments, the solid form of the Compound A freebase Pattern 8 is the crystalline Compound A freebase Pattern 8 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.9°2θ, 15.9°2θ, 18.2°2θ, 9.3°2θ, 17.4°2θ, 16.7°2θ and 23.3°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu radiation to1). In some embodiments, the solid form of the freebase Pattern 8 of Compound A is the crystalline freebase Pattern 8 of Compound A characterized by XRPD signals at 4.9°2θ, 15.9°2θ, 18.2°2θ, 9.3°2θ, 17.4°2θ, 16.7°2θ and 23.3°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). Petition 870250101903, dated 06 / 11 / 2025, page 64 / 230 60 / 175

[0274] In some embodiments, the solid form of the Compound A freebase Pattern 8 is the crystalline Compound A freebase Pattern 8 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.9°2θ, 15.9°2θ, 18.2°2θ, 9.3°2θ, 17.4°2θ, 16.7°2θ, 23.3°2θ, 12.8°2θ, 18.7°2θ and 21.8°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 8 of Compound A is the crystalline freebase Pattern 8 of Compound A characterized by XRPD signals at 4.9°2θ, 15.9°2θ, 18.2°2θ, 9.3°2θ, 17.4°2θ, 16.7°2θ, 23.3°2θ, 12.8°2θ, 18.7°2θ and 21.8°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0275] In some embodiments, the freebase Pattern 8 of crystalline Compound A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, or twenty-two XRPD signals selected from those set forth in Table 8. Table 8: Peak XRPD table of the Freebase Standard 8 No. Pos. [°2θ] spacing d [Â] Height [cts] King. Int. [%] 1 4.9271 17.93558 1408.55 100 2 7.3721 11.99163 201.90 14.33 3 8.2925 10.66268 123.26 8.75 4 9.3164 9.49295 452.53 32.13 5 9.8468 8.98276 101.69 7.22 6 11.0294 8.02213 75.81 5.38 7 12.8200 6.90543 243.26 17.27 8 13.8335 6.40170 127.75 9.07 9 15.4236 5.74510 158.30 11.24 10 15.9237 5.56579 755.83 53.66 11 16.6601 5.32140 319.47 22.68 Petition 870250101903, dated 06 / 11 / 2025, page 65 / 230 61 / 175 12 17.3530 5.11043 433.99 30.81 13 18.2047 4.87323 536.78 38.11 14 18.6651 4.75406 221.38 15.72 15 19.7961 4.48491 76.21 5.41 16 21.7500 4.08623 211.02 14.98 17 22.3220 3.98281 180.80 12.84 18 23.2977 3.81816 252.51 17.93 19 25.1152 3.54582 180.34 12.80 20 25.9684 3.43123 119.03 8.45 21 26.8884 3.31588 59.74 4.24 22 29.7854 2.99964 31.67 2.25 Compound A 9 Free Base Standard

[0276] In some embodiments, the present disclosure provides solid forms of Compound A, for example, crystalline forms of the freebase Standard 9 of Compound A. In some embodiments, the XRPD profile of the freebase Standard 9 of Compound A is substantially similar to that shown in FIG. 94. In some embodiments, the TGA profile of the freebase Standard 9 of Compound A is substantially similar to that shown in FIG. 35. In some embodiments, the DSC profile of the freebase Standard 9 of Compound A is substantially similar to that shown in FIG. 35.

[0277] In some embodiments, the solid form of the freebase Pattern 9 of Compound A is the crystalline freebase Pattern 9 of Compound A characterized by two or three XRPD signals selected from the group consisting of 17.2°2θ, 21.0°2θ and 24.2°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 9 of Compound A is the crystalline freebase Pattern 9 of Compound A characterized by XRPD signals at 17.2°2θ, 21.0°2θ and 24.2°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). Petition 870250101903, dated 06 / 11 / 2025, page 66 / 230 62 / 175

[0278] In some embodiments, the solid form of the Compound A freebase Pattern 9 is the crystalline Compound A freebase Pattern 9 characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.2°2θ, 21.0°2θ, 24.2°2θ, 17.8°2θ and 19.8°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu radiation to1). In some embodiments, the solid form of the freebase Pattern 9 of Compound A is the crystalline freebase Pattern 9 of Compound A characterized by XRPD signals at 17.2°2θ, 21.0°2θ, 24.2°2θ, 17.8°2θ and 19.8°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0279] In some embodiments, the solid form of the Compound A freebase Pattern 9 is the crystalline Compound A freebase Pattern 9 characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.2°2θ, 21.0°2θ, 24.2°2θ, 17.8°2θ, 19.8°2θ, 5.3°2θ and 21.5°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 9 of Compound A is the crystalline freebase Pattern 9 of Compound A characterized by XRPD signals at 17.2°2θ, 21.0°2θ, 24.2°2θ, 17.8°2θ, 19.8°2θ, 5.3°2θ and 21.5°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0280] In some embodiments, the solid form of the Compound A freebase Pattern 9 is the crystalline Compound A freebase Pattern 9 characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.2°2θ, 21.0°2θ, 24.2°2θ, 17.8°2θ, 19.8°2θ, 5.3°2θ, 21.5°2θ, 18.9°2θ, 15.9°2θ and 21.9°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of the freebase Pattern 9 of Compound A is the crystalline freebase Pattern 9 of Compound A characterized by XRPD signals at 17.2°2θ, 21.0°2θ, 24.2°2θ, 17.8°2θ, 19.8°2θ, 5.3°2θ, 21.5°2θ, 18.9°2θ, 15.9°2θ and 21.9°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0281] In some embodiments, the free base Pattern 9 of crystalline Compound A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, Petition 870250101903, dated 06 / 11 / 2025, page 67 / 230 63 / 175 eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, or forty-two XRPD signals selected from those set out in Table 9. Table 9: Peak XRPD table of the Freebase Standard 9 No. Pos. [°2θ] spacing d [Â] Height [cts] King. Int. [%] 1 5.2587 16.80532 992.19 66.02 2 7.5444 11.71813 324.36 21.58 3 8.7729 10.07985 78.14 5.20 4 9.4016 9.40715 58.15 3.87 5 10.3019 8.58699 100.94 6.72 6 12.1271 7.29836 195.38 13.00 7 12.4455 7.11233 232.02 15.44 8 13.8319 6.40244 350.20 23.30 9 14.6420 6.04999 651.41 43.35 10 15.1567 5.84565 464.66 30.92 11 15.4935 5.71936 551.68 36.71 12 15.9189 5.56745 780.38 51.93 13 16.2899 5.44147 667.44 44.41 14 16.7350 5.29773 698.90 46.51 15 17.2001 5.155552 1502.83 100 16 17.7980 4.98364 1172.54 78.02 17 18.1364 4.89143 543.12 36.14 18 18.4086 4.81971 649.76 43.24 19 18.8565 4.70623 925.93 61.61 Petition 870250101903, dated 06 / 11 / 2025, p. 68 / 230 64 / 175 20 19.3271 4.59267 419.40 27.91 21 19.8046 4.48301 1046.15 69.61 22 20.1561 4.40561 455.07 30.28 23 20.5053 4.33137 448.81 29.86 24 21.0399 4.22251 1316.04 87.57 25 21.5464 4.12439 964.82 64.20 26 21.9024 4.05814 747.69 49.75 27 22.2780 3.99056 583.12 38.80 28 22.4942 3.95270 357.81 23.81 29 22.9214 3.87999 341.68 22.74 30 23.2816 3.82077 371.69 24.73 31 23.9028 3.72286 597.05 39.73 32 24.2477 3.67069 1187.96 79.05 33 25.0625 3.55316 279.90 18.62 34 25.4298 3.50267 344.69 22.94 35 26.3415 3.38347 190.53 12.68 36 26.5879 3.35267 147.05 9.78 37 27.1133 3.28889 68.60 4.56 38 27.8973 3.19821 115.46 7.68 39 28.6140 3.11972 72.51 4.82 40 30.2340 2.95615 343.46 22.85 41 30.8780 2.89595 204.79 13.63 42 33.1838 2.69980 111.90 7.45 Standard 1 Tosylate Compound A

[0282] In some embodiments, the present disclosure provides solid forms of Compound A, for example, crystalline forms of the tosylate Standard 1 of Compound A. In some embodiments, the XRPD profile of the tosylate Standard 1 of Petition 870250101903, dated 06 / 11 / 2025, page 69 / 230 65 / 175 Compound A is substantially similar to that shown in FIG. 95. In some embodiments, the FT-IR spectrum of Compound A's tosylate Standard 1 is substantially similar to that shown in FIG. 17. In some embodiments, the NMR spectrum of Compound A's 11H tosylate Standard is substantially similar to that shown in FIG. 19 or FIG. 68. In some embodiments, the TGA profile of Compound A's tosylate Standard 1 is substantially similar to that shown in FIG. 18 or FIG. 69. In some embodiments, the DSC profile of Compound A's tosylate Standard 1 is substantially similar to that shown in FIG. 18 or FIG. 69.

[0283] In some embodiments, the solid form of Compound A tosylate Pattern 1 is the crystalline Compound A tosylate Pattern 1 characterized by two or three XRPD signals selected from the group consisting of 3.5°2θ, 22.0°2θ and 23.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of Compound A tosylate Pattern 1 is the crystalline Compound A tosylate Pattern 1 characterized by XRPD signals at 3.5°2θ, 22.0°2θ and 23.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0284] In some embodiments, the solid form of Compound A tosylate Pattern 1 is the crystalline Compound A tosylate Pattern 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.5°2θ, 22.0°2θ, 23.0°2θ, 21.7°2θ and 7.2°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of Compound A tosylate Standard 1 is the crystalline Compound A tosylate Standard 1 characterized by XRPD signals at 3.5°2θ, 22.0°2θ, 23.0°2θ, 21.7°2θ and 7.2°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0285] In some embodiments, the solid form of Compound A tosylate Standard 1 is the crystalline Compound A tosylate Standard 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 3,5 Petition 870250101903, dated 06 / 11 / 2025, page 70 / 230 66 / 175 °2θ, 22.0°2θ, 23.0°2θ, 21.7°2θ, 7.2°2θ, 21.0 °2θ and 14.7 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Κα1 radiation). In some embodiments, the solid form of Compound A tosylate Standard 1 is the crystalline Compound A tosylate Standard 1 characterized by XRPD signals at 3.5°2θ, 22.0°2θ, 23.0°2θ, 21.7°2θ, 7.2°2θ, 21.0°2θ and 14.7°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0286] In some embodiments, the solid form of Compound A tosylate Pattern 1 is the crystalline Compound A tosylate Pattern 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.5°2θ, 22.0°2θ, 23.0°2θ, 21.7°2θ, 7.2°2θ, 21.0°2θ, 14.7°2θ, 10.7°2θ, 12.7°2θ and 18.4°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of Compound A tosylate Standard 1 is the crystalline Compound A tosylate Standard 1 characterized by XRPD signals at 3.5°2θ, 22.0°2θ, 23.0°2θ, 21.7°2θ, 7.2°2θ, 21.0°2θ, 14.7°2θ, 10.7°2θ, 12.7°2θ and 18.4°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0287] In some embodiments, the tosylate Pattern 1 of crystalline Compound A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen XRPD signals selected from those set forth in Table 10. Table 10: Peak XRPD table for Tosylate Standard 1 No. Pos. [°2θ] spacing d [Â] Height [cts] King. Int. [%] 1 3.4707 25.45815 436.59 100 2 7.1537 12.35734 312.20 71.51 3 10.7124 8.25880 220.78 50.57 4 12.6695 6.98713 204.28 46.79 5 14.6897 6.03044 226.52 51.88 6 17.3482 5.11185 104.42 23.92 7 18.3591 4.83257 113.92 26.09 Petition 870250101903, dated 06 / 11 / 2025, page 71 / 230 67 / 175 8 21.0208 4.22631 311.07 71.25 9 21.7151 4.09273 327.09 74.92 10 22.0225 4.03629 429.59 98.40 11 22.9548 3.87442 329.26 75.42 12 24.2064 3.67685 102.00 23.36 13 27.8589 3.20254 35.48 8.13 Standard 1 Phosphate Compound A

[0288] In some embodiments, the present disclosure provides solid forms of Compound A, for example, crystalline forms of the phosphate Standard 1 of Compound A. In some embodiments, the XRPD profile of the phosphate Standard 1 of Compound A is substantially similar to that shown in FIG. 96. In some embodiments, the FT-IR spectrum of the phosphate Standard 1 of Compound A is substantially similar to that shown in FIG. 23. In some embodiments, the NMR spectrum of the 11H phosphate Standard of Compound A is substantially similar to that shown in FIG. 25 or FIG. 72. In some embodiments, the 31P NMR spectrum of the phosphate Standard 1 of Compound A is substantially similar to that shown in FIG. 26 or FIG. 73. In some embodiments, the TGA profile of the phosphate Standard 1 of Compound A is substantially similar to that shown in FIG. 24 or FIG. 74. In some embodiments, the DSC profile of Compound A phosphate Standard 1 is substantially similar to that shown in FIG. 24 or FIG. 74.

[0289] In some embodiments, the solid form of Compound A phosphate Standard 1 is the crystalline phosphate Standard 1 of Compound A characterized by two or three XRPD signals selected from the group consisting of 23.6°2θ, 3.3°2θ and 19.9°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of Compound A phosphate Standard 1 is the crystalline phosphate Standard 1 of Compound A characterized by XRPD signals at 23.6°2θ, 3.3°2θ and 19.9°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). Petition 870250101903, dated 06 / 11 / 2025, page 72 / 230 68 / 175

[0290] In some embodiments, the solid form of Compound A phosphate Standard 1 is the crystalline phosphate Standard 1 of Compound A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6°2θ, 3.3°2θ, 19.9°2θ, 14.6°2θ and 18.4°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of Compound A phosphate Standard 1 is the crystalline phosphate Standard 1 of Compound A characterized by XRPD signals at 23.6°2θ, 3.3°2θ, 19.9°2θ, 14.6°2θ and 18.4°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0291] In some embodiments, the solid form of Compound A phosphate Standard 1 is the crystalline phosphate Standard 1 of Compound A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6°2θ, 3.3°2θ, 19.9°2θ, 14.6°2θ, 18.4°2θ, 20.6°2θ and 16.1°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu radiation to1). In some embodiments, the solid form of Compound A phosphate Standard 1 is the crystalline phosphate Standard 1 of Compound A characterized by XRPD signals at 23.6°2θ, 3.3°2θ, 19.9°2θ, 14.6°2θ, 18.4°2θ, 20.6°2θ and 16.1°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0292] In some embodiments, the solid form of Compound A phosphate Standard 1 is the crystalline phosphate Standard 1 of Compound A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6°2θ, 3.3°2θ, 19.9°2θ, 14.6°2θ, 18.4°2θ, 20.6°2θ, 16.1°2θ, 11.9°2θ, 5.0°2θ and 10.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of Compound A phosphate Standard 1 is the crystalline phosphate Standard 1 of Compound A characterized by XRPD signals at 23.6°2θ, 3.3°2θ, 19.9°2θ, 14.6°2θ, 18.4°2θ, 20.6°2θ, 16.1°2θ, 11.9°2θ, 5.0°2θ and 10.0°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0293] In some embodiments, the crystalline phosphate Pattern 1 of Compound A is characterized by one, two, three, four, five, six, seven, eight, nine, Petition 870250101903, dated 06 / 11 / 2025, page 73 / 230 69 / 175 ten, eleven, twelve, thirteen or fourteen XRPD signals selected from those set out in Table 11. Table 11: XRPD peak table of phosphate Standard 1 No. Pos. [°2θ] spacing d [Â] Height [cts] King. Int. [%] 1 3.3199 26.61348 537.58 75.81 2 4.9733 17.76900 218.73 30.85 3 6.6513 13.28944 33.29 4.69 4 8.2888 10.66739 82.56 11.64 5 9.9769 8.86592 178.25 25.14 6 11.8812 7.44884 236.08 33.29 7 12.8688 6.87934 155.37 21.91 8 14.5722 6.07880 371.13 52.34 9 16.0609 5.51856 244.72 34.51 10 18.4101 4.81932 278.09 39.22 11 19.9435 4.45209 411.94 58.09 12 20.6004 4.31158 265.54 37.45 13 23.5976 3.77031 709.09 100 14 26.0194 3.42462 120.54 17.00 Standard 1 of Compound A Besylate

[0294] In some embodiments, the present disclosure provides solid forms of Compound A, for example, crystalline forms of Compound A besylate Standard 1. In some embodiments, the XRPD profile of Compound A besylate Standard 1 is substantially similar to that shown in FIG. 97. In some embodiments, the FT-IR spectrum of Compound A besylate Standard 1 is substantially similar to that shown in FIG. 20. In some embodiments, the NMR spectrum of Compound A besylate Standard 1 is substantially similar to that shown in FIG. 22 or FIG. 70. In some embodiments, the profile of Petition 870250101903, dated 06 / 11 / 2025, p. 74 / 230 70 / 175 The TGA of Compound A besylate Standard 1 is substantially similar to that shown in FIG. 21 or FIG. 71. In some embodiments, the DSC profile of Compound A besylate Standard 1 is substantially similar to that shown in FIG. 21 or FIG. 71.

[0295] In some embodiments, the solid form of Compound A besylate Standard 1 is the crystalline Compound A besylate Standard 1 characterized by two or three XRPD signals selected from the group consisting of 18.5°2θ, 18.3°2θ and 22.6°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of Compound A besylate Standard 1 is the crystalline Compound A besylate Standard 1 characterized by XRPD signals at 18.5°2θ, 18.3°2θ and 22.6°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0296] In some embodiments, the solid form of Compound A besylate Standard 1 is the crystalline Compound A besylate Standard 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.5°2θ, 18.3°2θ, 22.6°2θ, 11.1°2θ and 14.6°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of Compound A besylate Standard 1 is the crystalline Compound A besylate Standard 1 characterized by XRPD signals at 18.5°2θ, 18.3°2θ, 22.6°2θ, 11.1°2θ and 14.6°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0297] In some embodiments, the solid form of Compound A besylate Standard 1 is the crystalline Compound A besylate Standard 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.5°2θ, 18.3°2θ, 22.6°2θ, 11.1°2θ, 14.6°2θ, 23.5°2θ and 13.3°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu radiation to1). In some embodiments, the solid form of Compound A besylate Standard 1 is the crystalline Compound A besylate Standard 1 characterized by XRPD signals at 18.5°2θ, 18.3°2θ, 22.6°2θ, 11.1°2θ, 14.6°2θ, 23.5°2θ and 13.3°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). Petition 870250101903, dated 06 / 11 / 2025, page 75 / 230 71 / 175

[0298] In some embodiments, the solid form of Compound A besylate Standard 1 is the crystalline Compound A besylate Standard 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.5°2θ, 18.3°2θ, 22.6°2θ, 11.1°2θ, 14.6°2θ, 23.5°2θ, 13.3°2θ, 11.3°2θ, 17.8°2θ and 4.8°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation). In some embodiments, the solid form of Compound A besylate Standard 1 is the crystalline Compound A besylate Standard 1 characterized by XRPD signals at 18.5°2θ, 18.3°2θ, 22.6°2θ, 11.1°2θ, 14.6°2θ, 23.5°2θ, 13.3°2θ, 11.3°2θ, 17.8°2θ and 4.8°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu^1 radiation).

[0299] In some embodiments, the besylate Standard 1 of crystalline Compound A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine or thirty XRPD signals selected from those set forth in Table 12. Table 12: Peak XRPD table for Besylate Standard 1 No. Pos. [°2θ] spacing d [Â] Height [cts] King. Int. [%] 1 3.2079 27.54304 165.64 10.55 2 4.8192 18.33697 559.47 35.65 3 6.3869 13.83909 31.40 2.00 4 9.6657 9.15070 163.56 10.42 5 11.1338 7.94716 936.62 59.68 6 11.3464 7.79870 607.64 38.72 7 11.8678 7.45723 462.85 29.49 8 12.4881 7.08821 339.69 21.64 9 13.1324 6.74183 508.82 32.42 10 13.3327 6.64101 619.35 39.46 Petition 870250101903, dated 06 / 11 / 2025, page 76 / 230 72 / 175 11 14.5689 6.08018 929.90 59.25 12 14.8502 5.96561 349.60 22.28 13 15.4179 5.74723 245.36 15.63 14 16.1567 5.48604 383.37 24.43 15 16.7843 5.28228 164.80 10.50 16 17.7518 4.99651 570.62 36.36 17 18.2687 4.85629 1306.02 83.22 18 18.5421 4.78529 1569.44 100 19 19.3548 4.58616 423.95 27.01 20 19.8401 4.47507 220.93 14.08 21 20.2426 4.38699 250.20 15.94 22 20.7061 4.28981 207.10 13.20 23 22.3403 3.97958 460.24 29.33 24 22.5739 3.93893 1209.04 77.04 25 23.4851 3.78811 679.64 43.30 26 24.7073 3.60343 407.06 25.94 27 26.0343 3.42269 226.70 14.44 28 26.8719 3.31788 457.13 29.13 29 28.2913 3.15456 137.28 8.75 30 31.4664 2.84313 65.23 4.16 Ubiquitination / degradation methods for a target protein in a cell.

[0300] This disclosure provides a method for ubiquitinating / degrading a target protein in a cell.

[0301] In some embodiments, the method comprises administering a solid form of the Disclosure Compound A or a salt form of the Disclosure Compound A, wherein Compound A is a bifunctional compound comprising an E3 ubiquitin ligase-binding moiety and a protein-targeting moiety. Petition 870250101903, dated 06 / 11 / 2025, p. 77 / 230 73 / 175 linked through a bonding fraction.

[0302] In some embodiments, the E3 ubiquitin ligase-binding fraction is coupled to the protein-targeting fraction, wherein the E3 ubiquitin ligase-binding fraction recognizes a protein of the ubiquitin pathway (e.g., a ubiquitin ligase, preferably an E3 ubiquitin ligase) and the protein-targeting fraction recognizes the target protein, such that degradation of the target protein occurs when the target protein is placed in proximity to the ubiquitin ligase, thus resulting in degradation / inhibition of the target protein's effects and control of protein levels. The control of protein levels provided by this disclosure offers treatment of a disease state or condition, which is modulated through the target protein, by decreasing the level of that protein in a patient's cells.

[0303] In some embodiments, this application provides a solid form of Disclosure Compound A or a salt form of Disclosure Compound A that degrades androgen receptor (AR) protein.

[0304] In some embodiments, the present disclosure is directed to a method of treating a patient in need of a disease state or condition modulated by a protein wherein the degradation of that protein will produce a therapeutic effect in that patient, the method comprising administering to a patient in need an effective amount of a solid form of Compound A of the disclosure or a salt form of Compound A of the disclosure, optionally in combination with another anticancer agent. The disease state or condition may be a disease caused by the overexpression of a protein, which leads to a disease state and / or condition. Treatment Methods

[0305] In one aspect, the present application relates to a method of treating and / or preventing cancer comprising administering to a subject in Petition 870250101903, dated 06 / 11 / 2025, p. 78 / 230 74 / 175 need for the same a therapeutically effective quantity of a solid form of Compound A of the disclosure or a salt form of Compound A of the disclosure.

[0306] In one aspect, the present application relates to a method of treating and / or preventing cancer comprising administering to a subject in need thereof a therapeutically effective amount of a solid form of the Disclosure Compound A or a salt form of the Disclosure Compound A, in combination with one or more additional anticancer agents.

[0307] The cancer treatment methods described in this document result in a reduction in tumor size. Alternatively, or additionally, the cancer is metastatic cancer and this treatment method includes inhibiting the invasion of metastatic cancer cells.

[0308] In some forms, the cancer is prostate cancer.

[0309] In some forms, the cancer is metastatic prostate cancer.

[0310] In some forms, the cancer is castration-resistant prostate cancer.

[0311] In some forms, the cancer is metastatic castration-resistant prostate cancer (mCRPC).

[0312] In some forms, prostate cancer is castration-sensitive prostate cancer.

[0313] In some forms, prostate cancer is metastatic castration-sensitive prostate cancer.

[0314] In some forms, prostate cancer is naive to new hormonal agents (NHA).

[0315] In some forms, prostate cancer is metastatic prostate cancer not exposed to new hormonal agents (NHA).

[0316] In some forms, prostate cancer is castration-resistant prostate cancer not exposed to new hormonal agents (NHA). Petition 870250101903, dated 06 / 11 / 2025, page 79 / 230 75 / 175

[0317] In some forms, prostate cancer is castration-sensitive prostate cancer not exposed to new hormonal agents (NHA).

[0318] In some forms, prostate cancer is metastatic castration-resistant prostate cancer not exposed to new hormonal agents (NHA).

[0319] In some forms, prostate cancer is metastatic castration-sensitive prostate cancer not exposed to new hormonal agents (NHA).

[0320] In some modalities, prostate cancer is not naive to new hormone-resistant prostate cancer (NHA). In some modalities, prostate cancer that is not naive to new hormone-resistant prostate cancer (NHA) is also metastatic prostate cancer, castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, castration-sensitive prostate cancer, or metastatic castration-sensitive prostate cancer.

[0321] In one aspect, the application relates to the treatment of prostate cancer with a solid form of Disclosure Compound A or a salt form of Disclosure Compound A in combination with another anticancer agent.In some embodiments, prostate cancer treated with the combination of a solid form of Disclosure Compound A or a salt form of Disclosure Compound A and another anticancer agent is metastatic prostate cancer, castration-resistant prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), castration-sensitive prostate cancer, metastatic castration-sensitive prostate cancer, hormone-naive prostate cancer (NHA), metastatic hormone-naive prostate cancer (NHA), castration-resistant prostate cancer (NHA), castration-sensitive prostate cancer (NHA), metastatic hormone-naive castration-resistant prostate cancer (NHA), metastatic hormone-naive castration-resistant prostate cancer (NHA), or cancer. Petition 870250101903, dated 06 / 11 / 2025, page 80 / 230 76 / 175 metastatic castration-sensitive prostate naive to new hormonal agents (NHA).

[0322] In some embodiments, prostate cancer treated with the combination of a solid form of Disclosure Compound A or a salt form of Disclosure Compound A and another anticancer agent is not prostate cancer naive to new hormonal agents (NHA). In some embodiments, prostate cancer that is not prostate cancer naive to new hormonal agents (NHA) is also metastatic prostate cancer, castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, castration-sensitive prostate cancer, or metastatic castration-sensitive prostate cancer.

[0323] In some embodiments, the other anticancer agent is abiraterone, estramustine, docetaxel, ketoconazole, goserelin, histrelin, triptorelin, buserelin, cyproterone, flutamide, bicalutamide, nilutamide, pamidronate, zoledronate or a pharmaceutically acceptable salt thereof.

[0324] In some modalities, cancer treatment results in a reduction in the size of a tumor. A reduction in the size of a tumor may also be referred to as tumor regression. Preferably, after treatment, the size of the tumor is reduced by 5% or more compared to its size before treatment; more preferably, the size of the tumor is reduced by 10% or more; more preferably, reduced by 20% or more; more preferably, reduced by 30% or more; more preferably, reduced by 40% or more; even more preferably, reduced by 50% or more; and most preferably, reduced by more than 75% or more. The size of a tumor can be measured by any reproducible means of measurement. In a preferred aspect, the size of a tumor can be measured as a tumor diameter.

[0325] In some modalities, cancer treatment results in a reduction in tumor volume. Preferably, after treatment, the tumor volume is reduced by 5% or more compared to its volume before treatment; more Petition 870250101903, dated 06 / 11 / 2025, page 81 / 230 77 / 175 preferably, the tumor volume is reduced by 10% or more; more preferably, reduced by 20% or more; more preferably, reduced by 30% or more; more preferably, reduced by 40% or more; even more preferably, reduced by 50% or more; and most preferably, reduced by more than 75%. The tumor volume can be measured by any reproducible measuring method.

[0326] In some modalities, cancer treatment results in a decrease in the number of tumors. Preferably, after treatment, the number of tumors is reduced by 5% or more compared to their number before treatment; more preferably, the number of tumors is reduced by 10% or more; more preferably, reduced by 20% or more; more preferably, reduced by 30% or more; more preferably, reduced by 40% or more; even more preferably, reduced by 50% or more; and most preferably, reduced by more than 75%. The number of tumors can be measured by any reproducible means of measurement. In a preferred aspect, the number of tumors can be measured by counting tumors visible to the naked eye or at a specified magnification. In some modalities, the specified magnification is 2x, 3x, 4x, 5x, 10x, or 50x.

[0327] In some modalities, cancer treatment results in a decrease in the number of metastatic lesions in other tissues or organs distant from the primary tumor site. Preferably, after treatment, the number of metastatic lesions is reduced by 5% or more compared to the number before treatment; more preferably, the number of metastatic lesions is reduced by 10% or more; more preferably, reduced by 20% or more; more preferably, reduced by 30% or more; more preferably, reduced by 40% or more; even more preferably, reduced by 50% or more; and most preferably, reduced by more than 75%. The number of metastatic lesions can be measured by any means. Petition 870250101903, dated 06 / 11 / 2025, page 82 / 230 78 / 175 reproducible measurement. In some modalities, the number of metastatic lesions can be measured by counting metastatic lesions visible to the naked eye or with a specified magnification. In some modalities, the specified magnification is 2x, 3x, 4x, 5x, 10x, or 50x.

[0328] In some modalities, cancer treatment results in an increase in the median survival time of a population of treated subjects compared with a population receiving carrier alone. Preferably, the median survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in the median survival time of a population can be measured by any reproducible means. In some modalities, an increase in the median survival time of a population can be measured, for example, by calculating for a population the median length of survival after the start of treatment with an active agent or compound of the disclosure.In some modalities, an increase in the average survival time of a population can also be measured, for example, by calculating for a population the average survival time after completion of a first round of treatment with an active agent or compound of the disclosure.

[0329] In some modalities, cancer treatment results in an increase in the median survival time of a population of treated subjects compared with a population of untreated subjects. Preferably, the median survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in the median survival time of a population can be measured by any reproducible means. In some modalities, an increase in the median survival time of a population can be measured by calculating for a population the median duration of survival after Petition 870250101903, dated 06 / 11 / 2025, page 83 / 230 79 / 175 the start of treatment with an active agent or disclosure compound. In some modalities, an increase in the median survival time of a population can be measured by calculating for a population the median survival time after completion of a first round of treatment with a disclosure compound.

[0330] In some modalities, cancer treatment results in a decrease in the tumor growth rate. Preferably, after treatment, the tumor growth rate is reduced by at least 5% compared to the growth rate before treatment; more preferably, the tumor growth rate is reduced by at least 10%; more preferably, reduced by at least 20%; more preferably, reduced by at least 30%; more preferably, reduced by at least 40%; more preferably, reduced by at least 50%; even more preferably, reduced by at least 50%; and most preferably, reduced by at least 75%. The tumor growth rate can be measured by any reproducible means of measurement. In some modalities, the tumor growth rate is measured according to a change in tumor diameter per unit of time.

[0331] In some modalities, cancer treatment results in a decrease in tumor regrowth. Preferably, after treatment, tumor regrowth is less than 5%; more preferably, tumor growth is less than 10%; most preferably, less than 20%; most preferably, less than 30%; most preferably, less than 40%; most preferably, less than 50%; even more preferably, less than 50%; and most preferably, less than 75%. Tumor regrowth can be measured by any reproducible measurement method. In some modalities, tumor regrowth is measured by measuring an increase in the diameter of a tumor after a previous tumor shrinkage that followed treatment. In some modalities, a decrease in tumor regrowth is indicated by the failure of Petition 870250101903, dated 06 / 11 / 2025, page 84 / 230 80 out of 175 tumors recur after treatment has stopped.

[0332] Dosages of the solid forms of Compound A disclosure or salt forms of Compound A disclosure for any of the methods and uses described in this document vary depending on the agent, the age, weight and clinical condition of the recipient subject, and the experience and judgment of the clinician or professional administering the therapy, among other factors affecting the dosage selected.

[0333] The therapeutically effective amount of the solid form of Compound A disclosure or the salt form of Compound A disclosure may be administered one or more times throughout the day for up to 30 or more days, followed by one or more days of non-administration of the compound. This type of treatment regimen, i.e., administration of the solid form of Compound A disclosure or the salt form of Compound A disclosure on consecutive days followed by non-administration of solid / saline forms on consecutive days, may be referred to as a treatment cycle. A treatment cycle may be repeated as many times as necessary to achieve the desired effect.

[0334] In some embodiments, the therapeutically effective amount of the solid form of Compound A of the disclosure or the salt form of Compound A of the disclosure is 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, Petition 870250101903, dated 06 / 11 / 2025, p. 85 / 230 81 / 175 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795, 800, 805, 810, 815, 820, 825, 830, 835, 840, 845, 850, 855, 860, 865, 870, 875, 880, 885, 890, 895, 900, 905, 910, 915, 920, 925, 930, 935, 940, 945, 950, 955, 960, 965, 970, 975, 980, 985, 990, 995, or 1,000 mg administered once, twice, three times, four times, or more daily for one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, twenty, twenty-five, thirty consecutive days, or once, twice, three times, four times or more daily, in single or divided doses, for 2 months, 3 months, 4 months, 5 months, 6 months or more.

[0335] In some embodiments, the therapeutically effective amount of the solid form of Compound A of the disclosure or the salt form of Compound A of the disclosure is about 10 to about 40 mg, about 20 to about 50 mg, about 30 to about 60 mg, about 40 to about 70 mg, about 50 to about 80 mg, about 60 to about 90 mg, about 70 to about 100 mg, about 80 to about 110 mg, about 90 to about 120 mg, about 100 to about 130 mg, about 110 to about 140 mg, about 120 to about 150 mg, about 130 to about 160 mg, about 140 to about 170 mg, about 150 to about 180 mg, about 160 to about 190 mg, about 170 to about 200 mg, about 180 to about 210 mg, about 190 to about 220 mg, about 200 to about 230 mg, about 210 to about 240 mg, about 220 to about 250 mg, about 230 to about 260 mg, about 240 to about 270 mg, about 250 to about 280 mg, about 260 to about 290 mg,about 270 to about 300 mg, about 280 to about 310 mg, about 290 to about 320 mg, about 300 to about 330 mg, about 310 to about 340 mg, about 320 to about 350 mg, about 330 to about 360 mg, about 340 to about 370 mg, about 350 to about 380 mg, about 360 to, Petition 870250101903, dated 06 / 11 / 2025, page 86 / 230 82 / 175 approximately 390 mg, approximately 370 to approximately 400 mg, approximately 380 to approximately 410 mg, approximately 390 to approximately 420 mg, approximately 400 to approximately 430 mg, approximately 410 to approximately 440 mg, approximately 420 to approximately 450 mg, approximately 430 to approximately 460 mg, approximately 440 to approximately 470 mg, approximately 450 to approximately 480 mg, approximately 460 to approximately 490 mg, approximately 470 to approximately 500 mg, approximately 480 to approximately 510 mg, approximately 490 to approximately 520 mg, approximately 500 to approximately 530 mg, approximately 510 to approximately 540 mg, approximately 520 to about 550 mg, about 530 to about 560 mg, about 540 to about 570 mg, about 550 to about 580 mg, about 560 to about 590 mg, about 570 to about 600 mg, about 580 to about 610 mg, about 590 to about 620 mg, about 600 to about 630 mg, about 610 to about 640 mg, about 620 to about 650 mg, about 630 to about 660 mg, about 640 to about 670 mg, about 650 to about 680 mg, about 660 to about 690 mg,approximately 670 to approximately 700 mg, approximately 680 to approximately 710 mg, approximately 690 to approximately 720 mg, approximately 700 to approximately 730 mg, approximately 710 to approximately 740 mg, approximately 720 to approximately 750 mg, approximately 730 to approximately 760 mg, approximately 740 to approximately 770 mg, approximately 750 to approximately 780 mg, approximately 760 to approximately 790 mg, approximately 770 to approximately 800 mg, approximately 780 to approximately 810 mg, approximately 790 to approximately 820 mg, approximately 800 to approximately 830 mg, approximately 810 to approximately 840 mg, approximately 820 to approximately 850 mg, approximately 830 to about 860 mg, about 840 to about 870 mg, about 850 to about 880 mg, about 860 to about 890 mg, about 870 to about 900 mg, about 880 to about 910 mg, about 890 to about 920 mg, about 900 to about 930 mg, about 910 to about 940 mg, about 920 to about 950 mg, about 930 to about 960 mg, about 940 to about 970 mg, about 950 to about 980 mg, about 960 to about 990 mg, or about 970 to about 1,000 mg administered once, twice, three times, four times or more daily in single or divided doses (the dose of which may be adjusted for the patient's weight in kg, surface area, Petition 870250101903, dated 06 / 11 / 2025, page 87 / 230 83 / 175 body mass in m2 and / or age in years).

[0336] In some embodiments, the therapeutically effective amount of the solid form of Compound A of the disclosure or the salt form of Compound A of the disclosure is from about 70 mg to about 1000 mg administered once, twice, three times, four times or more daily in single or divided doses (the dose may be adjusted for the patient's weight in kg, body surface area in m2 and / or age in years).

[0337] In some embodiments, the therapeutically effective amount of the solid form of Compound A of the disclosure or the salt form of Compound A of the disclosure is about 70 mg, 100 mg, 105 mg, 140 mg, 150 mg, 175 mg, 210 mg, 245 mg, 280 mg, 300 mg, 315 mg, 350 mg, 385 mg, 420 mg, 455 mg, 490 mg, 525 mg, 560 mg, 595 mg, 630 mg, 665 mg or 700 mg administered once, twice, three times, four times or more daily in single or divided doses (the dose may be adjusted for the patient's weight in kg, body surface area in m2 and / or age in years).

[0338] In some embodiments, the therapeutically effective amount of the solid form of Compound A disclosure or the salt form of Compound A disclosure is administered to the subject once daily. In some embodiments, this daily dose of the solid form of Compound A disclosure or the salt form of Compound A disclosure may be administered to the subject all at once. In some embodiments, this daily dose of the solid form of Compound A disclosure or the salt form of Compound A disclosure may be administered to the subject in two portions (i.e., a divided dose). In some embodiments, this daily dose of the solid form of Compound A disclosure or the salt form of Compound A disclosure may be administered to the subject in three divided doses. In some embodiments, this daily dose of the solid form of Compound A disclosure or the salt form of Compound A disclosure may be administered to the subject in four Petition 870250101903, dated 06 / 11 / 2025, p. 88 / 230 84 / 175 divided doses. In some embodiments, this daily dose of the solid form of Compound A of the disclosure or the salt form of Compound A of the disclosure may be administered to the subject in five or more divided doses. In some embodiments, these portions or divided doses are administered to the subject at regular intervals throughout the day, for example, every 12 hours, every 8 hours, every 6 hours, every 5 hours, every 4 hours, etc.

[0339] The therapeutically effective amount of the solid form of Compound A of the disclosure or the salt form of Compound A of the disclosure can be initially estimated in cell culture assays or in animal models, generally rats, mice, rabbits, dogs, or pigs. The animal model can also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic / prophylactic efficacy and toxicity can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, ED50 (the therapeutically effective dose in 50% of the population) and LD50 (the lethal dose for 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and can be expressed as the ratio, LD50 / ED50. Pharmaceutical compositions exhibiting large therapeutic indices are preferred.Dosage may vary within this range, depending on the dosage form used, patient sensitivity, and route of administration.

[0340] Dosage and administration are adjusted to provide sufficient levels of the solid form of Compound A or the salt form of Compound A to maintain the desired effect. Factors that may be taken into consideration include the severity of the disease state, the subject's general health, age, weight and sex, diet, timing and frequency of administration, drug combination(s), reaction sensitivities and tolerance / response to therapy. Petition 870250101903, dated 06 / 11 / 2025, page 89 / 230 85 / 175 Long-acting pharmaceutical compositions can be administered every 3 to 4 days, weekly, once every two weeks, or monthly, depending on the half-life and clearance rate of the particular formulation.

[0341] In some embodiments, for methods of treating prostate cancer with the combination of the solid form of Compound A of the disclosure or the salt form of Compound A of the disclosure and another anticancer agent, the therapeutically effective amount of the solid form of Compound A of the disclosure or the salt form of Compound A of the disclosure is described in this document, and the therapeutically effective amount of the other anticancer agent is 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190,195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275,280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360,365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445,450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530,535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595, 600, 605, 610, 615,620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700,705, 710, 715, 720, 725, 730, 735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785,790, 795, 800, 805, 810, 815, 820, 825, 830, 835, 840, 845, 850, 855, 860, 865, 870,875, 880, 885, 890, 895, 900, 905, 910, 915, 920, 925, 930, 935, 940, 945, 950, 955,960, 965, 970, 975, 980, 985, 990, 995, or 1,000 mg administered once, twice, three times, four times, or more daily for one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or thirty consecutive days, Petition 870250101903, dated 06 / 11 / 2025, p. 90 / 230 86 / 175 or, once, twice, three times, four times, or more daily, in single or divided doses, for 2 months, 3 months, 4 months, 5 months, 6 months, or more.

[0342] In some embodiments, the solid form of Compound A of the disclosure or the salt form of Compound A of the disclosure and the other anticancer agent are administered to the subject simultaneously. In some embodiments, the solid form of Compound A of the disclosure or the salt form of Compound A of the disclosure and the other anticancer agent are administered to the subject sequentially.

[0343] In some embodiments, the solid form of Disclosure Compound A or the salt form of Disclosure Compound A and the other anticancer agent are administered to the subject in close temporal proximity.

[0344] In some embodiments, temporal proximity means that administration of the solid form of Compound A disclosure or the salt form of Compound A disclosure occurs within a period before or after administration of the additional anticancer agent, such that the therapeutic effect of the solid form of Compound A disclosure or the salt form of Compound A disclosure overlaps with the therapeutic effect of the additional anticancer agent. In some embodiments, the therapeutic effect of the solid form of Compound A disclosure or the salt form of Compound A disclosure completely overlaps with the therapeutic effect of the additional anticancer agent.In some embodiments, temporal proximity means that administration of the solid form of Compound A disclosure or the salt form of Compound A disclosure occurs within a period before or after administration of the additional anticancer agent, so that there is a synergistic effect between the solid form of Compound A disclosure or the salt form of Compound A disclosure and the anticancer agent.

[0345] “Temporal proximity” can vary according to several factors, including, but not limited to, the age, gender, weight, genetic background, clinical picture, disease history, and treatment history of the subject to whom the agents are applied. Petition 870250101903, dated 06 / 11 / 2025, page 91 / 230 87 / 175 therapeutic agents to be administered; the disease or condition to be treated or improved; the therapeutic outcome to be achieved; the dosage, frequency of dose administration, and duration of dosing of the therapeutic agents; the pharmacokinetics and pharmacodynamics of the therapeutic agents; and the routes by which the therapeutic agents are administered. In some embodiments, temporal proximity means within 15 minutes, within 30 minutes, within one hour, within two hours, within four hours, within six hours, within eight hours, within 12 hours, within 18 hours, within 24 hours, within 36 hours, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within one week, within 2 weeks, within 3 weeks, within 4 weeks, within 6 weeks, or within 8 weeks.In some modalities, multiple administrations of one therapeutic agent may occur in close temporal proximity to a single administration of another therapeutic agent. In some modalities, the temporal proximity may change during a treatment cycle or within a dosing regimen. EXAMPLES EXAMPLE 1. GENERAL METHODS OF ANALYSIS X-ray powder diffraction (XRPD)

[0346] XRPD analysis was performed on a PANalytical X'pert pro with a PIXcel detector (128 channels), scanning the samples between 3 and 35° 2θ. The material was gently milled to release any agglomerates and loaded onto a multi-well plate with a Kapton or Mylar polymer film to support the sample. The multi-well plate was then placed in the diffractometer and analyzed using Cu K radiation (α1 λ = 1.54060 Å; α2 = 1.54443 Å; β = 1.39225 Å; ratio α1 : α2 = 0.5) running in transmission mode (step size 0.0130° 2θ, step time 18.87 s) using 40 kV / 40 mA generator settings. The data were visualized and images generated using the HighScore Plus 4.7 desktop application. Petition 870250101903, dated 06 / 11 / 2025, page 92 / 230 88 / 175 (PANalytical, 2017). Spinning stage X-ray powder diffraction (XRPD)

[0347] XRPD analysis of the second set of competitive paste experiments was performed on a Philips X'Pert Pro multipurpose diffractometer equipped with a rotating stage autosampler. Samples were scanned between 5 and 34.997°2θ using Cu K radiation (α1 λ = 1.54060 Å; α2 = 1.54443 Å; β = 1.39225 Å; ratio α1 : α2 = 0.5) running in Bragg-Brentano geometry (step size 0.008 °2θ, step time 10.160 s, rotation period 2 s) using 40 kV / 40 mA generator settings. Data were visualized and images generated using the HighScore Plus 4.7 desktop application (PANalytical, 2017). Polarized light microscopy (PLM)

[0348] The presence of crystallinity (birefringence) was determined using an Olympus BX50 microscope, equipped with cross-polarizing lenses and a Motic camera. Images were captured using Motic Images Plus 2.0. All images were recorded using the 20x objective unless otherwise indicated. Thermogravimetric / Differential Thermal Analysis (TG / DTA)

[0349] Approximately 5 mg of material were weighed into an open aluminum pan and loaded into a simultaneous thermogravimetric / differential (TG / DTA) thermal analyzer and kept at room temperature. The sample was then heated at a rate of 10°C / min from 20°C to 300°C during which the change in sample weight was recorded along with any differential thermal events (DTA). Nitrogen was used as the purge gas, at a flow rate of 300 cm³ / min. Differential Scanning Calorimetry (DSC)

[0350] Approximately 5 mg of material were weighed into a DSC aluminum crucible and sealed non-hermetically with a perforated aluminum lid. The sample crucible was then loaded into a TA Instruments Discovery DSC 2500 differential scanning calorimeter equipped with an RC90 chiller. The sample Petition 870250101903, dated 06 / 11 / 2025, page 93 / 230 Samples 89 / 175 and the reference were heated to 270°C at a scan rate of 10°C / min, and the resulting heat flux response was directly measured. The sample was cooled again to 20°C and then reheated to 270°C, all at 10°C / min. Nitrogen was used as the purge gas at a flow rate of 50 cm³ / min. Infrared (IR) spectroscopy

[0351] Infrared spectroscopy was performed on a Bruker ALPHA P spectrometer. Sufficient material was placed in the center of the spectrometer plate and spectra were obtained using the following parameters: Resolution: 4cm-1 Background scan time: 16 scans Sample scan time: 16 scans Data collection: 4000 to 400 cm⁻¹ Result spectrum: transmittance Software: OPUS version 6 Nuclear Magnetic Resonance (NMR)

[0352] NMR experiments were performed on a Bruker AVIIIHD spectrometer operating at 400 MHz for protons. The experiments were performed in deuterated DMSO and each sample was prepared to a concentration of approximately 10 mM. Dynamic Vapor Sorption (DVS)

[0353] 10-20 mg of sample were placed in a mesh vapor sorption equilibrium pan and loaded into a DVS-1 dynamic vapor sorption equilibrium by Surface Measurement Systems. The sample was subjected to a ramp profile of 40-90% relative humidity (RH) in 10% increments, maintaining the sample at each step until a stable weight was reached (dm / dt 0.004%, minimum step length 30 minutes, maximum step length 500 minutes) at 25°C. After completion of the sorption cycle, the sample was dried using the same procedure to 0% RH and then a second sorption cycle was performed back to Petition 870250101903, dated 06 / 11 / 2025, page 94 / 230 90 / 175 40% RH. Two cycles were performed. The weight change during the sorption / desorption cycles was plotted, allowing the hygroscopic nature of the sample to be determined. XRPD analysis was then performed on any retained solids. Variable temperature X-ray powder diffraction (VT-XRPD)

[0354] VT-XRPD analysis was performed on a Philips X'Pert Pro multipurpose diffractometer equipped with a temperature chamber. Samples were scanned between 4 and 35.99 °2θ using Cu K radiation (αi λ = 1.54060 Å; α2 = 1.54443 Å; β = 1.39225 Å; ratio αi : α2 = 0.5) running on Bragg-Brentano geometry (step size 0.008 °2θ) using 40 kV / 40 mA generator settings. The sample was heated at a heating rate of 10°C / min and held at each temperature for 3 minutes before XRPD analysis. Measurements were taken at 25 °C, 164 °C, 180 °C, 203 °C, 216 °C, 234 °C, 250 °C and again at 25 °C. High-Performance Liquid Chromatography-Ultraviolet (HPLCUV) Detection Instrument: Waters H-Class UPLC Column: ACQUITY UPLC BEH C18 1.7 mm 2.1 x 50 mm (Part No. 186002350) Column Temperature: 45 °C Autosampler Temperature: Ambient UV wavelength: 254 nm Injection volume: 2 μL Flow rate: 0.8 mL / min Mobile Phase A: 0.1% TFA in water Mobile Phase B: 0.1% TFA in acetonitrile Diluent: 0.1% TFA in water:acetonitrile (50:50% v / v) Gradient program: Petition 870250101903, dated 06 / 11 / 2025, p. 95 / 230 91 / 175 Time (minutes) Solvent B [%] 0 5 0.5 5 9.20 99 9.50 99 9.55 5 15.0 5 EXAMPLE 2. CHARACTERIZATION OF COMPOUND A

[0355] Compound A was characterized by the following techniques: XRPD, PLM, Multinuclear NMR, TG / DSC, VT-XRPD, DSC, DSV and HPLC. • Initial characterization of Compound A determined that the material was amorphous by XRPD, see FIG. 1. This was confirmed by PLM where no birefringent solids were observed. The particles were approximately 5 μm in size with a plate-like morphology. • Multinuclear NMR (1H NMR, C HSQC and 19F) revealed that the data were consistent with the structure of Compound A. There was an approximately 1% impurity peak present in the 19F spectrum at -74.5 ppm, likely due to TFA. See FIGS 2 and 3. • TG / DSC analysis found a mass loss of 0.8% in wt% (0.36 eq.) of water at the beginning of the experiment in the TG trace of TG / DSC, probably due to surface moisture. Decomposition was observed above 300 °C. In the DSC trace, an endothermic melting event was observed with an onset of 236 °C. See Figure 4. • DSC analysis elucidated three events in the first heat. A small endothermic event with an onset of 164°C, likely caused by the melting of small amounts of crystalline material in the bulk sample. A large exothermic event with an onset of 203°C due to recrystallization of the material followed Petition 870250101903, dated 06 / 11 / 2025, page 96 / 230 92 / 175 by a pronounced endothermic event with an onset of 235°C due to melting. See Figure 5. These data correspond well to the data obtained in the TG / DSC. Glass transitions were observed in the cooling cycle, the second heating cycle, and the second cooling cycle with midpoints at 123°C, 129°C, and 128°C, respectively. See Figures 6-8. • VT-XRPD analysis determined that when Compound A was heated to 164°C, the temperature at which a small endothermic event was observed by DSC, no change in crystallinity was observed. When heated to the onset of the exothermic event observed by DSC (203°C), recrystallization to Pattern 1 was noted – slightly shifted compared to the reference diffractogram collected in transmission mode. When Pattern 1 was heated to the endothermic event (thought to be due to melting) observed by DSC, a slight reduction in crystallinity was observed. When heated further, melting was observed. No recrystallization was evident upon cooling. See Figure 9. • DVS analysis determined that the material was hygroscopic with an average mass absorption of 4.08 wt% (1.91 eq.) of water at 90% RH, see FIG. 10 for the isothermal graph and FIG. 11 for the kinetic graph. Crystallization was not observed by post-DVS XRPD, see FIG. 12. Table 13: Summary of the initial characterization XRPD Composite A: The material was amorphous. PLM: Non-birefringent solids, approximately 5 µm, with plate-like morphology. NMR: Consistent with structure, 1% impurity at 19°F. TG / DSC Trace: TG 0.8% by weight mass loss, decomposition from 300°C. DSC Trace: Melting beginning at 236°C, peak at 241°C. DSC: First small endothermic event: beginning at 164°C (material melting). Petition 870250101903, dated 06 / 11 / 2025, page 97 / 230 93 / 175 Crystalline heating (trace), exothermic event: beginning at 203 °C (crystallization), endothermic event: beginning at 235 °C (melting corresponding to TG / DSC). First cooling: Glass transition with midpoint at 123 °C. Second heating: Glass transition with midpoint at 129 °C. Second cooling: Glass transition with midpoint at 128 °C. DVS 4.08% by weight (1.91 eq. water) at 90% RH - The material is hygroscopic and remained amorphous by XRPD. HPLC 97.4% pure by relative area. EXAMPLE 3. SOLVENT SOLUBILITY SCREENING COMPOUND A

[0356] A known volume aliquot (typically 5 volumes) of solvent was added to approximately 5 mg of Compound A. See Table 14 for the solvents selected for solvent solubility screening. Table 14: Selected solvents used in solvent solubility screening Solvent System Number | ICH Classification | 1 | 1-Butanol | 3 | 2 | 1-Propanol | 3 | 3 | 1,4-Dioxane | 2 | 4 | 2-Butanone (MEK) | 3 | 5 | 2-Ethoxyethanol | 2 | 6 | 2-Methyl THF | Not classified | 7 | 2-Methyl-1-Propanol | 3 Petition 870250101903, dated 06 / 11 / 2025, page 98 / 230 94 / 175 8 2-Propanol 3 9 Acetone 3 10 Acetonitrile 2 11 Anisole 3 12 tert-Butyl methyl ether 3 13 Butyl acetate 3 14 Dichloromethane 2 15 Dimethyl sulfoxide 3 16 Ethanol 3 17 Ethyl acetate 3 18 Ethyl ether 3 19 Ethyl formate 3 20 Heptane 3 21 Isopropyl acetate 3 22 Methanol 2 23 Methyl isobutyl ketone 2 24 N,N'-Dimethylacetamide 2 25 N,N'-Dimethylformamide 2 26 N-Methylpyrrolidone 2 27 Tetrahydrofuran 2 28 Toluene 2 29 Water N / A 30 Acetone:Water (90:10% v / v) 3 31 Acetonitrile:Water (75:25 % v / v) 2 32 EthanokWater (50:50 % v / v) 3 33 2-Propanol:Water (90:10 % v / v) 3 Petition 870250101903, dated 06 / 11 / 2025, page 99 / 230 95 / 175 34 Tetrahydrofuran:Water (98:2% v / v) 2 35 Dichloromethane:Methanol (50:50% v / v) 2 36 Dichloromethane:Methanol (75:25% v / v) 2

[0357] Between each addition, the mixture was checked for dissolution and where no dissolution was apparent, the mixture was heated to ca. 40°C and checked again. This procedure was continued until dissolution was observed or until 100 volumes of solvent had been added.

[0358] Where dissolution was not observed, solids were isolated centrifugally and analyzed by XRPD. Saturated solutions were analyzed by HPLC to obtain solubility.

[0359] Where dissolution was observed, the clear solutions were left to evaporate under ambient conditions and the solids that were obtained were analyzed by XRPD. • High solubility of Compound A (above 100 mg / mL) was observed in 1,4-dioxane, DMSO, DMA, DMF, and DCM:methanol (75:25% v / v). • Moderately high solubility of Compound A (between 100 and 50 mg / mL) was observed in DCM, NMP, THF, THF:water (98:2% v / v) and DCM:methanol (50:50% v / v). • Moderate solubility of Compound A (between 50 and 25 mg / mL) was observed for anisole. • The material was insoluble (< 5 mg / mL) in the remaining 25 solvent systems tested. • Two new crystalline XRPD standards were obtained during solvent screening, named Freebase Standard 1 and Freebase Standard 2. [ 0360] See Table 15 for a summary table of solvent solubility screening. Table 15: Summary of solvent solubility screening Petition 870250101903, dated 06 / 11 / 2025, pages 100 / 230 96 / 175 No. System Solvent Approximate Solubility (mg / mL) XRPD 1 1-butanol 0.1881 P1 2 1-Propanol 0.2323 P1 3 1,4-Dioxane 100 A 4 2-Butanone (MEK) 2.1332 P1 5 2-Ethoxyethanol 1.5534 P1 6 2-Methyl THF 2.8922 + + p1 7 3-Methyl-1-butanol 1.2200 A 8 2-Propanol 0.2052 + + p1 9 Acetone 2.7252 P1 10 Acetonitrile 0.9948 *P1 11 Anisole 25 *P1 12 tert-Butylmethyl ether 0.1079 A 13 Butyl acetate 0.2087 P1 14 Dichloromethane 50 A 15 Dimethyl sulfoxide 100 N / A 16 Ethanol 0.2761 P1 17 Ethyl acetate 0.4438 P1 18 Diethyl ether 0.0020 *P1 19 Ethyl formate 1.0127 *P1 20 Heptane 0.0017 A 21 Isopropyl acetate 0.1742 *P1 22 Methanol 0.4366 *P2 23 Methyl isobutyl ketone 0.5305 *P1 24 N,N'-Dimethylacetamide 100 N / A 25 N,N'-Dimethylformamide 100 N / A Petition 870250101903, dated 06 / 11 / 2025, page 101 / 230 97 / 175 26 N-Methylpyrrolidone 50 N / A 27 Tetrahydrofuran 50 *P1 28 Toluene 0.0298 A 29 Water 0.0005 A 30 Acetone:Water (90:10% v / v) 5.6779 N / A 31 Acetonitrile:Water (75:25% v / v) 1.0507 A 32 EthanokWater (50:50% v / v) 0.0192 N / A 33 2-Propanol:Water (90:10% v / v) 0.1862 *P2 34 Tetrahydrofuran:Water (98:2% v / v) 50 N / A 35 Dichloromethane:Methanol (50:50% v / v) 50 A 36 Dichloromethane:Methanol (75:25% v / v) 100 A A: Amorphous, P1: Pattern 1, P2: Pattern 2, * Slightly crystalline, +pl: some peaks of pattern 1 EXAMPLE 4. SALT SCREENING OF COMPOUND A • 30 mg samples of Compound A were weighed into 2 mL screw-top sample bottles for 96 experiments. To these, 200 μL of the appropriate solvent system was added to dissolve the material or form a fluid paste. See Table 16 for the solvent systems selected for primary salt screening. Table 16: Solvent systems selected for primary salt screening Solvent System Approximate Solubility (mg / mL) 1,4-Dioxane 100 DCM 50 Dichloromethane:Methanol (50:50% v / v) 50 DMSO:Water (50:50% v / v) Not determined THF 50 Tetrahydrofuran:Water (98:2% v / v) 50 Petition 870250101903, dated 06 / 11 / 2025, page 102 / 230 98 / 175 • 1.05 eq. of solid counterions were weighed into six separate flasks each, and 1 molar stock solution was prepared for liquid counterions in 5 mL of THF. See Table 17 for selected counterions and mass / volume required for additions of 1.05 eq. • 100 μL of the appropriate solvent were added to the solid counter-ions. Table 17: Counter-ions selected for primary salt screening______ Counter-ion number, pKa class, MW (g / mol), pure addition 1.05 eq. (mg or pl_ of 1 molar stock solution) 1 2 3 1 Hydrochloric acid 1 -6.1 36.46 39 2 Sulfuric acid 1 -3 1.92 98.08 39 3 p-Toluenesulfonic acid monohydrate 2 -1.34 190.22 7.Q5 4 Methanesulfonic acid 2 -1.2 96.1 39 5 Benzenesulfonic acid 2 0.7 158.18 6.85 6 Maleic acid 1 1.92 6.23 116.07 4.57 7 Phosphoric acid 1 1.96 7.12 12.32 98 39 8 L-Glutamic acid 1 2.19 4.25 147.13 5.79 9 Malonic acid 2 2.83 5.7 104.06 4.10 10 L-tartaric acid 1 3.02 4.36 150.09 5.88 11 Fumaric acid 1 3.03 4.38 116.07 4.57 12 Citric acid 1 3.13 4.76 6.4 192.12 7.53 13 L-malic acid 1 3.46 5.1 134.09 5.39 14 Benzoic acid 2 4.19 122.12 4.78 15 Succinic acid 1 4.21 5.64 118.09 4.65 16 Acid acetic 1 4.76 60.05 39

[0361] The counter-ion fluid solution / paste was added to the free base material solution / paste. This was mixed using a vortex mixer and the Petition 870250101903, dated 06 / 11 / 2025, page 103 / 230 99 / 175 observations were recorded, see Table 18. Table 18: Observations made before the temperature cycle Hydrochloric acid Sulfuric acid p-Toluenesulfonic acid Methanesulfonic acid Benzenesulfonic acid Maleic acid Phosphoric acid l-Glutamic acid Malonic acid l-Tartaric acid Fumaric acid Citric acid l-Malic acid Benzoic acid Succinic acid Acetic acid 1,4-Dioxane SS WS S WS S WS S WS SMSSS WS SSSSSS DCM SS WS SS WS SSMSSSSSSS DCM: Methanol (50:50% v / v) SSSSN / ASSSSSSS DMSO: Water (50:50% v / v) SSSSSSSSSSSSSSSM THF SS WS SSSSMSSSSSSSS THF: Water (98:2% v / v) SS WS SSSSSSSSSSSSSS S - fluid paste; M - milky paste; WS - white solids • Samples were placed in an incubator shaker until the temperature cycle between room temperature and 40°C over 4-hour cycles. • After approximately 72 hours of temperature cycling, observations were made, see Table 19. Petition 870250101903, dated 06 / 11 / 2025, page 104 / 230 100 / 175 Hydrochloric acid Sulfuric acid Ptoluenesulfonic acid Methanesulfonic acid Benzenesulfonic acid Maleic acid Phosphoric acid L-Glutamic acid Malonic acid L-Tartaric acid Fumaric acid Citric acid L-Malic acid Benzoic acid Succinic acid Acetic acid 1,4-Dioxane SSGGGSSSSGSGSSS DCM SSS DCM:Methanol (50:50% v / v) SN / ASSS DMSO:Water (50:50% v / v) SGSGGSSGSSGSSSS THF SSSS THF:Water (98:2% v / v) SSS Table 19: Observations made after the temperature cycle S - fluid paste; G - gel • Where fluid pastes were obtained, solids were isolated by centrifugation. Solids and gels were analyzed by XRPD.

[0362] Any samples that were clear solutions after the temperature cycle were allowed to evaporate under ambient conditions. See Table 20 for observations made after evaporation. The solids obtained by evaporation were analyzed by XRPD. Table 20: Observations made after evaporation Hydrochloric acid Sulfuric acid p- Acid Benzenesulfonic acid Maleic acid Phosphoric acid l-Glutamic acid Malonic acid l-tartaric acid Fumaric acid Citric acid l-malic acid Benzoic acid Succinic acid Acetic acid 1,4-Dioxane N / AN / AN / AN / AN / AN / AN / AN / AN / AN / AN / AN / AGN / AN / AN / A DCM N / AN / ASSSSN / ASSSSSSGGS Petition 870250101903, dated 06 / 11 / 2025, page 105 / 230 101 / 175 • Samples obtained from the temperature cycle were dried under vacuum at 40°C for approximately 20 hours, while samples obtained from evaporation were dried under vacuum at 40°C for approximately 4 hours. The samples were then analyzed by XRPD. • The XRPD plate was then stored at 40°C / 75% RH for approximately 20 hours and reanalyzed by XRPD. • After initial XRPD analysis of the solids obtained during primary salt screening, potential salt forms were obtained for hydrochloric acid, ptoluenesulfonic acid, benzenesulfonic acid, maleic acid, phosphoric acid, and fumaric acid. • The fumarate salt potential decreased to amorphous after drying. • The potential for maleate salts decreased to amorphous after high humidity. • CAD analysis of potential chloride salts found only trace amounts of chloride. • Tosylate, besylate, and phosphate appear to be stable hydrates. • In addition, two new possibly free basis patterns were obtained from 1,4-dioxane samples. • Standard 3 of hydrochloric acid, L-glutamic acid, succinic acid, and acetic acid. • Pattern 4 from malonic acid and benzoic acid. Petition 870250101903, dated 06 / 11 / 2025, page 106 / 230 102 / 175

[0363] See Tables 21-23 for a summary of the XRPD results from the primary salt screening. Table 21: Summary of XRPD results after the temperature and evaporation cycle Hydrochloric acid Sulfuric acid p-Toluenesulfonic acid Methanesulfonic acid Ezenesulfonic acid Maleic acid Phosphoric acid l-Glutamic acid Malonic acid l-Tartaric acid Fumaric acid Citric acid l-Malic acid Benzoic acid Succinic acid Acetic acid 1,4-Dioxane t*3 At At At At St* At C e * 3 t*4 At St* At e*3 t4 t*3 t*3 DCM ts At A e A e A e Ce St* C e A e A e A e A e A e A e Ce e*2 DCM:Methanol (50:50 % v / v) ts A e A e N / AN / AA e St* e2 A e A e A e A ee*2 e2 t2 t2 DMSO:Water (50:50 % v / v) t2 At At At A e At t*2 At At At t*2 At At t*2 At t*2 THF e2 At St t2 At A e St Ce2 A e A e A e A e A ee*2 e*2 e*2 THF:Water (98:2% v / v) t 2 N / AA e A e S e A e S te * 2 A e A ee * 2 A ee * 2 e * 2 e * 2 t * 1 - Free base standard 1, 2 - Free base standard 2, 3 - Free base standard 3, 4 - Free base standard 4, S - Potential salt standard 1, A - Amorphous, C Counter-ion present, * - Poorly crystalline, t - Results obtained from temperature cycling, e - Results obtained from evaporation Table 22: Summary of XRPD results after drying Petition 870250101903, dated 06 / 11 / 2025, page 107 / 230 103 / 175 Hydrochloric acid Sulfuric acid p- Methanesulfonic acid Benzenesulfonic acid Maleic acid Phosphoric acid l-Glutamic acid Malonic acid l-Tartaric acid Fumaric acid Citric acid l-Malic acid Benzoic acid Succinic acid Acetic acid 1,4-Dioxane t*2 At At At At S1 t * At C e * 3 t*4 At Atd At e'3 t4 t*3 t*3 DCM S2 td At A e A e A e A ed S1 t * C e A e A e A e A e A e A e e e*2 DCM:Methanol (50:50 % v / v) S2 td A e A e N / AN / AA e S1 t * e2 A e A e A e A e e2 e2 t2 t2 DMSO:Water (50:50 % v / v) t2 At At At S1 ed At 11 d 11 d 11 d 11 d 11 d At 11 d 11 d 11 dt*2 THF e2 At S1 t t2 At A e S1 t * Ce2 A e A e A e A e A ee*2 e*2 e*2 THF:Water (98:2% v / v) t 2 N / AA e A e S1 e A e S1 t * e * 2 A e A ee * 2 A ee * 2 e * 2 e * 2 t * 1 - Free base standard 1, 2 - Free base standard 2, 3 - Free base standard 3, P4 - Free base standard 4, S1 - Potential salt standard 1, S2 - Potential salt standard 2, A - Amorphous, C - Counter-ion present, * - Slightly crystalline, t - Results obtained from temperature cycling, e - Results obtained from evaporation, d - XRPD altered after drying Table 23: Summary of XRPD results after 40°C / 75% RH Petition 870250101903, dated 06 / 11 / 2025, page 108 / 230 104 / 175 Hydrochloric acid Sulfuric acid p-Toluenesulfonic acid Methanesulfonic acid Benzenesulfonic acid Maleic acid Phosphoric acid l-Glutamic acid Malonic acid l-Tartaric acid Fumaric acid Citric acid l-Malic acid Benzoic acid Succinic acid Acetic acid 1,4-Dioxane t*2 At At At At Ath At Ce* 3 t*4 At At At e*3 t4 t*3 t*3 DCM S2t At A e A e A e A e Ath C e A e A e A e A e A e A e C ehe * 2 DCM:Methane (50:50 % v / v) S2t A e A e N / AN / AA e S1 t* e2 A e A e A e A e e2 e2 t2 t2 DMSO:Water (50:50 % v / v) A th At At At A eh At 11 11 11 t1 11 At 11 11 t1 A th THF e2 At S1 t t2 At A e S1 t* C e 2 A e A e A e A e A ee*2 e*2 e * 2 THF:Water (98:2% v / v) t 2 N / AA e A e S1 e A e S1 t * e * 2 A e A ee * 2 A ee * 2 e * 2 e * 2 t * 1 - Free base standard 1, 2 - Free base standard 2, 3 - Free base standard 3, P4 - Free base standard 4, S1 - Potential salt standard 1, S2 - Potential salt standard 2, A - Amorphous, C - Counter-ion present, * - Poorly crystalline, t - Results obtained from temperature cycling, e - Results obtained from evaporation, h - XRPD altered after high humidity EXAMPLE 5. CHARACTERIZATION OF NEW FORMS

[0364] Potential chloride salt standard 2, Tosylate standard 1, Besylate standard 1 and Phosphate standard 1 were characterized by the following techniques: • PLM Petition 870250101903, dated 06 / 11 / 2025, page 109 / 230 105 / 175 • FT-IR • TG / DSC • CAD (when applicable) • 1H NMR (when applicable) • 31P NMR (when applicable) Potential Chloride Salt Standard 2 • Potential Chloride Salt Standard 2 was observed after drying Potential Chloride Salt Standard 1, which was obtained from DCM and DCM:methanol. Drying was carried out in an oven at 40 °C for approximately 20 hours. • PLM showed birefringent rod-like particles. • FT-IR analysis showed a slight peak shift compared to the amorphous free base. A CC triple bond peak was evident at 2218 cm⁻¹. Amide peaks and possible presence of water were observed at higher wavenumbers. See Figure 14. • By TG / DSC on the DCM sample, no notable mass losses were observed in the TG trace before decomposition above 292°C, indicating that the material was anhydrous. In the DSC trace, a pronounced endothermic event was observed with an onset at 241°C, probably due to melting and similar to the melting observed for the freebase Standard 1. See FIG. 15. • TG / DSC analysis was repeated on the DCM:methanol sample. In the TG trace, no notable mass losses were observed before decomposition above 310 °C. In the DSC trace, a large endothermic melting event was observed with an onset at 243 °C, which matches well with the thermogram obtained previously. See FIG. 16. • CAD analysis of the two potential chloride salt samples (from DCM and DCM:methanol (50:50% v / v)) determined that only trace amounts of chloride were present. Petition 870250101903, dated 06 / 11 / 2025, pp. 110 / 230 106 / 175 • The Potential Chloride Salt Standard 2 was not a salt. Tosylate Pattern 1 • By PLM, no clear morphology was observed and agglomeration was noted. The material appeared birefringent under polarized light. • FT-IR analysis determined that there were some small differences in the spectra, probably due to the presence of p-toluenesulfonic acid. A CC triple bond peak was evident at 2220 cm⁻¹. No clear presence of water from a hydrate was observed. See FIG. 17. • TG / DSC analysis found a 1.8 wt% (0.25 eq. THF or 1 eq. water) mass loss in the TG trace from the start of heating to the potential melting event. Decomposition was observed above 278 °C. An endothermic event, likely due to melting, was observed in the DSC trace starting at 195 °C. See FIG. 18. • 1H NMR showed a 1:1 ratio of p-toluenesulfonic acid to Compound A. No significant amount of THF was observed in 1H NMR, indicating that the mass loss of TG / DSC was probably due to water. No peak shift was observed compared to the free base. See FIG. 19. Standard 1 of Tosylate was a hydrated salt with a 1:1 stoichiometry of p-toluenesulfonic acid for Compound A. Besylate Standard 1 • By PLM, large pink plate-like particles were observed. The material appeared weakly birefringent under polarized light. • FT-IR analysis determined that there were some small differences in the spectra, probably due to the presence of benzenesulfonic acid. A CC triple bond peak was evident at 2222 cm-1. See Figure 20. • By TG / DSC, two mass losses were observed in the TG trace. Petition 870250101903, dated 06 / 11 / 2025, page 111 / 230 107 / 175 from the start of heating to approximately 277°C: mass loss of 4.2% by weight (0.6 eq. of THF or 2.4 eq. of water) and a mass loss of 3.7% by weight (0.5 eq. of THF or 2.1 eq. of water). Decomposition was observed above 277°C. In the DSC trace, there was no clear evidence of melting. A large endothermic event was observed during the first mass loss, possibly related to desolvation. See FIG. 21. • 1H NMR showed a 1:1 ratio of benzenesulfonic acid to Compound A. 0.85 wt% (0.11 eq.) of THF was observed in 1H NMR. A smaller peak shift was observed when compared to the free base of Compound A. See FIG. 22. Besylate Standard 1 was a hydrated salt with a 1:1 stoichiometry of benzenesulfonic acid for Compound A. Phosphate Standard 1 • PLM analysis did not show a clear morphology. Agglomeration was noted and the material appeared weakly birefringent under polarized light. • FT-IR analysis determined that the spectra were comparable, with some slight peak shift observed, probably due to the presence of phosphoric acid. The CC triple bond peak was evident at 2221 cm⁻¹. No clear presence of water from a hydrate was found in the spectrum. See FIG. 23. • TG / DSC analysis found a gradual mass loss of 5.8% by weight (3 eq. water or 0.8 eq. THF) in the TG trace observed from the beginning up to approximately 170 °C. Decomposition was observed above 249 °C. In the DSC trace, a large endothermic event occurred after the mass loss between 165 °C and 245 °C. See FIG. 24. • The 1H NMR was consistent with the structure. No significant amount of THF was observed, indicating that the mass loss of the TG / DSC was likely due to water. A smaller peak displacement was observed when compared to Petition 870250101903, dated 06 / 11 / 2025, page 112 / 230 108 / 175 free base of Compound A and a broad water peak were present, both indicative of salt formation. A peak was observed in the 31P NMR, confirming the presence of phosphate. See FIGS. 25 and 26. CAD analysis found 22.9 wt% phosphate, which corresponds to approximately 2 eq. of phosphate (1 eq. = 10.5 wt% and 2 eq. = 18.9 wt%). Phosphate Standard 1 was a hydrated salt with a 2:1 stoichiometry of phosphoric acid to the free base of Compound A. Table 24: Summary of the characterization performed on the new forms of salt. Salt System Solvent 40°C / 75%RH PLM TG / DSC 1H NMR Comment Tosylate Standard 1 THF Standard 1 retained No dead log clear; appeared birefringent Loss of 0.25 equiv. of THF or 1 equiv. of water when heated to the beginning of melting (195°C). Decomposition start -278°C. 1:1 ratio of free base to p-toluenesulfonic acid, no significant amount of THF, suggesting that the mass loss in the TG / DSC was due to water. No peak shift, no broad water peak. Not clear if hydrated or anhydrous Besylate Standard 1 THF / water (98:2%v / v) Standard 1 retained Large pink plate-shaped particles; appeared weakly birefringent Loss of 0.6 equiv. of THF (or 2.4 equiv. of water) when heated to 140°C. Steady mass loss up to ~277°C, where decomposition was evident. No clear melting event observed. 1:1 ratio of free base to benzenesulfonic acid. 0.85% by weight (0.11 eq. THF). No peak shift, broad water peak.Possible THF solvate (or hydrate). Amorphous content observed. The material is red. Petition 870250101903, dated 06 / 11 / 2025, page 113 / 230 109 / 175 Phosphate Standard 1 THF and THF / water (98:2%v / v) Standard 1 retained, but slightly reduced crystallinity. No clear morphology; appeared birefringent. Constant loss of 3 equiv. of water or 0.8 equiv. of THF when heated to ~170°C. Evident decomposition above ~249°C. Broad endothermic event observed between 165 and 245°C after mass loss and before the onset of decomposition. No significant amount of THF suggesting that the mass loss in TG / DSC was due to water. No peak shift, broad water peak. Phosphate peak present in 31P NMR. CAD analysis found 2 eq. of phosphate. Possible hydrate. Some amorphous content observed. No clear melting onset observed. Aqueous solubility • The aqueous solubility of the promising salts was determined in unbuffered water. • To 2.2 mg of tosylate salt and 5 mg each of besylate salt and phosphate salt, 0.5 mL of unbuffered water was added to obtain pastes. See Table 25. • Each sample was capped and sealed in parafilm and placed in an incubator shaker at 25°C for approximately 24 hours. • After 24 hours, observations were recorded (see Table 25) and the pastes were centrifugally filtered. The saturated solutions were subjected to HPLC analysis and were injected pure due to their low solubility. Table 25: Aqueous solubility observations Salt Water volume (mL) Initial observations Observations after agitation Tosylate standard 1 0.5 Purple fluid paste Purple fluid paste Petition 870250101903, dated 06 / 11 / 2025, pp. 114 / 230 110 / 175 Besylate Standard 1 0.5 Red Fluid Paste Red Fluid Paste Phosphate Standard 1 0.5 Purple Fluid Paste Purple Fluid Paste

[0365] Unfortunately, the solubility of all three samples was below the LOQ and therefore could not be quantified. EXAMPLE 6. ADDITIONAL EXPERIMENTS ON CHLORIDE SALT FORMATION

[0366] Three additional chloride salt formation experiments were conducted to further investigate the possibility of stable chloride salt formation, which seemed elusive despite the large pKa difference between Compound A and hydrochloric acid. (Table 26) Table 26: Summary of additional chloride formation experiments No. Strength Mass of free base per vial (mg) Solvent system Volume of solvent (ML) HCl equivalents 1 Hydrochloric acid 30 DCM:Methanol (50:50% v / v) 400 1.05 eq. 1 M HCl in THF 2 Hydrochloric acid 30 DCM 400 2.1 eq. 1 M HCl in THF 3 Hydrochloric acid 200 DCM:Methanol (90:10% v / v) 2000 2 eq. 1.25 M HCl in MeOH • Experiment 1: 30 mg of free base were dissolved in 400 μL of DCM:methanol (50:50% v / v). A clear purple solution was observed. 1.05 eq. of 1 M HCl in THF was added to the clear solution. No change was observed. The solution was capped and sealed in parafilm and then placed in an incubator shaker until the temperature cycle between room temperature and 50°C was completed in 4-hour cycles over 72 hours. An orange solution was obtained, the sample was uncapped and allowed to evaporate. • Experiment 2: 30 mg of free base were dissolved in 400 μL of DCM. A clear purple solution was observed. 2.1 eq. of 1 M HCl in THF were Petition 870250101903, dated 06 / 11 / 2025, pp. 115 / 230 111 / 175 added. No change was observed. The solution was capped and sealed in parafilm and then placed in an incubator shaker until the temperature cycle between room temperature and 40°C was completed in 4-hour cycles over 72 hours. A yellow solution was obtained, the sample was uncapped and allowed to evaporate. • Experiment 3 followed the method: • 200 mg of free base were dissolved in 2 mL of a 9:1 DCM:methanol solution. A clear purple solution was obtained. An additional 1 mL of DCM was added. • 0.8 mL of 1.25 M HCl in methanol was added. • The solution was stirred on a heating plate of the stirrer at room temperature for 1 hour. • The solvent was removed using a rotary evaporator over a water bath at 40°C. A brown gel was obtained. • 5 mL of ethanol were added, resulting in a whitish, fluid paste. • The paste was stirred at room temperature for approximately 2.5 hours. • The paste was filtered by Buchner filtration and the material was left to dry on the filter bed for approximately 5 minutes. • The whitish solids were then placed in a scintillation jar, covered with tissue paper, and placed in an oven at 40°C to dry for approximately 96 hours. • The material obtained from these experiments was analyzed by XRPD, where amorphous material was obtained. This was then analyzed by CAD to determine the chloride content. The solids obtained from Experiment 1 produced an amorphous monochloride salt. This sample was further analyzed by TG / DSC and DSC. • Experiment 1, performed at elevated temperature, produced Standard 2, a free-base sample. The other two samples yielded amorphous material. • CAD analysis found 0.8% by weight of chloride in experiment 2. The amount of trace is outside the calibration range. Petition 870250101903, dated 06 / 11 / 2025, pp. 116 / 230 112 / 175 • CAD analysis found 7.7% by weight of chloride from experiment 3, which corresponds to approximately 2 eq. of chloride. (1 eq. = 4.2% by weight, 2 eq. = 8.0% by weight %) • TG / DSC of the amorphous chloride salt from experiment 3 found a mass loss of 7.97% by weight (4.23 eq. water, 0.90 eq. DCM, 2.38 eq. methanol, 1.66 eq. ethanol, or 2.09 eq. HCl) from the beginning of the experiment to ca. 110 °C. A gradual mass loss of 10.15% by weight (5.52 eq. water, 1.17 eq. DCM, 3.11 eq. methanol, 2.16 eq. ethanol, or 2.73 eq. HCl) was observed from 110°C until decomposition at ca. 300°C, probably due to sample degradation. These data suggest that chloride anions were lost early in the experiment. Two large endothermic events were observed in the DSC trace with peaks at 186°C and 232°C. (FIGs. 27-33) • The first heating cycle in the DSC yielded two endothermic events.A broad endothermic event began at 45°C and peaked at 99°C, corresponding to the mass loss observed in the TG / DSC. The second endothermic event was more pronounced and likely corresponds to melting, beginning at 184°C and peaking at 189°C. The melt mass was lower than any previously obtained free-base melt mass, so the DSC was repeated to confirm the temperature. The repeated DSC gave the same results. • A glass transition with a midpoint at 148°C was observed in the cooling cycle. • A glass transition with a midpoint at 154°C was observed in the second heating cycle. EXAMPLE 7. SCREENING OF COMPOUND A COCRYSTAL Dry Milling • Approximately 30 mg of Compound A were weighed into 48 x 2 mL granule mill vials. Petition 870250101903, dated 06 / 11 / 2025, pp. 117 / 230 113 / 175 • 1.05 eq. of each co-former was added to six granule mill flasks. • Two stainless steel bead mill balls were added to each vial and the samples were dry-ground using the following procedure: • 6500 RPM • 40 x 60s cycles (total grinding time: 40 minutes) • 10s pauses • A subsample from each co-former was analyzed by XRPD after dry grinding. Temperature cycling • Each sample was dissolved in the appropriate solvent • The solutions were subjected to temperature cycling in an incubator shaker between ambient and 40°C over cycles of approximately 4 hours to 72 hours. • After 3 days, the pastes were centrifugally filtered and all the solids obtained were analyzed by XRPD. • After XRPD analysis, the XRPD plate was placed in a RH of 40°C / 75% for approximately 30 hours, and then the samples were reanalyzed by XRPD. • Samples that produced a new XRPD pattern were analyzed by TG / DSC and PLM. Storage at 40°C / 75% RH • The XRPD plate containing the cocrystal screen samples was stored in a humidity chamber at 40°C / 75% RH for approximately 24 hours, and then the samples were reanalyzed by XRPD. Results • The cocrystal screen produced freebase patterns 1, 2, 4 and a new pattern. • The new pattern was obtained from 5 different co-formers in 1,4-dioxane, indicating that this was likely a new free base pattern. It was Petition 870250101903, dated 06 / 11 / 2025, pp. 118 / 230 114 / 175 named Potential Free Base Standard 9. See Table 27 for a summary of the XRPD results after temperature cycling. • Standard 9 converted to freebase Standard 4 after storage at 40°C / 75% RH. See Table 28 for a summary of XRPD results after storage at 40°C / 75% RH. Table 27: Summary of XRPD results obtained during the cycle of Post-screening temperature of primary cocrystal Niacinamide Methylparaben Urea L-Tyrosine L-Phenylalanine L-Histidine L-Proline L-Tryptophan Dry mill AAAAAXXA 1,4-Dioxane 4 4* 9 9 9 9 9 9* DCM GGGGGGGG DCM:Methanol (50:50% v / v) 2 1 2 2 2 + 2 2 2 DMSO:Water (50:50% v / v) 2 AAAAAAA THF 1 1 1 1 + 1 + 1 1 1 + THF:Water (98:2% v / v) GGG 2 * G 2 * 1+* 2+* A - Amorphous; X - Predominantly amorphous with some potential free base pattern; 9 peaks; G - Glassy material at the bottom of the flask; 1 - Free base pattern 1; 2 - Free base pattern 2; 4 - Free base pattern 4; 9 - Potential new free base pattern 9; + - Additional peaks observed (probably due to the presence of a coformer); * - Poorly crystalline Table 28: Summary of XRPD results obtained during post-screening storage of primary cocrystal at 40°C / 75% RH Petition 870250101903, dated 06 / 11 / 2025, pp. 119 / 230 115 / 175 Niacinamide Methylparaben Urea L-Tyrosine L-Phenylalanine L-Histidine L-Prol i na L-Tryptophan 1,4-Dioxane 4 4* 4 4 4 4 4 4* DCM GGGGGGGG DCM:Methanol (50:50% v / v) 2 1 2 2 2 + 2 2 2 + DMSO:Water (50:50 % v / v) 2 2* 2* 2 * 2+* 2 * 2 * 2* THF 1 1 1 1 + 1 + 1 1 1 + THF:Water (98:2% v / v) GGG 2 * G 2 * 1+* 2+* G - Vitreous material at the bottom of the vial; 1 - Freebase pattern 1; 2 - Freebase pattern 2; 4 - Freebase pattern 4; + - Additional peaks observed (probably due to the presence of a co-former); * - Poorly crystalline Characterization of Freebase Standard 9 • The new freebase Standard 9 converts to Standard 4 after storage at 40°C / 75% RH, see FIG. 34. • Very small (~5 μm) weakly birefringent particles were observed by PLM. Agglomeration was observed. • TG / DSC determined that there were two mass losses in the TG trace. The first was an 8.2% by weight loss (4 eq. water, 0.82 eq. 1,4-dioxane, or 0.5 eq. L-histidine) and occurred between 55 °C and 175 °C. The second was a 3.8% by weight loss (1.75 eq. water, 0.36 eq. 1,4-dioxane, or 0.2 eq. L-histidine) between 255 °C and 290 °C. Decomposition began above 289 °C. There were several events in the DSC trace. One exothermic event with onset: 146 °C, peak: 164 °C. A second exothermic event with onset: 187 °C, peak: 195 °C. An endothermic event with a start temperature of 238 °C and a peak of 243 °C. A second endothermic event with a start temperature of 264 °C and a peak of 271 °C. See FIG. 35 for the TG / DSC. EXAMPLE 8. CRYSTALLIZATION SCREENING OF COMPOUND A • 34 x 40 mg of Compound A were weighed into vials before the solvents Petition 870250101903, dated 06 / 11 / 2025, pages 120 / 230 116 / 175 selected to be added to prepare pastes, whenever possible. See Table 29 for a list of solvent systems used and the volume of solvent used. • Stirring bars were added to the flasks before they were sealed and subjected to temperature cycles with agitation between 5°C and 40°C. The heating rate was 0.1°C / min and the samples were kept at 5°C and 40°C for 2 hours. • After temperature cycling for 4 days, observations were made (see Table 29). The pastes were centrifuged and the solids were analyzed by XRPD. • The solids were dried at 40°C for approximately 18 h before being reanalyzed by XRPD. • The saturated solutions were then divided into 3 flasks for the following experiments: • Evaporation at room temperature • Cooling (5 °C) • Where no solid was obtained after 72 hours, the samples were moved to the freezer at -20°C for further cooling. • Where no solid was obtained from further cooling, the samples were allowed to evaporate at room temperature. • Addition of antisolvent at room temperature • Where no solid was obtained after 72 hours, the samples were moved to the freezer at -20°C to encourage crystallization. • Where no solid was obtained from cooling, the samples were allowed to evaporate at room temperature. [ 0367] The free base forms were characterized by PLM, TG / DSC and 1H NMR. Petition 870250101903, dated 06 / 11 / 2025, pages 121 / 230 117 / 175 Table 29: List of solvent systems used in the primary crystallization screen with the volume used and observations after temperature cycling_______ No. System Solvent Solvent Volume (mL) Observations after temperature cycle 1 1-butanol 20 Whitish fluid paste 2 1-Propanol 20 Whitish fluid paste 3 1,4-Dioxane 0.3 Whitish solid, orange solution 4 2-Butanone (MEK) 20 Colorless solution 5 2-Ethoxyethanol 20 Whitish thin fluid paste 6 2-Methyl THF 20 Colorless solution 7 3-Methyl-1-butanol 20 Whitish fluid paste 8 2-Propanol 20 Whitish fluid paste 9 Acetona 20 Colorless solution 10 Acetonitrile 20 Whitish fluid paste 11 Anisole 0.3 Whitish solid, gray solution 12 tert-Butylmethyl ether 20 Whitish fluid paste 13 Butyl acetate 20 Whitish fluid paste 14 Dichloromethane 0.3 Whitish solid,Gray solution 15 Ethanol 20 Whitish fluid paste 16 Ethyl acetate 20 Whitish fluid paste 17 Diethyl ether 20 Whitish fluid paste 18 Ethyl formate 20 Whitish fluid paste 19 Isopropyl acetate 20 Whitish fluid paste 20 Methanol 20 Whitish fluid paste 21 Methyl isobutyl ketone 20 Whitish fluid paste 22 N,N'-Dimethylacetamide 0.3 Pale brown solution Petition 870250101903, dated 06 / 11 / 2025, pages 122 / 230 118 / 175 23 N,N'-Dimethylformamide 0.3% Pale brown solution 24 N-Methylpyrrolidone 0.3% Orange solution 25 Tetrahydrofuran 0.3% Whitish solid, gray solution 26 Toluene 20% Whitish fluid paste 27 Water 20% Whitish fluid paste 28 Acetone:Water (90:10% v / v) 20% Colorless solution 29 Acetonitrile:Water (75:25% v / v) 20% Whitish fluid paste 30 Ethane:Water (50:50% v / v) 20% Whitish fluid paste 31 2-Propanol:Water (90:10% v / v) 20% Whitish fluid paste 32 Tetrahydrofuran:Water (98:2% v / v) 0.3 Yellow solution 33 Dichloromethane:Methanol (50:50% v / v) 0.3 Whitish solid, gray solution 34 Dichloromethane:Methanol (75:25% v / v) 0.3 Gray / purple solution • Six free-base patterns were elucidated on the primary crystallization screen. • Patterns 1 and 2 were observed previously. • Patterns 5 through 8 were recently obtained. • Patterns 3 and 4, which were obtained on the salt screen, and Pattern 9, which was obtained on the cocrystal screen, were not observed on the crystallization screen. • Freebase Pattern 1 was most commonly recovered from the experiments. • Standards 5 and 7 were converted to Standard 8 after drying at 40°C.

[0368] See Table 30 for a summary of the XRPD Patterns obtained during Petition 870250101903, dated 06 / 11 / 2025, pages 123 / 230 119 / 175 primary crystallization screening. Table 30: Summary of XRPD patterns obtained during primary crystallization screening. Solvent Post-Thermal Cycling Post-Thermal Cycling (dry) Evaporation Cooling Addition of Antisolvent 1-butanol 1 * 1 * 1-Propanol 1 * 1 * A 1,4-Dioxane AA* A x A e A 2-Butanone (MEK) 1 1 *e 1 * e 2-Ethoxyethanol 1 * 1 * 1 * 2-Methyl THF 1 * 1 e 1 * 3-Methyl-1-butanol 1 * 1 * 2-Propanol 1 * 1 * Aceto em 1 * 2*e 1 e Acetonitrile 1 1 A+ Ax Anisole 5 8 tert-Butylmethyl ether A; Some peaks of 1 A; Some peaks of 1 Butyl acetate 1 1 Dichloromethane 6 6 6* 6* and Ethanol 1 * 1 * Ax Ethyl acetate 1 1 A; Some peaks of 1 Diethyl ether 1 * 1 * Ax Ethyl formate 1 * A; Some peaks of 1 X 1 * and Isopropyl acetate 1 * 1 * Ax Methanol 2* 2* A x A and Methyl isobutyl ketone 1 1 Ax N,N'-Dimethylacetamide 1 * 1 N,N'-Dimethylformamide 1 A and 1 N-Methylpyrrolidone 1 * Tetrahydrofuran 1 1 1 * Toluene 7 8 Water AA Petition 870250101903, dated 06 / 11 / 2025, pp. 124 / 230 120 / 175 Acetone:Water (90:10% v / v) 2 6* and 2* Acetonitrile:Water (75:25% v / v) 6 6 6 6* and 2* Ethanol:Water (50:50% v / v) A; Some peaks of 2 A; Some peaks of 2 Ax 2-Propanol:Water (90:10% v / v) A; Some peaks of 2 A; Some peaks of 2 Tetrahydrofuran:Water (98:2% v / v) 1 * A Dichloromethane:Methanol (50:50% v / v) 2 2 2* 2* 2* Dichloromethane:Methanol (75:25% v / v) 6 * A and A empty - No solid; A - Amorphous; 1 - Free base pattern 1; 2 - Free base pattern 2; 5 - Free base pattern 5; 6 - Free base pattern 6; 7 - Free base pattern 7; 8 - Free base pattern 8; + - Additional peaks observed (probably due to the presence of a co-former); * - Poorly crystalline; x - Very little solid; e - Solids obtained by evaporation Characterization of Free-Based Forms Standard Solvent System PLM TG / DSC 1H NMR Comment 1 21 of 34 solvent systems tested (via temperature cycling, evaporation and antisolvent addition) No clear morphology; appeared weakly birefringent Onset of melting 240 °C; <0.1 equiv. of 2-ethoxyethanol (or 0.3 equiv. of water) released on melting. Decomposition above ~ 295 Consistent with Anhydrous Compound A; potential thermodynamic form Petition 870250101903, dated 06 / 11 / 2025, pages 125 / 230 121 / 175 °C 2 Methanol (temperature cycling), acetone / water (90:10 %v / v) by evaporation and addition of antisolvent, MeCN / water (75:25 %v / v) by addition of antisolvent and DCM / MeOH (50:50 %v / v) by all methods. Distinct, needle-like and lath-like particles; appeared birefringent. Loss of 0.3 equiv. of MeOH, 0.1 equiv. of DCM or 0.5 equiv. of water below 50 °C. Decomposition onset -314 °C. Melting onset 243 °C. Consistent with Compound A. Potential anhydrous form containing unbound solvent. Melting onset similar to Standard 1. Alternatively, it could be a bemi-hydrate that dehydrated to Standard 1. 3 1,4-dioxane (converted from amorphous when dried). Also observed during salt screening with HCl, glutamic acid, succinic acid, and acetic acid; all in 1,4- Some rod-like particles and clusters; appeared birefringent 0.2 equiv. of 1,4-dioxane or 1 equiv. of water lost up to 150 °C. Loss of 0.6 equiv. of 1,4-dioxane or 2.9 equiv.of water associated with a melt (initial 178 °C) and N / A Potential solvate of 1,4-dioxane that desolvated and recrystallized to Standard 1. Petition 870250101903, dated 06 / 11 / 2025, pp. 126 / 230 122 / 175 Recrystallization event of dioxane (onset 198 °C). Obvious decomposition above -302 °C. Onset of melting 236 °C. 4 Observed during salt screening with malonic acid and benzoic acid; both in 1,4-dioxane. Some rod-like and lath-like particles and clusters; appeared birefringent. Loss of 0.5 equiv. of 1,4-dioxane or 2.6 equiv. of water between 60 and 150 °C, immediately followed by a melting (onset 169 °C) and recrystallization event (onset 192 °C). Obvious decomposition above -302 °C. Onset of melting 235 °C. N / A Potential solvate of 1,4-dioxane that desolvated and recrystallized to Standard 1. 5 Anisole - - - Potential anisole solvate Petition 870250101903, dated 06 / 11 / 2025, pp. 127 / 230 123 / 175 (Converted to Standard 8 on drying) 6 DCM (temperature cycling), MeCN / water (75:25% v / v) by temperature cycling and evaporation and DCM / MeOH (75:25% v / v) by evaporation. Some needle-like particles and appeared birefringent. Loss of 0.2 equiv. of DCM or 1 equiv. of water up to 120 °C. Decomposition onset -306 °C. Melting onset 242 °C. Consistent with Compound A. 2.4% wt. % (0.23 eq.) ethyl acetate. It is unclear whether it is anhydrous or hydrated. Melting onset similar to Standard 1. Diffraction pattern similar to Standard 2. 7 Toluene (converted to Standard 8 on drying). Potential toluene solvate. 8 Drying of Standards 5 and 7. No clear morphology; Appeared weakly birefringent. 1 equiv. of anisole lost below 100 °C (0.2 equiv. of toluene in another sample). Onset of decomposition ~291 °C. Onset of N / A. Potential anhydrous form produced on desolvation of anisole (Standard 5) and toluene (Standard 7) solvates. Possibly recrystallized to Standard 1. Petition 870250101903, dated 06 / 11 / 2025, pages 128 / 230 124 / 175 Recrystallization 192 °C. Onset of melting 238 °C. 9 1,4-Dioxane from cocrystal sieve (Converted to Standard 4 after storage at 40°C / 75% RH) No clear morphology; appeared weakly birefringent. Agglomeration observed 8.2% by weight (4 equiv. of water or 0.8 eq. 1,4-dioxane) lost between 55°C and 175°C. 3.8% by weight (1.75 eq. water or 0.4 eq. 1,4-dioxane) lost between 255 °C and 290 °C. Onset of decomposition ~ 289 °C. Exothermic event with onset: 146 °C, peak: 164 °C. Exothermic event with onset: 187 °C, peak: 195 °C. Endothermic event - 1,4-dioxane solvate potential. Petition 870250101903, dated 06 / 11 / 2025, pages 129 / 230 125 / 175 Starting temperature: 238 °C, peak: 243 °C. Endothermic event starting temperature: 264 °C, peak: 271 °C. Free base pattern 1 • A 0.6% mass loss associated with melting was observed in the TG trace – probably due to the release of trapped solvent after melting. Decomposition observed above approximately 295 °C. A pronounced endothermic event was observed in the DSC trace (beginning 240 °C) probably due to melting. See FIG. 39. • No clear morphology observed by PLM. The clumps were visible. The material appeared weakly birefringent under polarized light. • FT-IR analysis revealed that the spectra of the freebase Pattern 1 were very similar to the amorphous freebase. A CC triple bond peak was evident at 2214 cm⁻¹. Some potential THF peaks were observed at higher wavenumbers. See FIG. 40. Freebase Standard 2 • TG / DSC analysis determined that there was an initial mass loss of 1.1% in the TG trace from the start of heating, probably due to the unbound solvent (0.3 eq. methanol, 0.1 eq. DCM, or 0.5 eq. water). Decomposition was evident at approximately 314 °C. A pronounced endothermic event due to melting was observed in the DSC trace with an onset of 243 °C. Melting occurred at a temperature similar to Standard 1. See FIG. 41. • PLM analysis determined that the morphology of the free-based Pattern 2 consisted of needles and lath-like particles of various sizes. The material Petition 870250101903, dated 06 / 11 / 2025, pages 130 / 230 126 / 175 appeared birefringent under polarized light, indicative of a crystalline material. • FT-IR analysis revealed that the spectra of the freebase Standard 2 were very similar to the amorphous freebase. A CC triple bond peak was evident at 2220 cm⁻¹. There was no clear evidence of solvent or water. See FIG. 42. Freebase Standard 3 • TG / DSC analysis determined that there was a gradual mass loss of 2.3% from the start of heating to approximately 150°C observed in the TG trace. This mass loss was likely a result of the loss of unbound solvent (0.2 or 1 eq. of 1,4-dioxane or water, respectively). A second stepped mass loss (6.1%) was observed between 150 and 240°C (0.6 or 2.9 eq. of 1,4-dioxane or water, respectively). In the DSC trace, a possible melting / recrystallization event appeared to occur during this mass loss with onsets at 178 and 198°C. After the recrystallization event, an endothermic event associated with melting was observed (onset at 236°C) – similar to Standard 1. See FIG. 43. • PLM analysis determined that the morphology appeared to consist of rods and clusters. The material appeared birefringent under polarized light. • FT-IR analysis revealed that the spectra of the freebase Pattern 3 were very similar to the amorphous freebase; however, some additional weak peaks were present at higher wavenumbers. Possibly due to the presence of 1,4-dioxane and / or water. A CC triple bond peak was evident at 2222 cm⁻¹. See FIG. 44. Free base standard 4 • In TG / DSC, a gradual mass loss of 1.0% was observed in the TG trace from the beginning of heating, up to approximately 50°C - probably a result of the loss of unbound solvent. A second stepped mass loss of 5.4% was observed between 60 and 150°C (0.5 or 2.6 eq. of 1,4-dioxane or Petition 870250101903, dated 06 / 11 / 2025, pages 131 / 230 127 / 175 water, respectively). This indicated that Pattern 4 was a possible dioxane solvate. Following this potential desolvation, a possible melting / recrystallization event was observed in the DSC trace with onsets of 169 and 192 °C. After the recrystallization event, an endothermic event associated with melting was observed (onset at 235 °C) – similar to Pattern 1. See FIG. 45. • PLM analysis determined that the morphology appeared to consist of rods, strips, and clusters. The material appeared birefringent under polarized light. • FT-IR analysis revealed that the spectra of the freebase Pattern 4 were very similar to the amorphous freebase; however, some additional weak peaks were present at higher wavenumbers, possibly due to the presence of 1,4-dioxane and / or water. A CC triple bond peak was evident at 2223 cm⁻¹. See FIG. 46. Freebase Standard 6 • TG / DSC analysis found a 2.1% mass loss in the TG trace from the beginning to approximately 120°C (0.2 eq. of DCM or 1 eq. of water). Decomposition was observed above 306°C. In the DSC trace, a pronounced endothermic event due to melting was observed (beginning at 242°) – similar to Standard 1. Additionally, a 0.3% mass loss was observed in the TG trace during melting – likely trapped solvent. See FIG. 47. • PLM analysis revealed that the morphology consisted of needle-like particles, with some clusters visible. The material appeared weakly birefringent under polarized light. • FT-IR analysis revealed that the spectra of the freebase Pattern 6 were very similar to the amorphous freebase. A CC triple bond peak was evident at 2221 cm-1. See FIG. 48. Free base standard 8 • TG / DSC analysis of the dried anisole sample found a loss of Petition 870250101903, dated 06 / 11 / 2025, pages 132 / 230 128 / 175 14% by mass from the start of heating up to 100°C (1.2 eq. of anisole - possible solvate). Decomposition was observed above 307°C. In the DSC trace, a series of weak thermal events were observed after possible desolvation before a pronounced endothermic event (onset 237°C) was observed - similar to Pattern 1. See FIG. 49. • The anisole sample was further dried and then reanalyzed by TG / DSC. In this TG trace, a mass loss of 12.4% was observed from the beginning of heating up to 100°C (1.1 equiv. of anisole - possible solvate). Decomposition was observed above 291°C. In the DSC trace, a potential recrystallization event (onset 192°C) was observed after dissolution and a pronounced endothermic event (onset 238°C) due to melting was observed. See FIG. 50. • TG / DSC analysis of the dry toluene sample revealed two mass losses of 1% and 1.1% from the start of heating up to 125 °C (0.2 eq. of toluene). Decomposition was observed above 290 °C. A potential recrystallization event (onset 193 °C) was observed in the DSC trace after solvent loss. Finally, a pronounced endothermic event (onset 238 °C) due to melting was observed in the DSC trace, and a small mass loss associated with melting was observed in the TG trace. See FIG. 51. • PLM analysis did not find a clear morphology and that agglomeration was present. The material appeared birefringent under polarized light. • FT-IR analysis revealed that the spectra of the free-base anisole Pattern 8 were very similar to the amorphous free-base, although some slight shifts were observed. A CC triple bond peak was evident at 2220 cm⁻¹. Some peaks potentially due to anisole were present just above 3000 cm⁻¹. See FIG. 52. • FT-IR analysis revealed that the spectra of toluene freebase Pattern 8 were very similar to the amorphous freebase, although some shifts Petition 870250101903, dated 06 / 11 / 2025, pages 133 / 230 129 / 175 have been observed. A CC triple bond peak was evident at 2220 cm-1. See FIG. 53. EXAMPLE 9. SECONDARY CRYSTALLIZATION SCREENING OF COMPOUND A Amplification of Free Base Standards 1, 2 and 6 • Ca. Samples of 250 mg of Compound A were weighed into three scintillation vials. • The samples were dissolved in the appropriate solvents and the observations were recorded, see the table below. • A magnetic stirrer bar was added to each sample, and the solutions were subjected to temperature cycles between 5°C and 40°C at a heating rate of 0.1°C / min, with a holding time of 2 hours at each temperature for a total of 72 hours. • After approximately 72 hours, the observations were recorded, and the samples were uncovered and left to evaporate under ambient conditions for approximately 20 hours.

[0369] See Table 31 for experimental details and observations made during the first magnification attempt on free-base Patterns 1, 2, and 6. Table 31: Details of the first attempt to extend the Freebase Standards 1, 2, and 6 Petition 870250101903, dated 06 / 11 / 2025, pp. 134 / 230 130 / 175 Target Standard Solvent Volume (mL) Observations before temperature cycle Observations after temperature cycle Observations after evaporation 1 THF 2.5 Purple solution Whitish fluid paste White solids 2 DCM:Methanol (50:50 % v / v) 2.5 Purple solution Purple fluid paste Whitish solids 6 DCM 2.5 Purple solution Purple fluid paste Whitish solids • The correct shapes were obtained, but the samples were less crystalline than desired; therefore, 1 mL of the appropriate solvent was added to each sample to re-process and improve the crystallinity of the solids. • The pastes were subjected to temperature cycles between room temperature and 40°C over 4-hour cycles in an incubator shaker. • After approximately 72 hours, observations were made and the solids were isolated by centrifugation. • The solids were analyzed by XRPD and then gently dried in an oven at 40°C for approximately 20 hours. • Once dry, the material was characterized by XRPD, TG / DSC and 1H NMR. • The freebase Standard 1 was further characterized by DSC, DVS, and optical rotation.

[0370] See Table 32 for experimental details and observations made during the second magnification attempt on freebase Patterns 1, 2, and 6. Table 32: Details of the second attempt to extend the Freebase Patterns 1, 2, and 6 Standard | Solvent Volume (mL) Observations before the cycle Observations after the cycle Observations after centrifugation Petition 870250101903, dated 06 / 11 / 2025, pages 135 / 230 131 / 175 Destination Temperature Temperature 1 THF 1 Whitish fluid paste Whitish fluid paste White solids 2 DCM:Methanol (50:50 % v / v) 1 Purple fluid paste Purple fluid paste Whitish solids 6 DCM 1 Purple fluid paste Purple fluid paste Whitish solids Characterization of Freebase Patterns 1, 2 and 6.

[0371] XRPD analysis of the dry freebase forms determined that the forms were retained Freebase pattern 1 • PLM analysis found small particles with a needle-like morphology. Agglomeration was observed. The material appeared slightly birefringent under polarized light. • For TG / DSC, no notable mass losses were observed in the TG trace before decomposition (above 310 °C). An endothermic event due to melting was observed (onset at 239 °C) in the DSC trace. See FIG. 54. • The 1H NMR spectrum was consistent with the structure. 0.32 wt% (0.04 eq.) of THF was present in the sample. See FIG. 55. No peak shift was observed compared to the 1H NMR of Compound A. • DSC analysis of the freebase Pattern 1 found a pronounced endothermic event in the first heating cycle with an onset at 239°C and a peak at 242°C; this was due to the melting of the material. See FIG. 56. • During the cooling cycle, an exothermic event was observed, starting at 164°C and peaking at 158°C. A glass transition with a midpoint at 119°C was also observed. See FIG. 57. Petition 870250101903, dated 06 / 11 / 2025, pages 136 / 230 132 / 175 • The exothermic event was also observed in the DSC analysis of the 3 g batch of Standard 1 of Compound A and, therefore, was confirmed as intrinsic to the form. • The second heating cycle encountered a glass transition with a midpoint at 123°C and a broad endothermic event starting at 147°C. See FIG. 58. • The endothermic event was also observed in the DSC analysis of the 3 g batch of Standard 1 of Compound A and was therefore confirmed as intrinsic to the form. See FIGS. 83-85. • Modulated DSC analysis was performed on a 3 g batch of Standard 1 of Compound A. It showed that the endothermic melting event was present in both the reversal and non-reversal heat flow with slightly different onsets at 239°C and 237°C, respectively. Additionally, an exothermic event was observed in the non-reversible heat flow with an onset at 245°C, likely due to decomposition. (FIG. 59) • DVS analysis of the freebase Standard 1 determined that the material was slightly hygroscopic with a mass absorption of 1.17 wt% (0.53 eq.) of water. The isothermal plot was a type 1 isothermal. See FIG. 60. No shape change was observed in the kinetic plot. See FIG. 61. XRPD analysis confirmed that there was no shape change after DVS. See FIG. 62. • For optical rotation, samples and blanks were prepared with DCM. Optical rotation produced a relative rotation [σ]^η^ of -11.460° at 0.00969 g / mL in DCM for the free-base Standard 1. Freebase pattern 2 • PLM analysis found small particles with an unclear morphology. Agglomeration was observed. The material appeared birefringent under polarized light. • Freebase TG / DSC of Pattern 2 found a small loss of mass. Petition 870250101903, dated 06 / 11 / 2025, pages 137 / 230 133 / 175 of 0.97% by weight at the beginning of the experiment in the TG trace, probably due to surface moisture. Decomposition was observed above 305 °C. In the DSC trace, a small exothermic event was observed (beginning 222 °C). Followed by an endothermic event due to melting (beginning 242 °C). • The 1H NMR spectrum was consistent with the structure. No residual solvent was observed in the sample. No peak shift was observed compared to the 1H NMR of Compound A. Freebase pattern 6 • PLM analysis found very small particles with unclear morphology. Agglomeration was observed. The material was weakly birefringent under polarized light. • TG / DSC analysis found a small mass loss in the TG trace of 1.3% by weight at the beginning of the experiment, probably due to surface moisture. Decomposition was observed above 305 °C. In the DSC trace, an endothermic event due to melting was observed (beginning 241 °C). See FIG. 65. • The 1H NMR spectrum was consistent with the structure. 0.67 wt% (0.08 eq.) of THF was present in the sample. See FIG. 66. No peak shift was observed compared to the 1H NMR of Compound A. Competitive Paste Experiments • Eight samples were prepared containing 10 mg of free base standards 1, 2, and 6. • The appropriate solvent systems were added and observations were recorded. • After agitation at room temperature or 40°C, observations were recorded and samples were centrifugally filtered. The resulting solids were analyzed by XRPD.

[0372] See Table 33 for details and experimental observations. Petition 870250101903, dated 06 / 11 / 2025, pages 138 / 230 134 / 175 Table 33: Details of the competitive paste experiments Number System Solvent Volume (ML) Notes before stirring Temperature Notes after stirring 1 THF:Heptane (50:50 % v / v) 200 Purple fluid paste Room temperature Whitish fluid paste 2 DCM:Methanol (20:80 % v / v) 200 Purple fluid paste Whitish fluid paste 3 DCM:Heptane (50:50 % v / v) 200 Purple fluid paste Whitish fluid paste 4 Water 200 Purple fluid paste Whitish fluid paste 5 THF:Heptane (50:50 % v / v) 200 Purple fluid paste 40 °C Whitish fluid paste 6 DCM:Methanol (20:80 % v / v) 200 Purple fluid paste Whitish fluid paste 7 DCM:Heptane (50:50 % v / v) 200 Purple fluid paste Whitish fluid paste 8 Water 200 Purple fluid paste Whitish fluid paste • Due to inconclusive results, the solids were returned to the sample vials and 100 μL of the appropriate solvent was added to each sample. The samples were then capped and sealed with parafilm and shaken at room temperature or 40°C as before. • After agitation for 72 hours, the solids were analyzed by XRPD. Competitive fluid paste in ethanol • An additional competitive fluid paste experiment was created by combining approximately 5 mg of each of Standards 1, 2, and 6 of Compound A. • 200 μL of ethanol were added to obtain a whitish, fluid paste. • The sample was agitated at 40°C for approximately 72 hours. • After 72 hours, a whitish, fluid paste was obtained, which was then centrifugally filtered. • The solids were analyzed by XRPD. Petition 870250101903, dated 06 / 11 / 2025, pages 139 / 230 135 / 175 • Competitive fluid paste in ethanol yielded Freebase Standard 1 Competitive flowable pastes in DCM / ethanol • A 1:1 mixture of 5 mg of Standards 1 and 2 of Compound A was prepared in a 2 mL screw-cap sample vial. • A mixture of 1 mg of Standard 1 of Compound A and 4 mg of Standard 2 of Compound A was prepared in a 2 mL screw-top sample vial. • There was not enough Standard 1 material remaining from the scale for the material to be recovered from the primary crystallization screen and dried at 40°C for approximately 3 hours. • 500 μL of 5% DCM in ethanol were added to the 1:1 mixture and 500 μL of 10% DCM in ethanol were added to the 1:4 mixture to form fluid pastes. • Both samples were capped, sealed in parafilm, and shaken at room temperature over the weekend. • After approximately 72 hours, the solids were isolated by centrifugation at 7500 rpm for 60 seconds and analyzed by XRPD. • The sample with 5% DCM in ethanol produced Standard 1 of Compound A, and the sample with 10% DCM in ethanol produced Standard 2 of Compound A. • Free-base Pattern 1 was determined to be the thermodynamic form; however, DCM showed a preference for Free-base Pattern 2. Table 34: Summary table of XRPD results from the first set of competitive fluid paste experiments. Petition 870250101903, dated 06 / 11 / 2025, pages 140 / 230 136 / 175 Number System Solvent Temperature XRPD 1 THF:Heptane (50:50% v / v) Ambient Standard 1 2 DCM:Methanol (20:80% v / v) Standard 2 3 DCM:Heptane (50:50% v / v) Mix of Standards 1 and 2 4 Water Mix of Standards 1 and 2 5 THF:Heptane (50:50% v / v) 40°C Standard 1 6 DCM:Methanol (20:80% v / v) Mix of Standards 1 and 2 7 DCM:Heptane (50:50% v / v) Standard 2 8 Water Mix of Standards 1 and 2 Table 35: Summary table of XRPD results from the second set of competitive fluid paste experiments Number System Solvent Temperature XRPD 1 THF:Heptane (50:50% v / v) Ambient Standard 1 2 DCM:Methanol (20:80% v / v) Standard 2 3 DCM:Heptane (50:50% v / v) Mix of Standards 1 and 2 4 Water Standard 1 5 THF:Heptane (50:50% v / v) 40°C Standard 1 6 DCM:Methanol (20:80% v / v) Standard 2 7 DCM:Heptane (50:50% v / v) Mix of Standards 1 and 2 8 Water Standard 1 Heating Experiment of Standard 1 of Compound A • Approximately 4 mg of Standard 1 of Compound A were heated to 250°C using the TG / DSC. • The sample was then analyzed by 1H NMR. • No change was observed in the 1H NMR spectrum after heating the sample to 250°C. This indicated that the sample did not degrade after being heated to this temperature. (FIG. 67) Petition 870250101903, dated 06 / 11 / 2025, pp. 141 / 230 137 / 175 Table 36: Characterization of the scaled freebase patterns 1, 2 and 6 XRPD Standard Solvent PLM TG / DSC 1H NMR 1 DCM Small needle-like particles. Agglomeration. Weakly birefringent. No mass loss. Decomposition above 310 °C. Melting onset 239 °C. Consistent with structure. 0.32 wt% (0.04 eq.) THF 2 DCM: methanol Small particles, unclear morphology. Agglomeration. Birefringent. No mass loss. Decomposition above 305 °C. Melting onset 242 °C. Consistent with structure. No residual solvent observed. 6 THF Very small particles, unclear morphology. Agglomeration. Weakly birefringent. No mass loss. Decomposition above 305 °C. Melting onset 241 °C. Consistent with structure. 0.67% by weight (0.08 eq.) of THF Table 37: Complete characterization of Standard 1 of the free base Standard 1 of Compound A PLM Very small birefringent particles, needle-shaped morphology < 5 μm in length 1H NMR Consistent with the structure. 0.32 wt% (0.04 eq.) of THF TG / DSC No mass loss, degradation above 310 °C. Melting start 239 °C DSC First heating cycle Melting start 239 °C (241 °C) Cooling cycle Broad exothermic event starting at 164 °C followed by a glass transition with a midpoint at 119 °C (Sharp exothermic event starting at 168 °C followed by a glass transition with a midpoint at 118 °C) Second heating cycle Glass transition with a midpoint of 123 °C followed by a broad endothermic event starting at 147 °C (Glass transition with a midpoint at 123 °C followed by an endothermic event starting at 166 °C and a shoulder peaking at 156 °C) DVS Slightly hygroscopic 1.17% by weight (0.53 eq.) of water at 90% RH. No change in form Petition 870250101903, dated 06 / 11 / 2025, pages 142 / 230 138 / 175 Optical rotation [a] value from -11.460°C to 19.5°C, 598 nm HPLC purity 99.01% relative area Table 38: Characterization of the 3 g batch of Standard 1 free base Standard 1 of Compound A (3 g batch) PLM Small birefringent particles (approx. 5 μm), unclear morphology TG / DSC No mass loss, degradation above 310 °C. Melting onset at 240 °C 1 _ H NMR Consistent with structure. 0.6% by weight (0.1 eq.) ethanol, 1.1% by weight (0.1 eq.) IPA Purity 97.35% relative surface area % Yield 90.2% Table 39: Summary of competitive fluid paste experiments Number System Solvent Temperature XRPD 1 THF:Heptane (50:50% v / v) Ambient Standard 1 2 DCM:Methanol (20:80% v / v) Standard 2 3 DCM:Heptane (50:50% v / v) Mix of standards 1 and 2 4 Water Standard 1 5 THF:Heptane (50:50% v / v) 40°C Standard 1 6 DCM:Methanol (20:80% v / v) Standard 2 7 DCM:Heptane (50:50% v / v) Mix of standards 1 and 2 8 Water Standard 1 9 Ethanol Standard 1 10 DCM:Ethanol (5:95% v / v) Ambient Standard 1 11 DCM:Ethanol (10:90% v / v) Standard 2 EXAMPLE 10. SCREENING OF SECONDARY SALT FROM COMPOUND A Expand • Three 250 mg samples of free base were dissolved in the appropriate solvent system to obtain light purple solutions. Petition 870250101903, dated 06 / 11 / 2025, pages 143 / 230 139 / 175 • 1.05 equivalents of the appropriate acids were added to each sample. • See Table 40 for experimental details of the scale-ups. Table 40: Details of the scale-up of the secondary salt screen No. Target Salt Solvent Volume (mL) Strength 1 Tosylate Standard 1 THF 2.2 1.05 eq. p-toluenesulfonic acid monohydrate in 200 μL of THF 2 Besylate Standard 1 THF 2.2 1.05 eq. Benzenesulfonic acid in 200 μL THF:Water (98:2% v / v) 3 Phosphate Standard 1 THF:Water (98:2% v / v) 2 1.05 eq. 1 M phosphoric acid in THF • The sample vials were capped and sealed in parafilm and then subjected to temperature cycles between room temperature and 40°C over 4-hour cycles for approximately 72 hours. • Observations were made before and after the temperature cycle, see Table 41. Table 41: Observations made during the scale-up No. Target Salt Observations before temperature cycle Observations after temperature cycle Observations after drying 1 Tosylate Standard 1 Whitish fluid paste Pale pink fluid paste Whitish solids 2 Besylate Standard 1 Whitish fluid paste Red gel in red solution Red solids 3 Phosphate Standard 1 Whitish fluid paste Light gray fluid paste Whitish solids • The samples were centrifugally filtered and the solids obtained from the pastes Petition 870250101903, dated 06 / 11 / 2025, pp. 144 / 230 140 / 175 were analyzed by XRPD. • The solids and gel were dried under vacuum at 40°C for approximately 20 hours. • The dry solids were analyzed by XRPD and subjected to NMR analysis. • The samples were again suspended in 1.5 mL of the appropriate solvent system. • An additional 1.05 eq. of the phosphoric acid stock solution was added to the phosphate sample. • The samples were then subjected to temperature cycles between room temperature and 40°C over 4-hour cycles for a total of 1 week. • After 1 week, the samples were isolated by centrifugation and the resulting solids were analyzed by XRPD.

[0373] See Table 42 for details and observations made during the second attempt. Table 42: Details of the second scale-up attempt No. Target Salt Solvent Volume (mL) Observations before temperature cycle Observations after temperature cycle Observations after drying 1 Tosylate Standard 1 THF 1.5 Pale pink runny paste Pale pink runny paste Whitish solids 2 Besylate Standard 1 THF:Water (98:2% v / v) 1.5 Red runny paste Light orange runny paste Whitish solids 3 Phosphate Standard 1 THF 1.5 Light gray runny paste Light gray runny paste Whitish solids • The solids were then gently dried at 40°C for approximately 20 hours. • The dry solids were analyzed by XRPD, multinuclear NMR, and CAD. Petition 870250101903, dated 06 / 11 / 2025, pages 145 / 230 141 / 175 (where applicable) and TG / DSC. NMR analysis of the material after the initial scale-up attempt • The 1H NMR spectrum of the tosylate sample before the new suspension determined that there was a 1:1 ratio of p-toluenesulfonic acid to the free base of Compound A. 0.32 wt% (0.04 eq.) of THF was present in the sample. A slight peak shift was observed compared to the 1H NMR of Compound A. • The 1H NMR spectrum of the besylate sample was consistent with the structure; a 1:1 ratio of benzenesulfonic acid to the free base of Compound A was observed. 4.04 wt% (0.5 eq.) THF was present in the sample. A slight peak shift was observed compared to the 1H NMR of Compound A. • The 1H NMR spectrum of the phosphate sample was consistent with the structure. No solvent was observed in the sample. No phosphorus peaks were observed in the 31P NMR spectrum. No peak shift was observed compared to the 1H NMR of Compound A. This was not a phosphate salt, therefore additional phosphoric acid was added to the sample. Characterization of Enlarged Salts Tosylate Standard 1 • The enlarged sample matched the target standard by XRPD. • PLM analysis found very small particles; the morphology was unclear due to the small particle size. Agglomeration was observed. The material appeared weakly birefringent under polarized light. • A 1:1 ratio of Compound A to p-toluenesulfonic acid was observed in the spectrum. Approximately 0.24 wt% (0.03 eq.) of THF was present in the sample. See FIG. 68. A slight peak shift was observed compared to the 1H NMR of Compound A. Petition 870250101903, dated 06 / 11 / 2025, pages 146 / 230 142 / 175 • A mass loss of 3.1% by weight (1.23 eq. water or 0.31 eq. THF) was observed in the TG trace between ca. 90 °C and 220 °C. Decomposition was observed above 280 °C. An endothermic melting event beginning at 197.5 °C was observed in the DSC trace. See FIG. 69. Besylate Standard 1 • The enlarged sample matched the target standard by XRPD. • PLM analysis found very small particles with an unclear morphology. Agglomeration was observed. The material appeared weakly birefringent under polarized light. • The 1H NMR spectrum determined that there was a 1:1 ratio of Compound A to benzenesulfonic acid. 3.02 wt% (0.4 eq.) THF was observed in the sample. See FIG. 70. A slight peak shift was observed compared to the 1H NMR of Compound A. • A mass loss of 0.9% by weight (0.5 eq. water or 0.12 eq. THF) was observed in the TG trace from the beginning of the experiment, likely due to surface moisture. A second mass loss of 0.9% by weight (0.5 eq. water or 0.12 eq. THF) was observed between 45 °C and 90 °C. A third, larger mass loss of 1.45% by weight (0.79 eq. water or 0.20 eq. THF) was observed between 100 °C and 175 °C. Decomposition was observed above 210 °C. Two endothermic events were observed in the DSC trace: the first starting at 184 °C (melting) and the second starting at 261 °C. See FIG. 71. Phosphate Standard 1 • The enlarged sample matched the target standard by XRPD. • PLM analysis found very small particles with an unclear morphology. Agglomeration was observed. The material appeared weakly birefringent under polarized light. • The 1H NMR spectrum was consistent with the structure and contained a wide range of colors. Petition 870250101903, dated 06 / 11 / 2025, pp. 147 / 230 143 / 175 water peak indicative of salt formation. No residual solvent was observed in the sample. See FIG. 72. No peak shift was observed compared to the 1H NMR of Compound A. A phosphorus peak was observed in the 31P NMR spectrum, see FIG. 73. • A mass loss of 0.5% by weight (0.24 eq. water or 0.06 eq. THF) was observed in the TG trace from the beginning of the experiment. Another mass loss of 6.5% by weight (3.5 eq. water or 0.9 eq. THF) was observed between 70°C and 160°C. Decomposition was observed above 270°C. A large endothermic event was observed in the DSC trace related to mass loss between 50°C and 160°C. See FIG. 74. • The CAD analysis found the presence of 22.2% w / w of phosphate, which corresponds to approximately 2 eq. of phosphate (1 eq. = 10.8% by weight, 2 eq. = 19.5% by weight). Table 43: Characterization performed on the salts in scale. XRPD Standard Solvent PLM TG / DSC 1H NMR Tosylate Standard 1 THF Very small particles, unclear morphology. Agglomeration. Weakly birefringent. 3.1% by weight mass loss (1.23 eq. of water or 0.31 eq. THF) from the beginning. Decomposition above 280°C. Onset of melting: 197.5°C. 1:1 acid to free base. Slight peak shift. 0.24% by weight (0.03 eq.) of THF Besylate Standard 1 THF:water Very small particles, unclear morphology. Agglomeration. Weakly birefringent. 0.9% by weight mass loss (0.5 eq. of water or 0.12 eq. of THF) from the beginning, 0.9% by weight mass loss (0.5 eq. of water or 0.12 eq. of THF) between 45°C-90°C, 1.45% by weight mass loss (0.79 eq. of water or 0.2 eq. of THF) between 100°C-175°C. Two endothermic events; first 1:1 acid to free base. Slight peak shift. 3.02% by weight (0.4 eq.) of THF Petition 870250101903, dated 06 / 11 / 2025, pages 148 / 230 144 / 175 Initial reaction at 184°C, second reaction at 261°C. Phosphate Standard 1 THF. Very small particles, unclear morphology. Agglomeration. Weakly birefringent. 0.47% by weight mass loss (0.24 eq of water or 0.06 eq of THF) from the beginning, 6.46% by weight mass loss (3.5 eq of water, 0.87 eq of THF, or 0.64 eq of phosphoric acid) between 70°C and 160°C. Decomposition above 270°C. Broad endothermic event observed during the second mass loss. Broad water peak. Phosphate detected in 31P. EXAMPLE 11. DETERMINATION OF THERMODYNAMIC SOLUBILITY

[0374] The following procedure was used to determine the solubility of Compound A free base Standard 1, Compound A tosylate, Compound A besylate and Compound A phosphate. • Approximately 5 mg of the selected form of Compound A were weighed into a clear glass vial and 2 mL of buffer were added. • In each case, one folder persisted. • The pH of the solution was determined, then adjusted when necessary. • The pastes were stirred at 25°C. • At each time point, an aliquot was isolated and filtered through a 0.22μm nylon filter, then injected undiluted into the HPLC. • The LOQ for the HPLC method was determined to be 0.00025 mg / mL. • All data were reported cf free base concentration of Compound A. • The solubility was unfortunately too low to be detected by HPLC for all samples at pH 3.0 and pH 4.0. These were reported as having a Petition 870250101903, dated 06 / 11 / 2025, pp. 149 / 230 145 / 175 solubility < 0.00025 mg / mL, which was the LOQ for the experiment. • Free base Standard 1 had the highest solubility of 0.0693 mg / mL after 24 hours at pH 1.2. • From the salts, phosphate showed the highest solubility of 0.0306 mg / mL after 24 hours at pH 1.2. No clear solubility advantage of the salts was observed in relation to the free base of Compound A.

[0375] See Table 44 for a complete summary of the thermodynamic solubility determination results. Table 44: Summary of results for the determination of thermodynamic solubility. Analyte Tampã 0 0 HrpH (adjusted pH) 0 Hr Solubility e (mg / mL) 4-hour pH (adjusted pH) 4-hour pH (mg / mL) 24-hour pH (adjusted pH) 24-hour pH (mg / mL) Padrão 1 de Base Livre do Compost o A pH1.2 1.26 0.0001 1.35 (1.23) 0.0262 1.28 0.0693 pH 3.0 2.92 < 0.00025 ( <LOQ) 3 < 0,00025 (<LOQ) 2,93 < 0,00025 (<LOQ) pH 4,0 3,99 < 0,00025 (<LOQ) 4,07 < 0,00025 (<LOQ) 3,93 < 0,00025 (<LOQ) Tosilato do Compost o A pH1,2 1,29 0,0122 1,27 0,0154 1,27 0,0063 pH 3,0 2,94 < 0,00025 (<LOQ) 2,99 < 0,00025 (<LOQ) 2,96 < 0,00025 (<LOQ) pH 4,0 3,91 < 0,00025 (<LOQ) 3,92 < 0,00025 (<LOQ) 3,92 < 0,00025 (<LOQ) Fosfato do Compost o A pH1,2 1,25 0,0059 1,32 (1,24) 0,0291 1,24 0,0306 pH 3,0 2,75 (2,93) < 0,00025 (<LOQ) 2,91 < 0,00025 (<LOQ) 2,88 (3,04) < 0,00025 (<LOQ) pH 4,0 3,70 (3,94) < 0,00025 (<LOQ) 4,02 < 0,00025 (<LOQ) 4,03 < 0,00025 (<LOQ) Besilato do Compost o A pH1,2 1,24 0,0133 1,34 (1,23) 0,0073 1,17 0,0093 pH 3,0 2,94 < 0,00025 (<LOQ) 2,94 < 0,00025 (<LOQ) 2,94 < 0.00025 ( <LOQ) pH 4,0 3,84 (3,93) < 0,00025 (<LOQ) 4 < 0,00025 (<LOQ) 4,05 < 0,00025 (<LOQ), Petition 870250101903, dated 06 / 11 / 2025, pages 150 / 230 146 / 175 EXAMPLE 12. 7-DAY STABILITY EVALUATION • Three 10-15 mg samples of Compound A freebase Standards 1 and 2, as well as the tosylate and besylate salts of Compound A, were prepared. These were stored under the following stability conditions: • 40°C / 75% RH (open vial) • 80°C (closed vial) • Ambient light (closed vial) • The appearance of the samples was observed daily to monitor color changes. • After 7 days, the samples were analyzed by HPLC and XRPD. • HPLC analysis was also performed prior to the stability test. • The appearance of the samples did not change after 7 days under any stability condition. All remained white or off-white solids. • XRPD analysis determined that the standards were retained. The tosylate salt samples gained an additional peak. See FIGS. 75-78. • High purity was maintained for all samples. >99% relative area for free base Standard 1; >98% relative area for free base Standard 2; >96% relative area for tosylate Standard 1; >97% relative area for besylate Standard 1

[0376] See below for a summary of the results and tables of impurity peaks. Table 45: Summary of results from the 7-day stability assessment Sample No. Stability Condition XRPD Purity HPLC (% relative area) 1 Free base standard 1 N / A FB standard 1 99.01 2 40°C / 75% RH No change 99.00 Petition 870250101903, dated 06 / 11 / 2025, pages 151 / 230 147 / 175 3 80 °C No change 99.03 4 Ambient light No change 99.07 5 Tosylate Salt Standard 1 N / A Tosylate Standard 1 97.44 6 40°C / 75% RH Additional peak 97.30 7 80 °C Additional peak 96.76 8 Ambient light Additional peak 97.09 9 Besylate Salt Standard 1 N / A Besylate Standard 1 97.33 10 40°C / 75% RH No change 97.31 11 80 °C No change 97.56 12 Ambient light No change 97.17 13 Freebase Standard 2 N / A FB Standard 2 98.39 14 40°C / 75% RH No change 98.37 15 80 °C No change 98.33 16 Ambient light No change 98.27 Table 46: Impurity Peak Table of Free Base Standard 1 Peak Name Retention Time (min) RRT Average RRT Rei. Area % Rei. Average % of Area Unknown na 3.04 na 0.58 na na 0.05 0.05 1 Unknown 4.48 4.48 0.85 0.85 0.847 0.67 0.66 0.66 13 Unknown 5.16 5.17 0.98 0.98 0.977 0.07 0.07 0.07 5 Unknown 5.47 5.47 1.04 1.04 1.035 0.16 0.15 0.15 14 Unknown 5.75 5.75 1.09 1.09 1.088 0.06 0.06 0.06 Petition 870250101903, dated 06 / 11 / 2025, pages 152 / 230 148 / 175 10 Total impurities 0.99 Reported purity 99.01 Table 47: Peak impurity table of Freebase Standard 1 after 7 days at 40°C / 75% RH Peak Name Time of RRT RRT King. Area Rel. average retention average % (min) % of Area Unknown 3.02 3.02 0.57 0.57 0.571 0.04 0.04 0.04 1 Unknown 4.47 4.47 0.85 0.85 0.846 0.67 0.67 0.67 Unknown 5.17 5.17 0.98 0.98 0.977 0.07 0.07 0.07 5 Unknown 5.42 5.48 1.03 1.04 1.025 0.16 0.15 0.16 14 Unknown 5.76 5.76 1.09 1.09 1.089 0.06 0.06 0.06 10 Total impurities 1.00 Reported purity 99.00 Table 48: Peak impurity table of Freebase Standard 1 after 7 days at 80°C Peak Name | Retention Time (min) | Average RRT | Area Ratio | % | Average Area Ratio | % | Unknown | 3.03 | 3.02 | 0.57 | 0.57 | 1 | 0.04 | 0.04 | 0.04 | 1 | Unknown | 4.49 | 4.48 | 0.85 | 0.85 | 0.84 | 7 | 0.70 | 0.67 | 0.68 Petition 870250101903, dated 06 / 11 / 2025, pages 153 / 230 149 / 175 13 Unknown 5 5.18 5.17 0.98 0.98 0.97 0.07 0.06 0.06 Unknown 14 5.47 5.47 1.03 1.03 1.03 0.12 0.12 0.12 Unknown 10 5.76 5.75 1.09 1.09 1.08 0.06 0.06 0.06 Total impurities 0.97 Reported Purity 99.03 Table 49: Peak impurity table of Freebase Standard 1 after 7 days at room temperature. Peak Name Time of RRT RRT King. Area Rel. average retention average % of Area (min) % Unknown 13 4.48 4.48 0.85 0.85 0.846 0.68 0.67 0.68 Unknown 5 5.17 5.18 0.98 0.98 0.977 0.07 0.08 0.07 Unknown 14 5.46 5.46 1.03 1.03 1.031 0.11 0.11 0.11 Unknown 10 5.77 5.76 1.09 1.09 1.090 0.07 0.06 0.07 Total impurities 0.93 Reported Purity 99.07 Table 50: Impurity peak table for Tosylate Standard 1 Peak Name | Retention Time (min) | Average RRT | Area Ratio | % | Average Ratio | % | Unknown Area | 1 | Unknown | 3.03 | 3.02 | 0.57 | 0.57 | 0.57 | 2 | 0.10 | 0.10 | 0.10 | 3.44 | 3.44 | 0.65 | 0.65 | 0.65 | 1 | 0.05 | 0.05 | 0.05 Petition 870250101903, dated 06 / 11 / 2025, pp. 154 / 230 150 / 175 2 Unknown 4.48 4.49 0.85 0.85 0.846 0.76 0.76 0.76 13 Unknown 4.98 4.98 0.94 0.94 0.940 0.07 0.07 0.07 3 Unknown 5.12 5.12 0.97 0.97 0.967 0.10 0.10 0.10 4 Unknown 5.17 5.17 0.98 0.98 0.977 0.06 0.06 0.06 5 Unknown 5.21 5.21 0.98 0.98 0.984 0.09 0.08 0.08 6 Unknown 5.41 5.41 1.02 1.02 1.021 0.15 0.13 0.14 7 Unknown 5.48 5.47 1.03 1.03 1.035 0.86 0.89 0.87 14 Unknown 5.55 1.05 0.06 0.06 17 Unknown 5.76 5.76 1.09 1.09 1.089 0.08 0.08 0.08 10 Unknown 6.02 6.01 1.14 1.14 1.137 0.13 0.13 0.13 11 Unknown 6.11 6.10 1.15 1.15 1,154 0.06 0.06 0.06 12 Total impurities 2.56 Reported purity 97.44 Table 51: Peak impurity table of Standard 1 tosylate after 7 days. 40°C / 75% RH Petition 870250101903, dated 06 / 11 / 2025, pages 155 / 230 151 / 175 Peak Name Retention Time (min) of 10 RRT Average RRT Rel. Area Average Rel. % of Area % Unknown 1 3.04 3.02 0.58 0.57 0.577 0.10 0.09 0.10 Unknown 2 3.47 3.44 0.66 0.65 0.658 0.05 0.05 0.05 Unknown 13 4.48 4.49 0.85 0.85 0.850 0.76 0.76 0.76 Unknown 3 4.96 4.98 0.94 0.94 0.941 0.12 0.13 0.13 Unknown 4 5.10 5.13 0.97 0.97 0.968 0.10 0.10 0.10 Unknown 5 5.16 5.18 0.98 0.98 0.978 0.08 0.08 0.08 Unknown 6 5.19 5.21 0.98 0.98 0.985 0.08 0.08 0.08 Unknown 7 5.39 5.41 1.02 1.02 1.022 0.16 0.11 0.14 Unknown na 5.44 na 1.03 nana 0.14 0.14 Unknown 14 5.46 5.48 1.03 1.03 1.035 0.80 0.49 0.65 Unknown 9 5.65 5.68 1.07 1.07 1.072 0.07 0.33 0.20 Unknown 10 5.74 5.77 1.09 1.09 1.088 0.08 0.07 0.08 Unknown 11 5.99 6.02 1.14 1.14 1.135 0.13 0.12 0.13 Unknown 12 6.08 6.11 1.15 1.15 1.153 0.08 0.07 0.07 Total impurities 2.70 Reported Purity 97.30 Table 52: Peak impurity table of Standard 1 tosylate after 7 days. 80°C Peak Name Retention Time (min) Average RRT Area Ratio % Average Ratio % of Unknown Area 1 3.02 3.02 0.57 0.57 0.57 0.10 0.10 0.10 Petition 870250101903, dated 06 / 11 / 2025, pages 156 / 230 152 / 175 Unknown 3.44 3.45 0.65 0.65 0.649 0.05 0.05 0.05 2 Unknown 4.49 4.50 0.85 0.85 0.848 0.66 0.66 0.66 13 Unknown 4.98 4.99 0.94 0.94 0.941 0.19 0.18 0.18 3 Unknown 5.13 5.13 0.97 0.97 0.968 0.11 0.12 0.12 4 Unknown 5.17 5.19 0.98 0.98 0.977 0.08 0.08 0.08 5 Unknown 5.21 5.22 0.98 0.98 0.984 0.12 0.11 0.11 6 Unknown 5.41 5.42 1.02 1.02 1.021 0.30 0.31 0.31 7 Unknown 5.48 5.49 1.03 1.03 1.034 1.0 0.98 1.00 14 Unknown 5.55 5.56 1.05 1.05 1.048 0.08 0.08 0.08 17 Unknown 5.61 5.62 1.06 1.06 1.059 0.06 0.06 0.06 Unknown 5.67 5.68 1.07 1.07 1.071 0.06 0.11 0.08 9 Unknown 5.76 5.77 1.09 1.09 1.087 0.09 0.09 0.09 10 Unknown 5.83 5.83 1.10 1.10 1.100 0.09 0.08 0.08 Unknown 6.01 6.02 1.13 1.13 1.134 0.17 0.16 0.16 11 Unknown 6.10 6.11 1.15 1.15 1.151 0.08 0.08 0.08 Petition 870250101903, dated 06 / 11 / 2025, pages 157 / 230 153 / 175 Total impurities 3.24 Reported Purity 96.76 Table 53: Peak impurity table of Tosylate Standard 1 after 7 days at room temperature. Peak Name | Retention Time (min) | Average RRT | Average RRT | Area | % | Average Rel. | % | Area | Unknown | 1 | 3.02 | 3.05 | 0.57 | 0.57 | 0.09 | 0.09 | 0.09 | Unknown | 2 | 3.44 | 3.48 | 0.65 | 0.66 | 0.65 | 0.05 | 0.07 | 0.06 | Unknown | 1 | 3 | 4.48 | 4.50 | 0.85 | 0.85 | 0.84 | 0.76 | 0.76 | 0.76 | Unknown | 3 | 4.98 | 4.98 | 0.94 | 0.94 | 0.10 | 0.10 | 0.10 | Unknown | 4 | 5.13 | 5.13 | 0.97 | 0.97 0.967 0.12 0.12 0.12 Unknown 5 5.18 5.18 0.98 0.98 0.977 0.14 0.14 0.14 Unknown 6 5.21 5.22 0.98 0.98 0.984 0.08 0.07 0.07 Unknown 5.42 5.42 1.02 1.02 1.023 0.16 0.16 0.16 Unknown 14 5.49 5.48 1.04 1.03 1.035 1.1 1.1 1.06 Unknown 9 5.68 5.68 1.07 1.07 1.072 0.07 0.07 0.07 Unknown 10 5.77 5.77 1.09 1.09 1.089 0.09 0.09 0.09 Unknown 11 6.02 6.02 1.14 1.13 1.136 0.14 0.14 0.14 Unknown 6.12 6.11 1.15 1.15 1.154 0.06 0.06 0.06 Total of 2.91 impurities Reported Purity 97.09 Petition 870250101903, dated 06 / 11 / 2025, pages 158 / 230 154 / 175 Table 54: Impurity peak table for Besylate Standard 1 Peak Name | Retention Time (min) | Average RRT | Average RRT | Area % | Average % | Area | Unknown | 13 | 4.49 | 4.50 | 0.85 | 0.85 | 0.847 | 0.43 | 0.41 | 0.42 | Unknown | 3 | 4.98 | 4.98 | 0.94 | 0.94 | 0.938 | 0.34 | 0.31 | 0.33 | Unknown | 4 | 5.13 | 5.14 | 0.97 | 0.97 | 0.967 | 0.13 | 0.12 | 0.13 | Unknown | 5 | 5.18 | 5.19 | 0.98 | 0.98 | 0.977 | 0.10 | 0.08 | 0.09 | Unknown | 6 | 5.22 | 5.22 | 0.98 | 0.98 0.984 0.13 0.10 0.12 Unknown 5.42 5.43 1.02 1.02 1.022 0.22 0.20 0.21 Unknown 14 5.49 5.49 1.03 1.03 1.034 0.68 0.65 0.67 Unknown 17 5.56 5.56 1.05 1.05 1.048 0.12 0.11 0.12 Unknown 9 5.68 5.68 1.07 1.07 1.070 0.07 0.06 0.07 Unknown 11 6.02 6.02 1.14 1.13 1.135 0.16 0.15 0.15 Unknown 15 6.41 6.40 1.21 1.21 1.207 0.09 0.06 0.08 Unknown 16 6.45 6.45 1.22 1.21 1.215 0.08 0.07 0.08 Petition 870250101903, dated 06 / 11 / 2025, pp. 159 / 230 155 / 175 Unknown 17 6.51 6.50 1.23 1.22 1.227 0.25 0.22 0.23 Total of 2.67 impurities Reported Purity 97.33 Table 55: Peak impurity table of Standard 1 besylate after 7 days. 40°C / 75% RH Peak Name | Retention Time (min) | Average RRT | Average RRT | Area % | Average Rel. % | Unknown | 13 | 4.49 | 4.50 | 0.85 | 0.85 | 0.847 | 0.41 | 0.42 | 0.42 | Unknown | 3 | 4.96 | 4.97 | 0.94 | 0.94 | 0.936 | 0.32 | 0.32 | 0.32 | Unknown | 4 | 5.12 | 5.14 | 0.97 | 0.97 | 0.967 | 0.13 | 0.13 | 0.13 | Unknown | 5 | 5.20 | 5.19 | 0.98 | 0.98 | 0.981 | 0.11 | 0.11 | 0.11 | Unknown | 6 | 5.23 | 5.22 | 0.99 | 0.98 0.987 0.15 0.09 0.12 Unknown 7 5.40 5.43 1.02 1.02 1.019 0.19 0.30 0.24 Unknown 14 5.48 5.50 1.03 1.04 1.035 0.67 0.66 0.67 Unknown 17 5.55 5.56 1.05 1.05 1.047 0.10 0.12 0.11 Unknown 5.67 5.68 1.07 1.07 1.070 0.05 0.07 0.06 Petition 870250101903, dated 06 / 11 / 2025, pages 160 / 230 156 / 175 9 Unknown 6.02 6.02 1.14 1.13 1.135 0.14 0.14 0.14 11 Unknown 6.40 6.40 1.21 1.21 1.208 0.07 0.08 0.07 15 Unknown 6.44 6.44 1.22 1.21 1.215 0.08 0.08 0.08 16 Unknown 6.50 6.50 1.23 1.22 1.226 0.20 0.22 0.21 17 Total of 2.69 impurities Reported Purity 97.31 Table 56: Peak impurity table of Standard 1 besylate after 7 days. 80°C Peak Name | Retention Time (min) | Average RRT | Average RRT | Area | % | Average Rel. | % of Area | Unknown | 1 | 4.51 | 4.51 | 0.85 | 0.85 | 0.85 | 2 | 0.40 | 0.41 | 0.41 | Unknown | 3 | 4.97 | 4.97 | 0.94 | 0.94 | 0.93 | 8 | 0.30 | 0.31 | 0.30 | Unknown | 4 | 5.13 | 5.14 | 0.97 | 0.97 | 0.96 | 9 | 0.13 | 0.13 | 0.13 | Unknown | 5 | 5.19 | 5.20 | 0.98 | 0.98 | 0.97 | 9 | 0.09 | 0.09 | 0.09 | Unknown | 6 | 5.21 | 5.23 | 0.98 | 0.98 0.984 0.09 0.09 0.09 Petition 870250101903, dated 06 / 11 / 2025, pages 161 / 230 157 / 175 Unknown 5.41 5.43 1.02 1.02 1.021 0.20 0.16 0.18 7 Unknown 5.48 5.50 1.03 1.03 1.033 0.66 0.64 0.65 14 Unknown 5.53 5.55 1.04 1.04 1.043 0.09 0.10 0.10 17 Unknown 5.65 5.67 1.07 1.07 1.066 0.05 0.09 0.07 9 Unknown 5.98 6.01 1.13 1.13 1.129 0.10 0.10 0.10 11 Unknown 6.37 6.39 1.20 1.20 1.20 0.06 0.06 0.06 15 Unknown 6.41 6.43 1.21 1.21 1.20 0.06 0.06 0.06 16 Unknown 6.47 6.49 1.22 1.22 1.22 0.21 0.18 0.20 17 Total of 2.44 impurities Reported Purity 97.56 Table 57: Peak impurity table for Besylate Standard 1 after 7 days at room temperature Peak Name Retention Time (min) RRT Average RRT Rel. Area % Average Rel. % of Area Unknown 13 4.50 4.51 0.85 0.85 0.848 0.42 0.43 0.43 Unknown 3 4.96 4.97 0.93 0.93 0.934 0.37 0.37 0.37 Unknown 4 5.13 5.14 0.97 0.97 0.967 0.14 0.14 0.14 Petition 870250101903, dated 06 / 11 / 2025, pages 162 / 230 158 / 175 Unknown 6 5.19 5.21 0.98 0.98 0.979 0.14 0.15 0.14 Unknown 5.43 5.44 1.02 1.02 1.023 0.14 0.18 0.16 Identification 5.46 5.47 1.03 1.03 1.028 0.13 0.16 0.15 manual Unknown 14 5.49 5.52 1.04 1.04 1.035 0.60 0.64 0.62 Unknown 17 5.54 5.57 1.04 1.05 1.045 0.11 0.12 0.11 Unknown 9 5.67 5.70 1.07 1.07 1.068 0.06 0.07 0.06 Unknown 10 5.78 na 1.09 na 1.089 0.05 na 0.05 Unknown 11 6.01 6.03 1.13 1.13 1.133 0.15 0.15 0.15 Unknown 15 6.39 6.40 1.20 1.20 1.205 0.08 0.11 0.10 Unknown 16 6.43 6.44 1.21 1.21 1.212 0.08 0.09 0.08 Unknown 17 6.49 6.50 1.22 1.22 1.224 0.25 0.27 0.26 Total of 2.83 impurities. Reported Purity 97.17 Table 58: Impurity peak table for Free Base Standard 2 Peak Name | Retention Time (min) | Average RRT | Average RRT | Area | % | Average Rel. | % | Area | Unknown | 1 | 3.03 | 3.04 | 0.57 | 0.57 | 0.57 | 0.08 | 0.07 | 0.07 | Unknown | 4.50 | 4.52 | 0.85 | 0.85 | 0.84 | 0.64 | 0.66 | 0.65 | 13 | Unknown | 4 | 5.14 | 5.15 | 0.97 | 0.97 | 0.96 | 0.08 | 0.08 | 0.08 | Unknown | 6 | 5.23 | 5.24 | 0.98 | 0.98 | 0.98 | 0.10 | 0.12 | 0.11 | Unknown | 5.51 | 5.51 | 1.04 | 1.04 1.036 0.45 0.54 0.50 14 Unknown 9 5.68 5.67 1.07 1.07 1.068 0.10 0.07 0.09 Petition 870250101903, dated 06 / 11 / 2025, pages 163 / 230 159 / 175 Unknown 5.79 1.09 0.05 0.05 10 Unknown 6.91 6.93 1.30 1.30 1.299 0.06 0.06 0.06 Total of 1.61 impurities Reported Purity 98.39 Table 59: Peak impurity table of Freebase Standard 2 after 7 days at 40°C / 75% RH Peak Name | Retention Time (min) | Average RRT | Average RRT | Area | % | Average Rel. | % | Area | Unknown | 1 | 3.05 | 3.04 | 0.57 | 0.57 | 0.57 | 4 | 0.07 | 0.07 | 0.07 | Unknown | 4.51 | 4.52 | 0.85 | 0.85 | 0.84 | 9 | 0.66 | 0.66 | 0.66 | 13 | Unknown | 4 | 5.14 | 5.18 | 0.97 | 0.97 | 0.96 | 8 | 0.08 | 0.07 | 0.07 | Unknown | 6 | 5.23 | 5.26 | 0.98 | 0.98 | 0.98 | 4 | 0.12 | 0.13 | 0.12 | Unknown | 5.50 | 5.54 | 1.04 | 1.04 1.036 0.50 0.48 0.49 14 Unknown 9 5.66 5.68 1.07 1.06 1.065 0.06 0.05 0.05 Unknown 5.78 5.81 1.09 1.09 1.089 0.05 0.05 0.05 10 Unknown na 6.01 na 1.12 nana 0.05 0.05 11 Unknown 6.93 6.92 1.30 1.29 1.304 0.06 0.06 0.06 Total impurities Reported Purity 1.63 98.37 Petition 870250101903, dated 06 / 11 / 2025, pp. 164 / 230 160 / 175 Table 60: Peak impurity table of Freebase Standard 2 after 7 days at 80°C Peak Name Time of RRT RRT King. Area Average Retention % of Area (min) % Unknown 3.04 3.07 0.57 0.57 0.571 0.06 0.07 0.07 1 Unknown 4.51 4.52 0.85 0.85 0.847 0.66 0.67 0.67 13 Unknown 5.15 5.18 0.97 0.97 0.967 0.08 0.08 0.08 5 Unknown 5.24 5.27 0.98 0.98 0.984 0.13 0.14 0.13 Unknown 5.52 5.54 1.04 1.04 1.036 0.51 0.52 0.51 17 Unknown 5.67 5.67 1.07 1.06 1.065 0.06 0.06 0.06 9 Unknown 5.80 5.80 1.09 1.08 1.089 0.05 0.05 0.05 10 Unknown na 5.99 na 1.12 nana 0.05 0.05 11 Unknown 6.93 6.92 1.30 1.29 1.301 0.06 0.06 0.06 Total of 1.67 impurities Reported Purity 98.33 Table 61: Impurity peak table of Freebase Standard 2 after 7 days at room temperature. Petition 870250101903, dated 06 / 11 / 2025, pages 165 / 230 161 / 175 Peak Name Time of RRT RRT King. Area Average Retention % of Area (min) % Unknown 3.11 3.07 0.58 0.57 0.58 2 0.07 0.06 0.07 1 Unknown 4.54 4.54 0.85 0.85 0.85 0.65 0.65 0.65 Unknown 5.17 5.18 0.97 0.97 0.96 8 0.08 0.08 0.08 5 Unknown 5.27 5.27 0.99 0.99 0.98 5 0.17 0.17 0.17 Unknown 5.54 5.54 1.04 1.04 1.036 0.54 0.53 0.53 17 Unknown 5.66 5.66 1.06 1.06 1.059 0.11 0.11 0.11 9 Unknown 5.82 5.82 1.09 1.09 1.089 0.06 0.06 0.06 Unknown 6.95 6.95 1.30 1.30 1.299 0.06 0.06 0.06 Total of 1.73 impurities Reported Purity 98.27 EXAMPLE 13. 3 G AMPLIFICATION OF COMPOUND A STANDARD 1 • Approximately 3 g of amorphous Compound A were added to a pre-weighed scintillation flask. 5 mL of THF were added, and a purple, fluid paste was obtained. A magnetic stirrer bar was added, and the sample was subjected to temperature cycles between 20°C and 40°C at a heating rate of 0.1°C / min with a 2-hour holding time at 20°C and 40°C. The sample was checked after approximately 3 hours, and a thick, whitish, fluid paste was observed. An additional 5 mL of THF was added to produce a mobile, fluid paste. • After approximately 72 hours, the sample was a thick, fluid paste. Petition 870250101903, dated 06 / 11 / 2025, pages 166 / 230 162 / 175 whitish. It was filtered over a Büchner funnel and allowed to dry on the filter bed for approximately 5 minutes. A subsample was analyzed by XRPD. Standard 1 was found to be weakly crystalline. The sample was gently dried at 40°C for approximately 20 hours and then reanalyzed by XRPD. • 25 mg of freebase Standard 1 seed material were added to the material and the sample was again suspended in 7 mL of ethanol. The fluid paste was subjected to temperature cycles between room temperature and 40°C over cycles of 4 hours to approximately 24 hours. A subsample was analyzed by XRPD and the material was then gently dried at 40°C and reanalyzed by XRPD. • The weakly crystalline Standard 1 sample was again suspended in 10 mL of methanol:DCM (90:10% v / v) with 5 mg of freebase Standard 1 seed and the temperature cycled between ambient and 40°C over 4-hour cycles for approximately 72 hours. • A mixture of freebase Standards 2 and 7 was obtained. The sample was filtered by Büchner filtration and then thoroughly dried at room temperature under vacuum for approximately 3 hours. • The dried sample was again suspended in 10 mL of ethanol with 3.5 mg of freebase Standard 1 seed, and the temperature was alternated between ambient and 40°C over cycles of 4 hours to approximately 48 hours. • After 48 hours, a thick paste was obtained and dried by Buchner filtration. A subsample was analyzed by XRPD, which confirmed that the sample was successfully converted to Standard 1. • The material was placed in a pre-weighed scintillation jar, covered with tissue paper, and gently dried in an oven at 40 °C for approximately 20 hours. • The dried material was analyzed by XRPD, PLM, TG / DSC, DSC, modulated DSC, 1H NMR and HPLC. Results Petition 870250101903, dated 06 / 11 / 2025, pp. 167 / 230 163 / 175 • The THF sample produced the weakly crystalline Standard 1. This standard was retained after resuspension with Standard 1 seed in ethanol. • This sample was analyzed by PLM, and very small, weakly birefringent particles with unclear morphology were observed. The small particle size likely influenced the appearance of the XRPD pattern. • A mixture of free base standards 2 and 7 was obtained after temperature cycling in methanol:DCM (90:10 %v / v) for approximately 72 hours. • Freebase Standard 1 was successfully extended by suspending material from freebase Standards 2 and 7 in ethanol with seed material from Standard 1. • Scale-up of 3 g of Standard 1 of Compound A produced 2.68 g (90.2% yield). Characterization of the 3 g scale-up of Compound A Standard 1 • The XRPD standard matched the previously found freebase Standard 1, see FIG. 80. • PLM analysis found small birefringent particles approximately 5 μm in size. The morphology was unclear. • The 1H NMR spectrum was consistent with the freebase spectrum. 0.6 wt% (0.1 eq.) of ethanol and 1.1 wt% (0.1 eq.) of IPA were observed in the spectrum. See FIG. 81. No peak shift was observed compared to Compound A. • No mass loss was observed in the TG trace until degradation after approximately 310 °C. A pronounced endothermic event was observed in the DSC trace with an onset at 240 °C corresponding to the melt mass. See FIG. 82. • DSC analysis was performed on this batch to confirm that the exothermic and endothermic events observed during cooling and second heating cycles, respectively, were indicative of the shape and not an artifact of it. Petition 870250101903, dated 06 / 11 / 2025, pp. 168 / 230 164 / 175 batch. A pronounced endothermic melting event beginning at 241 °C was observed in the first heating cycle, combining previous data. See FIG. 83. • In the DSC cooling cycle, an exothermic event was observed with an onset at 168°C and a peak at 167°C (the previous batch had a broader event with an onset at 164°C and a peak at 158°C). A glass transition was also observed with a midpoint at 118°C (previously 119°C). See FIG. 84. • The second heating cycle encountered a glass transition with a midpoint at 123°C (same temperature as before) and an endothermic event with an onset at 166°C and a peak at 168°C; the event had a rebound with a peak at 156°C. (Previously, the onset was found at 147°C and the peak at 162°C. See FIG. 85.) • The exothermic and endothermic event was obtained in the DSC analysis of this batch, as well as the previous batch, and thus was confirmed as being due to the free base form. See FIGS. 56-58 for the previous batch. • HPLC analysis determined that the batch purity was 97.35% by relative area. EQUIVALENTS

[0377] Although the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those skilled in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention. MODALITIES LISTED

[0378] The aspects of this disclosure are further described with reference to the following modalities: A. Solid form of Compound A: (Compound A). Petition 870250101903, dated 06 / 11 / 2025, pp. 169 / 230 165 / 175 B. The solid form of modality A, in which the solid form is crystalline. C. The solid form of modality A, where the solid form is amorphous. D. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 18.6 °2θ, 13.9 °2θ and 15.3 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). E. The solid form of any of the above embodiments, where the solid form is a crystalline polymorphic form characterized by XRPD signals at 18.6 °2θ, 13.9 °2θ and 15.3 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). F. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 80 or FIG. 86. G. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, or forty-one XRPD signals selected from those set forth in Table 1. H. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 14.4 °2θ, 19.1 °2θ and 15.8 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). I. The solid form of any of the preceding embodiments, where the solid form is a crystalline polymorphic form characterized by XRPD signals at 14.4 °2θ, 19.1 °2θ and 15.8 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). Petition 870250101903, dated 06 / 11 / 2025, pp. 170 / 230 166 / 175 J. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 87. K. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine or forty XRPD signals selected from those set forth in Table 2. L. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.6 °2θ, 16.1 °2θ, 16.3 °2θ, 17.3 °2θ and 16.8 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). M. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by XRPD signals at 20.6 °2θ, 16.1 °2θ, 16.3 °2θ, 17.3 °2θ and 16.8 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu radiation 1 <α1).N. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 88. O. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, or nineteen XRPD signals selected from those set forth in Table 3. Petition 870250101903, dated 06 / 11 / 2025, pp. 171 / 230 167 / 175 P. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 14.6 °2θ, 17.7 °2θ and 16.7 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). Q. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by XRPD signals at 14.6 °2θ, 17.7 °2θ and 16.7 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). R. The solid form of any of the previous embodiments, wherein the solid form is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 89. S. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, or twenty-four XRPD signals selected from those set forth in Table 4. T. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 14.9 °2θ, 22.6 °2θ and 7.1 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). U. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by XRPD signals at 14.9 °2θ, 22.6 °2θ and 7.1 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). V. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 90. W. The solid form of any of the above embodiments, where the solid form is a polymorphic crystalline form characterized by one, two, three, four, Petition 870250101903, dated 06 / 11 / 2025, pp. 172 / 230 168 / 175 five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four or thirty-five XRPD signals selected from those set out in Table 5. X. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 3.5 °2θ, 3.6 °2θ and 15.7 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). Y. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by XRPD signals at 3.5 °2θ, 3.6 °2θ and 15.7 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). Z. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 91. AA. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five or thirty-six XRPD signals selected from those set forth in Table 6. BB. The solid form of any of the preceding embodiments, where the solid form is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 4.8 °2θ, 15.7 °2θ and 17.9 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). CC. The solid form of any of the previous modalities, in which the Petition 870250101903, dated 06 / 11 / 2025, pp. 173 / 230 169 / 175 solid form is a crystalline polymorphic form characterized by XRPD signals at 4.8 °2θ, 15.7 °2θ and 17.9 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). DD. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 92. EE. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen XRPD signals selected from those set forth in Table 7. FF. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 4.9 °2θ, 15.9 °2θ and 18.2 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). GG. The solid form of any of the previous embodiments, wherein the solid form is a crystalline polymorphic form characterized by XRPD signals at 4.9 °2θ, 15.9 °2θ and 18.2 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). HH. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 93. II. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, or twenty-two XRPD signals selected from those set forth in Table 8. JJ. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 17.2 °2θ, 21.0 °2θ and 24.2 °2θ (±0.2 Petition 870250101903, dated 06 / 11 / 2025, pp. 174 / 230 170 / 175 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu radiation (Kαi). KK. The solid form of any of the previous embodiments, where the solid form is a crystalline polymorphic form characterized by XRPD signals at 17.2 °2θ, 21.0 °2θ and 24.2 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Ko1 radiation). LL. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 94. MM. The solid form of any of the preceding embodiments, wherein the solid form is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, or forty-two XRPD signals selected from those set forth in Table 9. NN. Tosylate salt of Compound A: (Compound A) OO. The tosylate salt of the OO embodiment, in which the tosylate salt is crystalline. PP. The tosylate salt of the PP embodiment, in which the tosylate salt is amorphous. QQ. The tosylate salt of any of the preceding embodiments, in which the tosylate salt is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 3.5 °2θ, 22.0 °2θ and 23.0 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Ko1 radiation). RR. The tosylate salt of any of the preceding embodiments, wherein the tosylate salt is a crystalline polymorphic form characterized by XRPD signals at 3.5 °2θ, 22.0 °2θ and 23.0 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Kq1 radiation). Petition 870250101903, dated 06 / 11 / 2025, pages 175 / 230 171 / 175 SS. The tosylate salt of any of the preceding embodiments, wherein the tosylate salt is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 95. TT. The tosylate salt of any of the preceding embodiments, wherein the tosylate salt is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen XRPD signals selected from those set forth in Table 10. UU. The tosylate salt of any of the preceding embodiments, wherein the tosylate salt is a tosylate salt:Compound A 1:1. VV. The tosylate salt of any of the preceding embodiments, wherein the tosylate salt is a tosylate salt:Compound A 2:1. WW. The tosylate salt of any of the preceding embodiments, wherein the tosylate salt is a tosylate salt:Compound A 1:2. XX. Phosphate salt of Compound A: (Compound A). YY. The phosphate salt of the YY embodiment, in which the phosphate salt is crystalline. ZZ. The phosphate salt of the ZZ embodiment, in which the phosphate salt is amorphous. AAA. The phosphate salt of any of the preceding embodiments, wherein the phosphate salt is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 23.6 °2θ, 3.3 °2θ and 19.9 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu^1 radiation). BBB. The phosphate salt of any of the preceding embodiments, wherein the phosphate salt is a crystalline polymorphic form characterized by XRPD signals at 23.6 °2θ, 3.3 °2θ and 19.9 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). CCC. The phosphate salt of any of the preceding embodiments, wherein the phosphate salt is a crystalline polymorphic form characterized by a spectrum of Petition 870250101903, dated 06 / 11 / 2025, pp. 176 / 230 172 / 175 XRPD substantially similar to that shown in FIG. 96. DDD.The phosphate salt of any of the preceding embodiments, wherein the phosphate salt is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen XRPD signals selected from those set forth in Table 11. EEE. The phosphate salt of any of the preceding embodiments, wherein the phosphate salt is a phosphate salt: Compound A 1:1. FFF. The phosphate salt of any of the preceding embodiments, wherein the phosphate salt is a phosphate salt: Compound A 2:1. GGG. The phosphate salt of any of the preceding embodiments, wherein the phosphate salt is a phosphate salt: Compound A 1: 2. HHH. Besylate salt of Compound A: (Compound A) III. The besylate salt of type III, in which the besylate salt is crystalline. JJJ. The besylate salt used in the JJJ modality, in which the besylate salt is amorphous. KKK. The besylate salt of any of the preceding embodiments, wherein the besylate salt is a crystalline polymorphic form characterized by two or three XRPD signals selected from the group consisting of 18.5 °2θ, 18.3 °2θ and 22.6 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu^1 radiation). LLL. The besylate salt of any of the preceding embodiments, wherein the besylate salt is a crystalline polymorphic form characterized by XRPD signals at 18.5 °2θ, 18.3 °2θ and 22.6 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu ^1 radiation). MMM. The besylate salt of any of the preceding embodiments, wherein the besylate salt is a crystalline polymorphic form characterized by an XRPD spectrum substantially similar to that shown in FIG. 97. NNN.O besylate salt of any of the previous modalities, in which the Petition 870250101903, dated 06 / 11 / 2025, pp. 177 / 230 173 / 175 besylate salt is a crystalline polymorphic form characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine or thirty XRPD signals selected from those set forth in Table 12. OOO. The besylate salt of any of the preceding embodiments, wherein the besylate salt is a besylate salt:Compound A 1:1. PPP. The besylate salt of any of the preceding embodiments, wherein the besylate salt is a besylate salt:Compound A 2:1. QQQ. The besylate salt of any of the preceding embodiments, wherein the besylate salt is a besylate salt:Compound A 1:2. RRR. A method of treating prostate cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a solid form or salt of any of the aforementioned modalities. SSS. The method of any of the previous modalities, further comprising the administration of an effective amount of at least one additional anticancer agent to the subject. TTT. The method of any of the previous modalities, in which the prostate cancer is metastatic prostate cancer. UUU.O.The method of any of the previous modalities, in which the prostate cancer is castration-resistant prostate cancer. VVV. The method of any of the previous modalities, in which the prostate cancer is metastatic castration-resistant prostate cancer. WWW. The method of any of the previous modalities, in which prostate cancer is castration-sensitive prostate cancer. XXX. The method of any of the previous modalities, in which the Petition 870250101903, dated 06 / 11 / 2025, pp. 178 / 230 174 / 175 prostate cancer is metastatic castration-sensitive prostate cancer. YYY. The method of any of the previous modalities, in which prostate cancer is naive to new hormonal agents (NHA). ZZZ. The method of any of the previous modalities, in which prostate cancer not exposed to new hormonal agents (NHA) has not been previously treated with a second-generation antiandrogen. AAAA. The method of any of the previous modalities, in which metastatic prostate cancer is metastatic prostate cancer not exposed to new hormonal agents (NHA). BBBB. The method of any of the previous modalities, in which the prostate cancer is castration-resistant prostate cancer not exposed to new hormonal agents (NHA). CCCC. The method of any of the previous modalities, in which castration-resistant prostate cancer not exposed to new hormonal agents (NHA) has not been previously treated with a second-generation antiandrogen. DDDD. The method of any of the previous modalities, in which the prostate cancer is castration-sensitive prostate cancer not exposed to new hormonal agents (NHA). EEEE. The method of any of the previous modalities, in which castration-sensitive prostate cancer not exposed to new hormonal agents (NHA) has not been previously treated with a second-generation antiandrogen. FFFF. The method of any of the previous modalities, in which the prostate cancer is metastatic castration-resistant prostate cancer not exposed to new hormonal agents (NHA). GGGG. The method of any of the previous modalities, in which metastatic castration-resistant prostate cancer not exposed to new agents Petition 870250101903, dated 06 / 11 / 2025, pp. 179 / 230 175 / 175 hormones (NHA) have not been previously treated with a second-generation antiandrogen. HHHH. The method of any of the previous modalities, in which the prostate cancer is metastatic castration-sensitive prostate cancer not exposed to new hormonal agents (NHA). III. The method of any of the previous modalities, in which metastatic castration-sensitive prostate cancer not exposed to new hormonal agents (NHAs) has not been previously treated with a second-generation antiandrogen. JJJJ. The method of any of the previous modalities, in which prostate cancer has not been previously treated with an androgen biosynthesis inhibitor or an androgen receptor blocker. KKKK. The method of any of the previous modalities, in which prostate cancer has not been previously treated with abiraterone acetate. LLLL. The method of any of the previous modalities, in which prostate cancer has not been previously treated with an androgen receptor blocker selected from enzalutamide, darolutamide, and apalutamide. MMMM. The method of any of the previous modalities, in which the subject has not previously received an inhibitor of androgen biosynthesis or an androgen receptor blocker. NNNN. The method of any of the above modalities, in which the subject has not been previously administered abiraterone acetate. OOOO. The method of any of the previous modalities, in which the subject has not been previously administered an androgen receptor blocker selected from enzalutamide, darolutamide, and apalutamide.

Claims

1. Solid form CHARACTERIZED by the fact that it is of Compound A: (Compound A), wherein the solid form is a crystalline polymorphic form defined by two or three XRPD signals selected from the group consisting of 18.6 °2θ, 13.9 °2θ and 15.3 °2θ (±0.2 °2θ of Cu ^1 radiation).

2. Solid form, according to claim 1, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by XRPD signals at 18.6°2θ, 13.9°2θ and 15.3°2θ (±0.2°2θ of Cu^1 radiation).

3. Solid form CHARACTERIZED by the fact that it is of Compound A: (Compound A), wherein the solid form is a crystalline polymorphic form defined by an XRPD spectrum substantially similar to that shown in FIG. 80 or FIG.

86.

4. Solid form CHARACTERIZED by the fact that it is of Compound A: wherein the solid form is a crystalline polymorphic form defined by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, Petition 870250086112, dated 09 / 23 / 2025, page 7 / 20 2 / 10 twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, or forty-one XRPD signals selected from those set out in Table 1.

5. Solid form CHARACTERIZED by the fact that it is Compound A: (Compound A).

6. Solid form according to claim 5, CHARACTERIZED in that the solid form is crystalline.

7. Solid form according to claim 5, CHARACTERIZED in that the solid form is amorphous.

8. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by two or three XRPD signals selected from the group consisting of 14.4 °2θ, 19.1 °2θ and 15.8 °2θ (±0.2 °2θ of Cu Kα1 radiation).

9. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by an XRPD spectrum substantially similar to that shown in FIG.

87.

10. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, or forty XRPD signals selected from those set forth in Table 2. Petition 870250086112, dated 09 / 23 / 2025, page 8 / 20 3 / 10 11. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by two or more, or three or more XRPD signals selected from the group consisting of 20.6 °2θ, 16.1 °2θ, 16.3 °2θ, 17.3 °2θ and 16.8 °2θ (±0.2 °2θ of Cu ^1 radiation).

12. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by an XRPD spectrum substantially similar to that shown in FIG.

88.

13. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen or nineteen XRPD signals selected from those set forth in Table 3.

14. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by two or three XRPD signals selected from the group consisting of 14.6 °2θ, 17.7 °2θ and 16.7 °2θ (±0.2 °2θ of Cu ^1 radiation).

15. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by an XRPD spectrum substantially similar to that shown in FIG.

89.

16. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three or twenty-four XRPD signals selected from those set forth in Table 4.

17. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by two or three XRPD signals selected from the group consisting of 14.9 °2θ, 22.6 °2θ and 7.1 °2θ (±0.2 °2θ of Cu ^1 radiation).

18. Solid form, according to claim 5 or 6, CHARACTERIZED Petition 870250086112, dated 09 / 23 / 2025, page 9 / 20 4 / 10 by the fact that the solid form is a crystalline polymorphic form defined by an XRPD spectrum substantially similar to that shown in FIG.

90.

19. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, or thirty-five XRPD signals selected from those set forth in Table 5.

20. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by two or three XRPD signals selected from the group consisting of 3.5 °2θ, 3.6 °2θ and 15.7 °2θ (±0.2 °2θ of Cu ^1 radiation).

21. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by an XRPD spectrum substantially similar to that shown in FIG.

91.

22. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five or thirty-six XRPD signals selected from those set forth in Table 6.

23. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by two or three XRPD signals selected from the group consisting of 4.8 °2θ, 15.7 °2θ and 17.9 °2θ (±0.2 °2θ of Cu ^1 radiation).

24. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by an XRPD spectrum substantially similar to that shown in FIG.

92.

25. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen or sixteen XRPD signals selected from those set forth in Table 7.

26. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by two or three XRPD signals selected from the group consisting of 4.9 °2θ, 15.9 °2θ and 18.2 °2θ (±0.2 °2θ of Cu Kα1 radiation).

27. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by an XRPD spectrum substantially similar to that shown in FIG.

93.

28. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one or twenty-two XRPD signals selected from those set forth in Table 8.

29. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by two or three XRPD signals selected from the group consisting of 17.2 °2θ, 21.0 °2θ and 24.2 °2θ (±0.2 °2θ of Cu Kα1 radiation).

30. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by an XRPD spectrum substantially similar to that shown in FIG.

94.

31. Solid form, according to claim 5 or 6, CHARACTERIZED in that the solid form is a crystalline polymorphic form defined by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, Petition 870250086112, dated 09 / 23 / 2025, page 11 / 20 6 / 10 thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one or forty-two XRPD signals selected from those set forth in Table 9.

32. Tosylate salt of Compound A, CHARACTERIZED by the fact that it is: (Compound A).

33. Tosylate salt, according to claim 32, CHARACTERIZED in that the tosylate salt is crystalline.

34. Tosylate salt, according to claim 32, CHARACTERIZED in that the tosylate salt is amorphous.

35. Tosylate salt, according to claim 32 or 33, CHARACTERIZED in that the tosylate salt is a crystalline polymorphic form defined by two or three XRPD signals selected from the group consisting of 3.5 °2θ, 22.0 °2θ and 23.0 °2θ (±0.2 °2θ of Cu ^1 radiation).

36. Phosphate salt of Compound A CHARACTERIZED by the fact that it is: (Compound A).

37. Phosphate salt, according to claim 36, CHARACTERIZED in that the phosphate salt is crystalline.

38. Phosphate salt, according to claim 36, CHARACTERIZED in that the phosphate salt is amorphous.

39. Phosphate salt, according to claim 36 or 37, CHARACTERIZED in that the phosphate salt is a crystalline polymorphic form Petition 870250086112, dated 09 / 23 / 2025, page 12 / 20 7 / 10 defined by two or three XRPD signals selected from the group consisting of 23.6 °2θ, 3.3° 2θ and 19.9 °2θ (±0.2 °2θ of Cu ^1 radiation).

40. Besylate salt of Compound A CHARACTERIZED by the fact that it is: (Compound A).

41. Besylate salt, according to claim 40, CHARACTERIZED in that the besylate salt is crystalline.

42. Besylate salt, according to claim 40, CHARACTERIZED in that the besylate salt is amorphous.

43. Besylate salt, according to claim 40 or 41, CHARACTERIZED in that the besylate salt is a crystalline polymorphic form defined by two or three XRPD signals selected from the group consisting of 18.5 °2θ, 18.3 °2θ and 22.6 °2θ (±0.2 °2θ of Cu ^1 radiation).

44. A method for treating prostate cancer in a subject in need, CHARACTERIZED in that it comprises administering to the subject a therapeutically effective amount of a solid form or salt, according to any one of claims 1-43.

45. Method, according to claim 44, CHARACTERIZED in that the prostate cancer is metastatic prostate cancer.

46. ​​Method according to claim 44, CHARACTERIZED in that the prostate cancer is castration-resistant prostate cancer.

47. Method, according to claim 44, CHARACTERIZED in that the prostate cancer is metastatic castration-resistant prostate cancer.

48. Method according to claim 44, CHARACTERIZED in that the prostate cancer is castration-sensitive prostate cancer. Petition 870250086112, dated 09 / 23 / 2025, page 13 / 20 8 / 10 49. Method according to claim 44, CHARACTERIZED in that the prostate cancer is castration-sensitive metastatic prostate cancer.

50. Method according to claim 44, characterized in that the prostate cancer is naive to new hormonal agents (NHA).

51. Method according to claim 50, CHARACTERIZED in that prostate cancer not exposed to new hormonal agents (NHA) has not been previously treated with a second-generation antiandrogen.

52. Method, according to claim 45, CHARACTERIZED in that the metastatic prostate cancer is metastatic prostate cancer not exposed to new hormonal agents (NHA).

53. Method according to claim 52, CHARACTERIZED in that metastatic prostate cancer not exposed to new hormonal agents (NHAs) has not been previously treated with a second-generation antiandrogen.

54. Method according to claim 46, CHARACTERIZED in that the castration-resistant prostate cancer is castration-resistant prostate cancer not exposed to novel hormonal agents (NHAs).

55. Method according to claim 54, CHARACTERIZED in that castration-resistant prostate cancer not exposed to novel hormonal agents (NHAs) has not been previously treated with a second-generation antiandrogen.

56. Method according to claim 48, CHARACTERIZED in that the castration-sensitive prostate cancer is castration-sensitive prostate cancer not exposed to novel hormonal agents (NHAs).

57. Method according to claim 56, CHARACTERIZED in that castration-sensitive prostate cancer not exposed to novel hormonal agents (NHAs) has not been previously treated with a second-generation antiandrogen.

58. Method, according to claim 47, CHARACTERIZED by the fact Petition 870250086112, dated 09 / 23 / 2025, page 14 / 20 9 / 10 that metastatic castration-resistant prostate cancer is metastatic castration-resistant prostate cancer not exposed to novel hormonal agents (NHA).

59. Method according to claim 58, CHARACTERIZED in that metastatic castration-resistant prostate cancer not exposed to novel hormonal agents (NHAs) has not been previously treated with a second-generation antiandrogen.

60. Method according to claim 49, CHARACTERIZED in that metastatic castration-sensitive prostate cancer is metastatic castration-sensitive prostate cancer not exposed to novel hormonal agents (NHA).

61. Method according to claim 60, CHARACTERIZED in that metastatic castration-sensitive prostate cancer not previously treated with a second-generation antiandrogen has not been exposed to novel hormonal agents (NHAs).

62. A method according to any one of claims 44-61, characterized in that the prostate cancer has not been previously treated with an androgen biosynthesis inhibitor or an androgen receptor blocker.

63. Method, according to any one of claims 44 to 62, CHARACTERIZED in that prostate cancer has not been previously treated with abiraterone acetate.

64. Method, according to any one of claims 44-62, CHARACTERIZED in that prostate cancer has not been previously treated with an androgen receptor blocker selected from enzalutamide, darolutamide, and apalutamide.

65. Method, according to any one of claims 44-62, CHARACTERIZED in that the subject has not previously received an androgen biosynthesis inhibitor or an androgen receptor blocker.

66. Method, according to any of claims 44 to 62, CHARACTERIZED by the fact that the subject has not previously received abiraterone acetate. Petition 870250086112, dated 09 / 23 / 2025, page 15 / 20 10 / 10 67. Method, according to any one of claims 44-62, CHARACTERIZED in that the subject has not been previously administered an androgen receptor blocker selected from enzalutamide, darolutamide, and apalutamide.

Images